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PART I: EFFECT OF NANOMICELLE SIZE ON TRANS-SCLERAL PERMEABILITY 
OF DEXAMETHASONE. 
Ravi D. Vaishya, Candidate for the Doctor of Philosophy Degree 
University of Missouri-Kansas City, 2015. 
 
ABSTRACT 
Our primary aim was to determine the effect of nanomicelle size on dexamethasone (DEX) 
transport across the sclera. Nanomicelles of various sizes were developed and characterized. 
Low molecular weight diblock co-polymers, mPEG750-PCL700 (DB1), mPEG2000-PCL1500 
(DB2) and mPEG5000-PCL4000 (DB3) were synthesized by ring opening polymerization. 
Polymers were characterized by H1 NMR (structure), gel permeation chromatography 
(molecular weights and polydispersity), critical micelle concentration (CMC) and in vitro 
cytotoxicity studies in corneal, conjunctival and retinal cell-lines. Newly synthesized 
polymers were purified and characterized for their structure and molecular weights by H1-
NMR and GPC, respectively. The CMCs were found to be 0.13, 4.48 and 6.04 µg/mL for 
DB1, DB2 and DB3, respectively. In order to understand the factors and interactions 
influencing drug solubilization in micelle core, an exploratory 2-factors 3-level response 
surface methodology was generated using SAS 9.02 (exploratory model). The independent 
factors were polymer amount (X1) and DEX amount (X2). Solubility of DEX in micelle 
solution was taken as response variable (Y). Micelle preparation method was modified based 
on the results obtained from exploratory model. The optimal drug:polymer ratio was 
identified by another response surface design (optimization model) to achieve DEX solubility 
of 1mg/mL for all the nanomicellar formulations. The optimized formulation was 
characterized for solubility of DEX, micelle size and polydispersity, morphology, in vitro 
release and in vitro transport across conjunctival cell line. Nanomicellar formulations 
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(referred to as DEXM) containing >1mg/mL DEX were developed for all three polymers 
using design of experiment. The optimized nanomicelle formulation exhibited mean size in 
range of 10nm, 30nm and 60nm with unimodal size distribution and low polydispersity for 
DB1, DB2 and DB3 polymers, respectively. The formulation was also subjected to ex vivo 
transport across excised rabbit sclera to determine influence of micelle size on DEX transport 
across the static barrier. DEX permeability across the excised rabbit sclera for DEXM and 
DEX suspension (control) were found to be 2.7x10-6, 3.0x10-6, 1.5x10-6 and 1.2x10-6 cm/sec, 
respectively. There were 2.2, 2.5 and 1.3-fold increase in DEX permeability with 
nanomicelles of mean sizes 10 nm, 25 nm and 60 nm, respectively.  
The permeability studies across the sclera, static barrier, indicates that the nanomicelles with 
average sizes 10nm and 30nm may have potential to deliver therapeutic agents to the back of 
the eye following topical administration. Therefore, nanomicellar formulation may provide 
therapeutic levels in the back of the eye following topical administration. 
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PART II: STRATEGIES TO MINIMIZE OCTREOTIDE ACYLATION DURING 
SUSTAINED RELEASE FROM BIODEGRADABLE POLYMERS. 
Ravi D. Vaishya, Candidate for the Doctor of Philosophy Degree 
University of Missouri-Kansas City, 2015. 
 
ABSTRACT 
Overall aim of this research was to minimize acylation of octreotide during sustained release 
from biodegradable polymers. Polymeric microparticle (MPs)-in-gel formulations for 
extended delivery of octreotide were developed. Polymer modification and reversible 
hydrophobic Ion-Pairing (HIP) complex strategies were investigated to achieve-mentioned 
goals. Polycaprolactone (PCL), polylactic acid (PLA) and polyglycolic acid (PGA) based 
triblock (TB = PCL10k-PEG2k-PCL10k) and pentablock (PB; PBA = PLA3k-PCL7k-
PEG2k-PCL7k-PLA3k and PBB = PGA3k-PCL7k-PEG2k-PCL7k-PGA3k) polymers were 
synthesized and characterized for structure, molecular weight and physical state. Octreotide 
was encapsulated in TB, PBA and PBB MPs using methanol-oil/water emulsion solvent 
evaporation method. Sodium dodecyl sulfate (SDS), dextran sulfate (DS; Mw 9-20kDa 
(DSA) and Mw 36-50kDa (DSB)) were used as ion-pairing agents to prepared reversible HIP 
complex with octreotide. Mechanics of HIP complex formation and dissociation were 
investigated. DSA-octreotide and DSB-octreotide complex encapsulated PLGA (50/50) 
microparticles (MPs) were prepared using S/O/W emulsion method. MPs were characterized 
for size, morphology, encapsulation efficiency, drug loading and in vitro release. Release 
samples were subjected to LC analysis for quantitation and LC-MS analysis for identification 
of native and chemically modified species. A significant fraction of released octreotide was 
acylated from lactide and glycolide based PBA (53%) and PBB (92%) polymers. Substantial 
amount of peptide was not released from PBB polymers after 330 days of incubation. 
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Complete release of octreotide was achieved from TB polymer over a period of 3 months 
with minimal acylation of peptide (~13%). Release of octreotide was sustained for 55 days 
for HIP complex-encapsulated MPs. A large fraction of peptide was released in chemically 
intact form (m/z 1019.3 and m/z 510.3) and <7% peptide was acylated from DSA-octreotide 
and DSB-octreotide encapsulated MPs. Polycaprolactone based polymers may be appropriate 
for extended peptide delivery. Conversely, polymers having PLA and PGA blocks may not 
be suitable for peptide delivery due to acylation and incomplete release. Reversible HIP 
complex is a viable strategy to maintain chemical stability of peptide during long-term 
delivery from PLA and PGA based polymers.   
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CHAPTER 1 
1. LITERATURE REVIEW1 
1.1. Ocular anatomy 
The eye can be broadly divided into two sections, (i) anterior segment and (ii) 
posterior segment (Figure 1-1). The anterior segment encompasses the cornea, conjunctiva, 
iris, ciliary body and lens. The posterior segment consists of the sclera, choroid, retina and 
vitreous humor. A brief description of these ocular tissues is provided in following section.  
Cornea: It is the outermost transparent multilayered membrane of the eye. It is devoid of 
blood vessels and obtains its nourishment from aqueous humor and limbal blood capillaries. 
Thickness of human cornea is around 0.5 mm and it comprises of five layers i.e. corneal 
epithelium, Bowman’s membrane, stroma, Descemet’s membrane and endothelium (arranged 
in the order of outermost to innermost) 2. The epithelial layer comprises of five to six layers 
of columnar cells. The first layer is composed of non-keratinized squamous cells. These cells 
have intercellular tight junctions. The innermost layer of columnar cells is known as germinal 
layer. Bowman’s layer and stroma (substantia propria) are mostly composed of collagen 
fibrils. Descemet’s membrane is a thick basal lamina sandwiched between stroma and 
endothelium. The endothelium represents a monolayer of squamous cells 2.  
Iris: It consists of pigmented epithelial cells and circular muscles (constrictor iridial sphincter 
muscles). These muscles cause miosis or constriction of the pupil by the action of cholinergic 
nerves. Iris also contains the dilator muscles , responsible for dilation of the pupils upon 
sympathetic stimulation 3. 
Ciliary body: It is comprised of ciliary muscles and processes. Ciliary muscles have fibrous 
bundles and are highly flexible. Non-pigmented epithelial cells form the blood-aqueous 
barrier, which restricts the movement of proteins and colloids into the aqueous humor 3. 
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Figure 1-1 Anatomy of the EYE. Credit: National Eye Institute.  
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Conjunctiva: It consists of a clear mucous membrane. This layer is divided into three parts 
i.e. palpebral, fornical, bulbar, and an underlying basement membrane. The tissue lines the 
inside of eyelids and spreads from the anterior surface of sclera (white part of the eye) up to 
the limbus. It is composed of non-keratinized stratified columnar epithelial cells. It helps 
lubricate the eye by producing mucus and tears 3. 
Sclera: It represents a matrix above the choroid, which principally shields the internal organs 
of the eye. Its thickness varies from 0.5 to 1 mm and mainly consist of collagen bundles with 
dispersed melanocytes and elastic fibers 4. The sclera is a porous tissue and hence 
permeability of molecules have been observed to be inversely proportional to molecular 
weight5. In addition, as these porous channels are filled with water, transport of hydrophilic 
molecules is favored over hydrophobic ones5.  
Choroid: It is sandwiched layer between retina and sclera. This layer is a highly vascularized 
tissue. It is further sub divided into vessel layer, choriocapillaries and Bruch’s membrane. 
The vessel layer comprises of arteries and veins, whereas choriocapillaries, as the name 
suggests is a dense network of capillaries. Bruch’s membrane is situated between choroid and 
retinal-pigmented epithelium (RPE). It is composed of basal lamellae of RPE and the 
endothelial cells of choroid 6.  
Retina: It is a light sensitive tissue comprising of two major layers i.e. (RPE) and 
neurosensory retina. RPE is directly in contact with the light sensing neural cells rods and 
cones. These cells are further associated with bipolar and ganglionic cells. The optic nerve is 
linked with the ganglionic cells, which are further coupled to amacrine cells. RPE functions 
as a nutrient source to the retina via the choroid. It forms a tight junction flanked by the 
choroid and retina. RPE cells also aid in the elimination of damaged photoreceptors via 
phagocytosis. Inner part of the neurosensory retina mainly obtains its blood supply from the 
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retinal artery, whereas the outer portions fulfill their nutritional requirements by the 
choriocapillaries 6a. 
Vitreous humor: It is a hydrogel matrix, localized between retina and lens. This matrix is 
separated from the anterior segment by anterior hyaloids membrane and is linked through 
ligaments to the retina. The vitreous consists of hyaluronic acid and collagen fibrils. 
However, cortical region contains dispersed hyalocytes. Vitreous humor is about 98 to 99.7% 
water and pH is around 7.5 7.  
1.2. Barriers to ocular drug delivery (ODD) 8 
Bioavailability of a dosage form in general is the percentage of the drug that absorbs 
and reaches the potential site of action regardless of the route of administration. The US Food 
and Drug Administration defines bioavailability as “the rate and extent to which the active 
ingredient or active moiety is absorbed from a drug product and becomes available at the site 
of action. For drug products that are not intended to be absorbed into the bloodstream, 
bioavailability may be assessed by measurements intended to reflect the rate and extent to 
which the active ingredient or active moiety becomes available at the site of action.”  Since 
pharmacological response is related to the amount of drug at the site of action, the availability 
of a drug from a formulation plays a critical role in deciding its clinical efficacy. However, 
the amount of drug normally cannot be measured directly at the site of action. Hence, most of 
the bioavailability studies involve the determination of drug concentration in the blood or 
urine assuming that the drug at the site of action is in equilibrium with the drug in the blood 9. 
Even though bioavailability is often interpreted as the percentage of the drug absorbed into 
the bloodstream, the blood levels in topical delivery (such as ophthalmic and dermatologic 
delivery) are generally used only to monitor side effects and toxicities and not as an 
indication of therapeutic efficacy.  
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For ocular considerations, both systemic and ocular bioavailability is important as 
ophthalmologists use both systemic and topical medications. However, a number of 
medications given orally to treat ocular infections is considerably less as most of the dosage 
forms are given either topically or by other drug delivery systems like site-specific injections. 
Some of the medications given intravenously suffer from poor ocular bioavailability and 
result in systemic side effects. Ocular drug delivery can be broadly classified into anterior 
segment drug delivery and posterior segment drug delivery. Understanding of the anatomical 
features of both these segments of the eye is vital in enhancing the efficacy of the drug 
product and bypassing the ocular barriers, which can negatively affect the bioavailability of 
the formulation.  
In spite of continued investigation of new drug delivery systems and frequent 
introduction of novel ophthalmic drugs, ocular drug delivery does not seem to progress at the 
same pace, which is typical of other delivery systems, such as oral, transdermal or 
transmucosal. The ocular delivery systems normally suffer from low bioavailability, poor 
patient compliance and systemic side effects. Poor bioavailability of formulations delivered 
topically to the anterior segment of the eye is due to efficient protective mechanisms, which 
ensure the proper functioning of the eye. It is also due to other concomitant factors such as 
short residence time as a result of rapid and efficient drainage by the nasolacrimal apparatus; 
non-corneal absorption; and relative impermeability of the cornea to both hydrophilic and 
hydrophobic molecules. Because of these mechanisms and factors, the rate of drug loss from 
the ocular surface can be 500 to 700 times greater than the rate of absorption into the anterior 
chamber, and 1-5% or less of the drug from the topically applied solutions reaches the 
anterior segment. Drug delivery to the posterior segment itself is a great challenge along with 
ocular bioavailability considerations. 
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Inefficiency of the current ocular drug products and an increased understanding of 
ocular drug absorption mechanisms have spurred researchers to design novel ways to enhance 
ocular bioavailability. Various approaches to increase the ocular bioavailability following 
topical instillation can broadly be divided into two categories. The first one is based on the 
use of sustained and novel drug delivery systems, such as implants, microspheres, 
nanoparticles, liposomes, in-situ gels, collagen shields, etc. These carriers prolong the 
precorneal residence time and provide the continuous and controlled delivery of drugs. The 
second approach involves maximizing corneal drug absorption/penetration by different 
strategies such co-administration of therapeutic agents and rational prodrug derivatization, 
which can improve the physicochemical properties of the active moiety and has the potential 
to bypass the efflux pumps. Prodrugs can further be targeted to influx transporters present on 
the ocular surfaces.  
Entry of drugs into the ocular tissues is restricted because of its unique anatomy and 
physiology. Several factors such as precorneal clearance of drugs, low corneal permeability 
and blood ocular barrier (BOB) deter the ocular bioavailability. These factors will be 
discussed in the following section.  
Precorneal factors 
Topically instilled conventional dosage forms have a very short precorneal residence 
time and poor ocular bioavailability (less than 5%). It is attributed to precorneal factors such 
as tear film, tear drainage, dilution by tear flow, reflux blinking and drainage of the 
formulation due to gravity. Upon instillation, the drug solution is diluted due to lachrymal 
secretion and tear flow. As most of the drugs cross the cornea by simple diffusion, the tear 
dilution decreases the concentration gradient, which is the driving force for passive 
absorption of drugs. Therefore, repeated administration is desired to maintain therapeutic 
drug level. Tears deliver the majority of nutrition and oxygen to cornea and remove the 
8 
 
metabolic waste of avascular corneal epithelium and anterior stroma 10. In an anatomical 
perspective, tear film is composed of three layers namely the inner most mucin film, middle 
aqueous layer and the outer oily layer that retards the evaporation of the water from tear film. 
Lachrymal gland contributes to the aqueous portion of tear film, goblet cells of conjunctiva 
provide mucin and meibomian gland in the eyelid supplies oil. The action of blinking 
continuously maintains tear film and drainage ducts present in the eye removes the excess 
tear. Aston et al. studied permeability of β-blockers across cornea and conjunctiva and found 
that the conjunctival permeability was higher for all the drugs used than the corneal 
permeability 11. It was inferred that tear film, in conjunction with cornea, limits the 
permeability of drugs12. 
While using topical instillation, a considerable amount of drug is lost through reflux 
blinking and reflux tearing. This phenomenon occurs because of some discomfort or irritation 
to the eye when the patient instills the formulation. The reasons for this discomfort or 
irritation can be a component of the formulation, pH of the formulation, osmolarity difference 
etc. When the drop volume is high, the nasolacrimal drainage and drainage due to gravity are 
the major pathways by which the drug is lost. 
Cornea as a barrier 
Cornea is 1 mm thick near limbus and 0.5 mm thick in the center 13. For the drugs 
instilled topically, the corneal route is considered as a major route for the absorption, despite 
of its poor permeability. Steroids, like dexamethasone are used for various ocular diseases, 
and have a poor corneal permeability. In an in vitro transport experiment, using excised rabbit 
corneas, the permeability of dexamethasone was found to be 5x10-6 cm/sec. Poor 
permeability is due to the corneal epithelium, which has inter-cellular tight junctions. 
However, dexamethasone acetate, which is a prodrug, had permeability of 3.7x10-5 cm/sec 14 
15. Most drugs cross the cornea by simple diffusion via paracellular or transcellular route. 
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However, there are distinct pathways for drug transport for hydrophilic and lipophilic drugs. 
Hydrophilic drugs were found more in intercellular spaces and lipophilic drugs were found 
more in lipid structures of the cells. This means that hydrophilic molecules prefer the 
paracellular route and the lipophilic molecules prefer the transcellular route 16. Cornea 
consists of five different layers, namely corneal epithelium, bowman’s membrane, corneal 
stroma, Descemet’s membrane and endothelium 13. The paracellular resistance across rabbit 
cornea is reported to be 12-16 kΩcm2 17. Presence of these tight junctions makes the cornea a 
formidable barrier for the ionized molecules 18. The Bowman’s membrane is an acellular 
layer and divides epithelium and stroma. It is made up of collagen fibers and has a thickness 
of 8 to 14 µm. This layer makes a strong barrier. The corneal stroma is also composed of 
collagen fibers and has greatest thickness of all the layers. Unlike the Bowman’s membrane 
and the corneal epithelium, this layer is hydrophilic and porous allowing rapid movement of 
hydrophilic molecules. Nevertheless, for the macromolecules and lipophilic drugs, it is a 
considerable barrier. Descemet’s membrane is a basement membrane for corneal endothelium 
which is a one cell layer thick (5-10 µm) with phospholipids as a major content. The 
endothelium is in direct contact with the aqueous humor and control the movement of 
molecules from aqueous humor to the stroma. The cells of this layer also have high 
enzymatic activity. Due to phospholipids as a major constituent, endothelium is permeable to 
lipophilic molecules and nearly impermeable to ions.18-19 
In summary, the corneal stroma is hydrophilic and allows the free passage of 
hydrophilic molecules and the epithelium is lipophilic and permits the passage of lipophilic 
molecules. The Descemet’s membrane prefers hydrophobic molecules. Overall, the cornea as 
a whole is a formidable barrier for transport of drug, as it comprises of multiple layers with 
hydrophilic and hydrophobic character. Molecule must possess optimal solubility in both oil 
and water as well as should be in non-ionized form to be able to permeate through cornea.  
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Blood ocular barrier 
The blood ocular barrier is a major barrier for the entry of the drug in to the eye and 
removal of the drug from the eye after systemic administration. BOB is comprised of blood 
aqueous barrier (BAB) and blood retinal barrier (BRB). These barriers are present to provide 
an immune privilege site to the delicate eye tissues. They restrict the entry of the pathogenic 
molecules into the eye and protect from the possibility of inflammation and tissue damage to 
the sensitive structures like retina and neurons. Overall, they control the movement of 
nutritional products, metabolic wastes and exogenous molecules and maintain an 
environment in which the visual cycle can work efficiently. The BAB is present in the 
anterior segment. The non-pigmented cell layer of ciliary epithelium and endothelial cells of 
blood vessels supplied to the iris, together constitute the BAB. Both these cellular layers have 
intercellular tight junctions. BAB is not considered as a complete barrier like BRB because of 
the fenestrated capillaries present on the ciliary processes. These capillaries are highly 
permeable and allow the passage of molecules with molecular weight 40 kDa, which cannot 
pass through the iris blood vessels20.  The permeation of substances across the iris blood 
vessel from the aqueous humor is less restrictive and the iris tissue is quite porous. Therefore, 
the drugs present in the aqueous humor, especially small and lipophilic ones can easily enter 
the circulation and be eliminated from the anterior chamber21.  
BRB is present in the posterior segment and prevents the entry of the drug molecules 
from the blood circulation into the retina. The BRB is further divided into inner BRB and 
outer BRB. The outer BRB is formed by the monolayer of retinal-pigmented epithelium 
(RPE), which separates the neural retina from the choroidal blood circulation (Figure 1-2) 22. 
Neural retina is firmly attached to the RPE that plays a major role in maintaining the viability 
of the retinal photoreceptors.  
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Figure 1-2 Schematic representation of inner BRB and outer BRB. 
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In nutshell, RPE is responsible for removal of the waste product of retina from subretinal 
space, retinoid transport and metabolism, absorption of light, synthesis of growth factors, 
enzymes and pigments, immunological role and very selectively allow the passage of 
nutritional molecules to retina from choroidal circulation.  
The inner BRB is composed of the tight junctions between the endothelial cells of the 
retinal blood vessels (Figure 1-2). These endothelial cells separate the blood and the neural 
retina. The tight junctions are made up of proteins like zonulae occludente present between 
the endothelial cells 23. The glial cells like Müller cells and astrocytes also cover the retinal 
blood vessels and generate the signals to stimulate the barrier properties of endothelial cells 
24. Anatomically, the inner BRB is quite similar to the blood brain barrier (BBB). In 
comparison to BBB, the inner BRB has more density of tight junctions and pericytes 25. Due 
to presence of higher amount of pericytes, the retinal blood vessel permeability was 4 times 
more than that of brain 25. The glial cells and the tight junctions of the endothelial cells 
together limit the entry of drugs into the retina through paracellular route and protect the 
neural retina 26. BAB and BRB play an important role in limiting the bioavailability of 
systemic or periocular routes such as subconjunctival route, which are usually employed to 
overcome the limitations of topical route. Apart from acting as a physiological barrier, these 
ocular structures (especially cornea, inner BRB and RPE) also express some influx 
transporters, like peptide transporter, and efflux transporters like ATP binding cassette 
proteins. Transporters can increase or decrease the drug permeation and modulate the 
bioavailability and will be discussed in a separate section.   
1.3. Routes of drug delivery 8 
Four modes of administration can be employed for drug delivery to the eye: topical, 
systemic, intraocular and periocular (including subconjunctival, Sub-Tenon’s, retrobulbar and 
peribulbar) 27. Figure 1-3 shows the various routes for Ocular drug delivery.  
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Figure 1-3 Schematic representation of local routes for ocular drug delivery. 
14 
 
Topical route 
Topical route is the most common route to deliver medications for treating both 
surface and intraocular conditions. This route is often preferred over other routes for 
management of various pathological diseases affecting anterior chamber (i.e. cornea, 
conjunctiva, sclera, anterior uvea). Three reasons account for this: (a) convenience in 
administration (b) higher ratio of ocular to systemic drug level and (c) cost affordability. 
Solutions, emulsions, suspensions, ointments, and rate-control release systems (devices) are 
commonly used dosage forms administered by topical route 28. Drug levels in intraocular 
tissues such as uveal track (choroid, iris and retina) is low due to precorneal factors and 
barrier properties of the cornea. Corneal and non-corneal (trans-scleral) are the two common 
routes of drug absorption following topical administration. Non-corneal/trans-scleral route 
specifically involves drug movement across the conjunctiva and sclera 28. Corneal absorption 
is the main pathway for most ophthalmic drugs and it is considered to be a rate-limiting 
process due to the presence of corneal epithelium 29. Lipophilicity and presence of tight 
junctions around the corneal epithelium cells reduces the entry of hydrophilic drug molecules 
into the corneal stroma. However, breaking tight epithelium junctions (e.g. by benzalkonium 
chloride) is one possible way of increasing hydrophilic drug penetration inside the stroma by 
paracellular pathway. On the other hand, lipophilic drug substances cross the corneal 
epithelium with ease but penetration into the hydrophilic corneal stroma is difficult 29. 
However, in most of the pathological conditions, like intraocular inflammation and  
glaucoma, drug penetration into intraocular tissues is desirable 30. 
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Figure 1-4 Pathways of absorption of drug into the eye following topical instillation. (a) 
Corneal pathway. Drugs transport through the cornea via passivie diffusion. Molecule 
must possess a balanced lipophilicity and hydrophilicity to have higher permeability. The 
drug transported across the cornea enters the aqueous humor, which is eliminated due to 
high aqueous humor turnover. Moreover, les is known to be lease permeable to drugs. (b) 
trans-corenal pathway. The conjucntiva and sclera are more permeable tissues compared 
to the corena. Once the drug crosses the sclera and enters the intraocular tissues, it may 
distribute in the surrounding tissues by diffusion.   
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Another path involves penetration across the conjunctiva and sclera (non-corneal 
route) into the intraocular tissues. However, it is a minor absorption pathway compared to the 
corneal route due to the presence of the local capillary beds that remove the drug from target 
sites into the blood circulation 31. The conjunctival epithelium is a weaker barrier compared 
to the corneal epithelium. The rest that enters the sclera seems to have rather good access into 
the eye. The poorly vascularized sclera is significantly more permeable than the cornea. In 
general, the sclera does not form a very tight barrier to penetration of the solutes even of 
relatively large molecular weight 30-31. Thus, ophthalmic drugs can be absorbed from 
conjunctiva and delivered to the eye via the sclera. However, drainage loss through blood 
vessels of the conjunctiva can greatly affect the conjunctival/scleral pathway. Nevertheless, it 
should be noted that the conjunctival epithelium is the most viable route for ocular delivery 
of peptides and oligonucleotides 32. It is much harder to deliver drugs to the posterior segment 
because of membrane barriers. These barriers, in conjunction with nasolacrimal drainage of 
administered drops, drug metabolism, protein binding, lens barrier and long diffusional path 
lengths result in poor drug delivery to the retina following topical administration 33. 
Moreover, the passage of drugs from the anterior segment to the posterior segment does not 
appear to be an efficient strategy because of the continuous drainage of the aqueous humor 
(i.e. a turnover of 2-3 mL/min). Thus, locally used ophthalmic therapies failed to provide an 
efficient pharmacological effect in the posterior segment (e.g. retina and vitreous) 31. Many 
efforts have been directed towards enhancing the corneal permeability of the drug following 
topical administration. The application of high concentrations of penetration enhancer to 
increase the bioavailability may cause mucosal irritation and corneal abrasion, leading to 
toxicological complications.  
The volume of the solution that can be instilled in the precorneal area is also limited. 
The eyelid and the conjunctival sac can take up a limited amount of the instilled solution. The 
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volume that the precorneal area can accommodate is ~50 µL. When instilled volume is more 
than 50 µL, the excess solution is removed from the precorneal area via nasolacrimal duct 
and the amount of drug in that volume of fluid is lost. Both in the nasolacrimal duct and in 
the nasopharynx, the drug can be absorbed systemically through the mucosa, avoiding 
presystemic hepatic first-pass metabolism34. Moreover, when the volume is more than the 
maximum volume, the reflux blinking and tearing remove the excess volume. The normal 
tear volume is restored within 2-3 min and the excess volume is lost within 20-30 sec by 
precorneal factors35. Higher the volume of drop instilled, more rapidly it will be lost via 
nasolacrimal duct system34b, 34c, 36. As the instilled volume is increased, more amount of drug 
is removed through nasolacrimal duct. When the instilled volume is very low, it may be 
diluted in the tear fluid, decreasing drug effect. 0.5% tropicamide, at drop volume of 5 µL 
produced less mydriasis than the one with 16 µL 37.  
In summary, drug absorption is limited to 5% at best following topical application due 
to precorneal and corneal barriers. Nonetheless, it is most patient compliant route.  As ocular 
barriers and the physicochemical properties of drug molecules govern drug availability in the 
anterior and posterior segment, research should be directed towards surpassing these barriers 
by novel routes of administration and/or altering the properties of drug molecules 27.   
Systemic route 
Drugs administered systemically (e.g. through the oral or intravenous route) also have 
poor access to the aqueous humor and the vitreous 30.  Ocular bioavailability of systemically 
administered drugs depends on the drug concentration gradient between serum and ocular 
tissues and as well as blood-ocular barrier characteristics. The limitations of this route for 
drug delivery are poor ocular bioavailability due to BOB and systemic toxicity.   
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Intraocular injection 
Intraocular injections may be either intracameral or intravitreal. Injections that are 
made into the aqueous humor of the eye may be referred to as intracameral injection, whereas 
injections into vitreous humor are referred to as intravitreal injection.  
Intracameral injection:  
This route may be sought for intraocular antibiotic therapy. Up to 100 µL volume in human 
can be injected in this route. Intracameral injections are used in cataract surgery and for the 
management of disease afflicting the anterior segment. This route of administration fails to 
deliver significant concentrations of drugs to the posterior segment. Since the trauma 
associated with this injection may severely damage the eye, this can be the last resort in 
controlling severe infections of the eye28, 33.  
Intravitreal injection:  
Drug access into the vitreous is desirable in various infections and inflammations. Examples 
of such situations are infection of the vitreous in endophthalmitis and various 
vitreoretinopathies. However, access of drugs into the vitreous is usually poor because there 
is virtually no penetration through the crystalline lens or between the ciliary process and 
crystalline lens. In addition to this, there is no satisfactory access from the blood vessels into 
the retina due to the pigment epithelium 30. Thus, the only remaining route will be by direct 
injection of drug into the posterior segment through the pars plana, evading all the barriers. 
Studies have been carried out to evaluate the pharmacokinetic parameters of intravitreal 
injections of antiviral agents such as: ganciclovir, foscarnet and sidofovir; antibiotics such as 
cefazolin, amikacin, moxifloxacin, ceftizoxime, ceftrioxone, ceftazidime and monoclonal 
antibodies such as rituximab, bevacizumab 27. 
It is noteworthy that the elimination half-life of drugs increases with molecular weight 
in the vitreous 33. Large molecules (linear molecules > 40kDa and globular molecule 
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>70kDa) tend to have longer retention times due to the tight barrier that surround the vitreous 
humor. This route of administration is more suitable for drugs with high molecular weight 
(>500Da) and longer half-life 27. On the other hand, in the plasma, peptide and protein drugs 
exhibit short elimination half-life 33. Due to this unique vitreal clearance property, drug 
therapy via intravitreal injection seems to be a viable option, as reported for treatment of age-
related macular degeneration (AMD) with the anti-vascular endothelial growth factor 
(VEGF) therapies, using pegaptanib (Macugen®), ranibizumab (Lucentis®) and 
bevacizumab (Avastin®) 31. Although drug delivery through intravitreal injection can achieve 
higher concentration in the neural retina, adverse effects such as retinal detachment from 
repeated injections, retinal hemorrhage, endophthalmitis, cataracts and other retinal toxicities 
due to high concentration upon bolus dose administration may result in patient incompliance. 
Ausayakhun et al. studied the efficiency and complications of intravitreal ganciclovir (2 mg 
in 0.1 mL per injection) to control CMV retinitis. The results indicated that 60% of the 
treated eyes remained stable, 13% showed improvement and 26% showed a decrease in 
visual acuity. Moreover, retinal detachment was observed in 6%, intravitreal hemorrhages in 
1% and endophthalmitis in 1% of treated eyes. This study clearly demonstrates the 
complications of the intravitreal injection that should be taken into consideration. Several 
studies were carried out on similar lines, which suggest that intravitreal injection, although 
useful, may not be ideal strategy for posterior segment diseases. Advancement in drug 
delivery system design and surgical techniques have led lead to the development of 
intravitreal implants that can be placed inside the vitreous to deliver constant drug levels over 
prolonged periods. Unlike single intravitreal injections administered 2 or 3 times a week, 
intravitreal implants can be conveniently replaced every 6 months. More about ocular 
implants will be discussed separately in this chapter. 
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Periocular injection  
Periocular region is the region surrounding the eye. Among existing routes, it is the 
most efficient and least painful route of drug delivery. Periocular injection is used when eye 
drops alone are not effective enough for treatment of eye inflammation and additional help is 
required. The drug is usually injected in close proximity to sclera in the posterior segment. 
Drugs delivered by this route can reach to the sclera, choroid, vitreous, retinal pigment 
epithelium, and neural retina. Peribulbar, retrobulbar, subconjunctival and Sub-Tenon’s 
injections are frequently used approaches offered by periocular route for drug delivery in to 
the eye. Time to reach drug vitreal level depends on available drug concentration and the 
intermittent barrier layers between target site and site of drug administration27, 33. Lack of 
efficacy, convenience and safety are few drawbacks of periocular route due to which it is yet 
not considered as a first line treatment and still serve as an additive to topical drug therapy 38.  
Subconjunctival injection:  
The outer sclera is covered by conjunctival membrane. Drug injection beneath the 
conjunctiva is a less invasive localized delivery technique for posterior eye segment. The 
potential reasons to give subconjunctival injection is to achieve high drug concentration at the 
target site along with better drug diffusion into the conjunctival, subconjunctival and scleral 
tissues. Larger surrounding area can be treated by subconjunctival injection rather than the 
wound margin alone which prevents migration of cell to the sclerectomy site from the 
surrounding area in filtering procedure.39 Pinilla et al. have demonstrated that low dose of 
mitomycin C by subconjunctival injection delays the fibroblastic proliferation from Tenon's 
capsule and scleral biopsies 39. It is easier and safer to perform subconjunctival injections as 
compared to Sub-Tenon’s. Routinely, subconjunctival injections of antibiotics are used to 
treat intraocular and severe corneal infections.  
Sub-Tenon’s injection:  
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The Tenon’s capsule is a facial sheath of connective tissue sandwiched between the 
conjunctiva and episcleral plexus. The episcleral or subtenon’s space is a void between the 
Tenon’s capsule and sclera. Subtenon’s injection places the drug in contact with sclera for 
longer period due to its avascular nature. The posterior Tenon’s capsule has the tendency to 
degenerate with age, thus helping the diffusion of anesthetic into the retrobulbar cone. A drug 
solution administered by subtenon’s injection has the disadvantage of decreased molecular 
penetration through the sclera and choroid. Moreover, rapid removal of the drug by the 
choroidal circulation can result in shortened duration of action. It is considered to be the most 
promising route of targeting posterior segment 40. In sub-Tenon’s injections, the needle tip 
passes through the conjunctiva and Tenon’s capsule in the inferior cul-de-sac, entirely out of 
your view. Risk of perforating the globe with subconjunctival injections is minimal in well-
trained hands and with a cooperative patient. However, given the closer proximity to the 
interior of the eye, and the fact that it is a “blind” injection, a sub-Tenon’s injection carries a 
higher risk of globe penetration.  
Retrobulbar injection: 
Injections through the lower eyelid into muscles surrounding the eye are frequently 
employed for administration of anesthetic agents or for corticosteroid therapy in severe 
inflammation to the posterior segment of the globe 28. With retrobulbar injection, higher local 
concentrations can be achieved for anesthesia or akinesia of the globe during surgery, and 
there is little to no influence on intraocular pressure 33. Retrobulbar injection involves 
deposition of drug solution into retrobulbar space within the muscle cone. This route is 
preferred when the medication needs to be in direct contact with macular region. Such 
injections are usually given with a special 23-gauge sharp 1.5-inch needle with a rounded tip 
and a 100 bend. The needle is introduced in the quadrant between the inferior and the lateral 
rectus muscles and directed posteriorly until orbital septum resists its penetration; the needle 
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is directed towards the apex of orbit and penetrated until it meets the resistance of 
intermuscular septum. Following penetration through this structure, the needle reaches the 
retrobulbar space, which can take 2-3 mL of solution. Care should be taken to minimize 
needle movement to prevent possible laceration of the blood vessels. Pressure should be 
applied on the globe to distribute the anesthetic effect and to ensure homeostasis 41. 
Retrobulbar injection of drugs may result in penetration through the sclera but the highly 
vascularized choroid will be a physiological barrier and finally the pigment epithelium will 
hinder the movement of drug into the retina and the vitreous 30.   
Peribulbar injection:  
Peribulbar injection has been devised to lower the risk of injury to intraorbital 
structures associated with retrobulbar administration during cataract surgery. The injection is 
made in the inferior lateral quadrant of the orbit using a 26-gauge half-inch disposable needle 
42. Peribulbar injection can be classified as circum-ocular (sub-tenon’s, episcleral); peri-
ocular (anterior, superficial); peri-conal (posterior, deep) and epical (ultra deep); based on the 
depth of the needle 43. Comparable clinical efficacy using the retrobulbar and peribulbar 
techniques have been reported 44. A total of 8-10 mL of anesthetic solution (mixture) can be 
injected in both sites. The peribulbar route is less effective than the retrobulbar route in 
anesthetizing the globe. However, it is the safer mode of administration. Although, peribulbar 
and retrobulbar injections are proven to be useful in analgesia, akinesia, the control of 
intraocular pressure and postoperative analgesia, complications such as diplopia, orbital 
hemorrhage, artery occlusion, brainstem anesthesia, optic nerve trauma and apoptosis have 
been reported 27.  
1.4. Micelles for topical ocular drug delivery45 
Micelles consists of amphiphilic molecules that, generally, self-assemble in aqueous 
media to form organized supramolecular structures. Micelles are formed in various size 
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(10nm to 1000nm) and shapes (spherical, cylindrical and star-shaped, etc.) depending on the 
molecular weights of the core and corona forming blocks. The self-assembly take place above 
certain concentration, referred to as critical micelle concentration (CMC). A schematic 
representation of micelle formation with amphiphilic polymers or surfactants is shown in the 
Figure 1-5. The force driving the self-assembly and maintenance of supramolecular assembly 
is hydrophobic interactions of core forming blocks, for typical micellar structures. The 
corona-forming block is water-soluble that renders micelles soluble in aqueous phase. Taking 
the advantage of hydrophobic core, these nanocarriers can been utilized to enhance the water 
solubility of hydrophobic molecules. Nanomicelles investigated for topical ODD thus far can 
be divided into two broad categories i.e., polymeric and surfactant micelles. The typical 
surfactant micelles are characterized by higher CMC where a dynamic equilibrium exists 
between micelle aggregates and unimers in the solution. Micellar aggregates formed by 
surfactants are weak and susceptible to physical instability upon dilution. In contrast, 
polymeric nanomicelles exhibit lower CMC and better stability against dilutions. 
Hydrophobic drugs are encapsulated in the nanomicelle core by hydrophobic interaction. 
Other interactions, such as van der Waals' forces and hydrogen bonding may also contribute 
to the encapsulation in micelle core. Selection of the type of nanomicelle carrier is dependent 
on the physicochemical properties of drug molecule, drug:polymer or drug:surfactant 
interactions, site of action, rate of drug release, biocompatibility and physical stability. A 
summary of micellar formulation investigated for ODD is presented in Table 1-1. 
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Figure 1-5 Schematic representation of micelle formation with amphiphilic polymers or 
surfactants. Hydrophobic block is driving force behind aggregation and hydrophilic block 
forms corona aiding solubilization of supramolecular assembly. Hydrophobic agents may 
be entrapped inside the core of micelle.  
Polymer Drug 
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1.4.1. Polymeric Nanomicelles 
Polymeric nanomicelles are formed by amphiphilic polymers with distinct 
hydrophobic and hydrophilic segments.  The polymer self-assemble to form micelles in 
aqueous solution, wherein water insoluble segment forms the core and hydrophilic segment 
forms the corona. In some cases, the self-assembly is not spontaneous and micelle formation 
is assisted by additional means, such as temperature46. The self-assembly occurs above the 
CMC. The hydrophilic segments forming corona aid the solubilization of entire 
supramolecular structure. Polymeric micelles are characterized by their low CMC in addition 
to excellent kinetic and thermodynamic stability in solution. Ideally, the polymers utilized to 
prepared nanomicelles should be biodegradable and/or biocompatible. The most widely 
studied core-forming polymers are poly(lactide), poly(propylene oxide) (PPO), 
poly(glycolide), poly(lactide-co-glycolide), and poly(ε-caprolactone) (PCL). Poly(ethylene 
glycol) (PEG) is the most frequently utilized hydrophilic segment due to its excellent water 
solubility and biocompatibility. Other polymers exploited for ODD include poloxamine 47, 
chitosan 48, chitosan/F127 49 and poly(ethylene glycol)–poly(hexyl-lactide) (mPEG-hexPLA) 
50.  Biodegradation of polymer ensures elimination of inactive polymer from ocular tissues. 
However, the degradation products should not be toxic or inflammatory to the sensitive 
ocular tissues particularly the neural retina. 
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Table 1-1 Summary of nanomicelle/micelle systems investigated thus far for ocular drug delivery. 
Polymer/ 
Surfactant 
Therapeutic 
agent 
Size  PDI 
Surface 
charge 
Remarks 
Refere
nce 
Pluronic F127 Pilocarpine  23.3 ± 0.5 nm (in 
DDI water), 
30.3 ± 0.3 nm (in 
buffer, pH 7.4) 
NR NR 64% increase in AUC along with significantly 
prolonged miotic activity with nanomicelles. 
51 
Poloxamine 
(Tetronic® 1107) 
 α-Tocopherol 30–40 nm 0.475 NR Micelles were stable for months at 4 oC 52 
Poloxamines 
(Tetronic® T908, 
T1107 and 
T1307) 
Ethoxzolamide Multimodal size 
distribution 
 
NR NR Tunable drug release profile was achieved with 
mixed micelle system.  
 
47 
MPEG–hexPLA Cyclosporin A 54 ± 1 nm 0.229 ± 
0.008 
NR The polymer well tolerated in in rabbits. In vivo 
transcorneal permeability was improved and 
nanomicelle formulation was significantly 
efficacious in preventing corneal graft rejection.  
53 
mPEG-PDLLA Pirenzepine 
hydrochloride 
 
PEG/PL
A wt 
ratio 
Size 
(nm) 
NR NR In vivo biocompatibility study in rabbits 
exhibited on significant toxicity for 9 months. 
Intraoculer levels of Pirenzepine hydrochloride 
following topical instillation were enhanced 
with nanomicelles. 
54 
80/20 152.5 
50/50 89.6  
40/60 50.2 
Pluronic F127 
with Chitosan  
Dexamethasone 25.4 - 28.9nm 0.39-
0.54 
+9.3 to 
+17.6 
mV 
In vitro permeability increased with increase in 
chitosan concentration. Improved in vivo 
bioavailability. 
48 
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Table 1-1 Summary of nanomicelle/micelle systems investigated thus far for ocular drug delivery. 
 
Pluronic F127 
with Chitosan 
(0.3-0.8%) 
metipranolol 123–232 nm 0.117-
0.157 
+6.1 to 
+9.2 mV 
Pharmacological response significantly 
improved upon incorporation of chitosan. 
55 
Crosslinked 
micelles made of 
NIPAAM, VP, 
and MAA with 
MBA and 
TEGDMA as 
cross linking 
agents 
Dexamethasone 300–450 nm NR NR Micelles exhibited very high entrapment 
efficiency and bioadhesive properties. It also 
resulted in higher anti-inflammatory activity for 
an extended duration. 
56 
mPEG-PCL Dexamethasone 28 nm NR 0.135 Aqueous solubility of dexamethasone was 
increased up to 1.36mg/mL. The nanomicelle 
enhanced dexamethasone permeability across 
the excised rabbit sclera by 2.5-fold. 
46 
Crosslinked 
micelles made of 
NIPAAM, VP 
and AA having 
cross-linked with 
MBA 
Ketorolac (free 
acid) 
35 nm NR NR A 2-fold increase in permeability was observed 
across excised rabbit cornea. Nanomicelles 
significantly improved In vivo ocular anti-
inflammatory activity. 
57 
Quaternary 
ammonium 
palmitoyl glycol 
chitosan 
Prednisolone 10-100 nm NR NR A significantly higher aqueous humor levels 
were achieved with formulation following 
single topical instillation.  
58 
Flt1 peptide-
hyaluronate (HA) 
conjugates 
Genistein 172.0 ± 18.7 nm 0.25 ± 
0.11 
–23.4 ± 
5.1 mV 
A significant suppression of corneal 
neovascularization was observed in silver 
nitrate cauterized corneas of rats. The retinal 
vascular hyper-permeability was reduced in 
diabetic retinopathy model rats. 
59 
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Table 1-1 Summary of nanomicelle/micelle systems investigated thus far for ocular drug delivery. 
PEG-P(Asp) FITC-P(Lys) 50.7 nm 0.046 NR PIC micelles specifically accumulated in CNV 
lesions following tail 
Injection in rat CNV model. 
 
PEO-PPO-PEO Mechanistic 
study with model 
plasmid 
DNA with lacZ 
gene 
155 ± 44 nm NR -4.4 ± 2.0 
mV 
Micelle significantly enhanced In vivo gene 
transfer efficiency to ocular tissues in rabbit and 
nude mice models. Endocytosis was delineated 
as major transport mechanism for micelles. 
60 
Polyethylene 
glycol 40 stearate 
Cyclosporine A 200 nm NR NR A significantly higher Cyclosporine A level in 
the cornea, conjunctiva, and lacrimal gland 
were found with micelles. 
61 
Sympatens AS Cyclosporine A 9.7 ± 0.05 nm, <0.1 −0.4 ± 
0.1 mV 
Nanomicelles enhanced corneal levels of 
cyclosporine A following topical dose 
compared to Restasis®. 
62 
PHEA-PEG5000-
C16  
Dexamethasone 
alcohol 
10-30 nm NR NR Nanomicelle formulation enhanced in vivo 
bioavailability of dexamethasone alcohol in 
rabbits. 
63 
Sympatens AS 
and Sympatens 
ACS 
Cyclosporine A 9-12 nm <0.16 neutral In the porcine in situ model (ex vivo), 
remarkably high cyclosporine A levels in the 
cornea were observed  for the nanomicellar 
solution 
64 
NR= Not reported 
mPEG-PDLLA = Methoxy poly(ethylene glycol)–poly(D,L-lactide)  
mPEG–hexPLA = Methoxy poly(ethylene glycol)-hexylsubstituted 
poly(lactide) 
mPEG-PCL = Methoxy poly(ethylene glycol)-polycaprolactone 
AUC = Area under curve 
NIPAAM = N-isopropylacrylamide 
AA = Acrylic acid 
MBA = N,N’-methylene bis-acrylamide 
TEGDMA = Triethyleneglycol dimethacrylate 
Flt1 peptide = Sequence GNQWFI 
PHEA= Polyhydroxyethylaspartamide 
PEG = Poly(ethylene glycol) 
FITC-P(Lys) = Fluorescein isothiocyanate-labeled poly-L-lysine 
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VP = Vinyl pyrrolidone 
MAA = Methacrylate 
PEG-P(Asp) = polyethylene glycol-block-poly-K,L-aspartic acid) 
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Several important attributes must be deliberated to design a nanomicellar formulation for 
ODD rationally. Some of the important factors are site of action, polymer composition, drug 
loading, release rate, nanomicelle-tissue interaction, size and surface charge. Hydrophobic drug 
is encapsulated in the micelle core during or after micelle formation depending on the 
preparation method. The process involves hydrophobic interactions and/or hydrogen bond 
formation between drug and polymer. The most commonly used methods of micelles formation 
are direct dissolution, solvent evaporation, film hydration and dialysis method 65. Encapsulation 
efficiency in the micelle core depends on the method used to prepare the micelles and extent of 
drug-polymer interactions. Generally, methods like solvent evaporation and film hydration result 
in higher encapsulation efficiency than direct dissolution and dialysis methods 65-66. For example, 
aqueous solubility of biphenyl dimethyl dicarboxylate in mPEG2000-PLA1000 carrier system with 
film hydration method was 13.2 mg/mL compared to 2 mg/mL with dialysis method 67. Direct 
dissolution is the simplest method of preparation and may be easy to scale up. Depending on the 
type of polymer and drug-polymer interaction, this method may also be modified to eliminate the 
use of organic solvents like acetone or DMF that must be removed before clinical use. For 
example, honokiol was encapsulated in nanomicelles using direct dissolution methods without 
using organic solvents. Triblock co-polymer PCL-PEG-PCL was dissolved in water to form 
micelles by heating at 50 oC followed by entrapment of honokiol 68. Film hydration method can 
also be an alternative to direct dissolution method. Exposure of polymer-drug film for extended 
duration under vacuum could completely remove volatile organic solvents 35b.  
Stability of nanomicelles is very important for efficacious ODD. As mentioned earlier, 
polymeric nanomicelles are kinetically and thermodynamically more stable compared to low 
molecular weight surfactant micelles. The rate of dissociation of unimers from polymeric 
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micelles is slower making the micelles kinetically stable 69. Thermodynamic stability is achieved 
by interactions of core-forming blocks as well as the ability of hydrophilic block to solubilize the 
supramolecular structure. In addition, stability of nanomicelles may also improve upon 
incorporation of hydrophobic drug molecules 13.  
The mechanism of drug release from nanomicelles is dependent on the nature and 
strength of interactions between core-forming polymer and drug molecules, micelle stability in 
ocular tissues, polymer degradation and rate of diffusion of drug molecules from micelle core. 
Drug release should be tailored keeping the site of action in mind. For example, if the site of 
action is at precorneal area such as conjunctiva or cornea, drug release must take place in the 
precorneal space and the released drug may be absorbed, following topical administration. 
Nevertheless, nanomicelles must provide good precorneal retention time to avoid loss of 
formulation via precorneal clearance mechanisms. In a more productive absorption scenario, 
topically administered nanomicelles may be absorbed followed by release in the target tissue. 
Stability of nanomicelles in the precorneal environment and cell-micelle interactions may 
determine length of precorneal residence time. Volume of lachrymal fluid is 7 µL and normal 
tear turnover rate is 0.66 µL/min70. On the other hand, vitreous humor is relatively stagnant 
compartment and the release rate could be dependent on physically stability, polymer 
degradation rate and drug-polymer interaction. However, no nanomicelle systems has been able 
to provide sustained release for more than a few days. Thus, nanomicelles delivery via IVT route 
would require frequent administrations. Frequent IVT injections are not patient compliant and 
associated with various side effects such as endophthalmitis, retinal detachment and retinal 
haemorrhage. Hence, nanomicelle systems should be avoided for IVT administration. 
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Size of the nanomicelles are critical aspects of designing an ODD system. For polymeric 
micelles, size may be controlled by the molecular weight of the polymer and drug loading. 
Ocular disposition of nanomicelles following topical instillation may be influenced by the size of 
nanomicelles 71. Transport of nanocarriers such as nanoparticles have been reported to be 
dependent on the size i.e., smaller the size higher is the permeability of nanocarrier 71. 
Paracellular transport of nanomicelles across the conjunctiva and the sclera may result in higher 
drug levels in the intraocular tissues following topical administration. Nanomicelles of 
pilocarpine were developed with amphiphilic pluronic (F127, Mw 12,600) polymer72. Pluronic 
polymers are triblock co-polymers having hydrophilic PEG flanking the hydrophobic PPO. 
Above CMC, F127 forms nanomicelles of size ~17nm and ~23nm in DDI water and PBS buffer, 
respectively. In addition, incorporation of hydrophobic agents into micelle core also increased 
the micelle size. Nanomicelle size of ~30nm was observed for pilocarpine base loaded 
nanomicelles in PBS, pH 7.4. When these nanomicelles were examined for miotic response in 
female albino rabbits, a higher effect and longer duration of mitotic response was observed for 
pilocarpine base-loaded pluronic micelles. Such augmentation in mitotic response may be due to 
productive absorption of drug-loaded nanomicelles or released hydrophobic pilocarpine base 
form.    
The eye is a specialized and isolated organ where most nutrients are supplied via 
specialized transporter mechanisms. Sterility and biocompatibility are very important aspects 
that must be studied thoroughly before selecting the type of polymers and excipients. Polymeric 
micelles have been recently investigated for their potential as ODD. One advantage with 
nanomicellar carrier is that it can be easily filter sterilized to lower the endotoxin/microbial 
burden.  
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1.4.2. Surfactant Nanomicelles 
Amphiphilic molecules having a hydrophilic head and hydrophobic tail are commonly 
referred to as surfactants. Hydrophilic head of surfactant molecules can be dipolar/zwitterionic, 
charged or anionic/cationic, or neutral/non-ionic. Commonly used surfactants for nanomicellar 
formulation are sodium dodecyl sulphate (SDS, anionic surfactant), dodecyltrimethylammonium 
bromide (DTAB, cationic surfactant), ethylene oxide (N-dodecyl; tetra, C12E4), Vitamin E 
TPGS (d-alpha tocopheryl polyethylene glycol 1000 succinate), octoxynol-40 (non-ionic 
surfactants) and dioctanoyl phosphatidyl choline (zwitterionic surfactants). A hydrophobic tail 
commonly comprises of a long chain hydrocarbon and rarely includes a halogenated/oxygenated 
hydrocarbon/siloxane chain. 
Micelles are formed when surfactants are dissolved in water at concentration above 
CMC. A balance between intermolecular forces such as Van der Waals interactions, hydrogen 
bonding, hydrophobic, steric and electrostatic interactions are vital for nanomicellar formulation. 
Shape of nanomicelles i.e. spherical, cylindrical or planar/discs/bilayers depends on the non-
covalent aggregation of surfactant monomers. Alteration in the chemical structure of surfactant 
and conditions such as surfactant concentration, pH, temperature, ionic strength may determine 
the shape and size of nanomicelles. Transformation of nanomicelles can take place from one 
dimension into cylindrical micelles or two-dimension into bilayers/discoidal nanomicelles, which 
can be controlled by surfactant heads. Such transformation results from reduced forces of 
repulsion between the charged head groups. 
Nanomicellar formulation for the topical delivery of small as well as macromolecules has 
been exploited by several investigators. Surfactant nanomicellar formulation has been utilized for 
improving the diffusion of topically delivered drugs through cornea thus improving ocular 
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bioavailability. Luschmann C et al., developed a nanomicelle solution of cyclosporine A (CyA) 
containing non-ionic surfactants (Sympatens AS)62. The average size of formulated nanomicelles 
ranges between 9.7 and 10.1 nm. Nanomicelle solution showed no signs of ocular irritation. It 
may be considered as a seamless drug delivery system for administration of CyA to the anterior 
segment. It also exhibited high levels of CyA in cornea. The nanomicelle solution exhibited high 
levels of CyA (826±163 ng/gcornea), which exceeded the tissue levels reported for cationic 
emulsion of CyA (750 ng/gcornea) and Restatsis® (350 ng/gcornea). Therefore, nanomicelles of 
CyA promises an efficient method of treatment for inflammatory corneal diseases and may 
improve the patient compliance by reducing the number of instillations per day.  
Vadlapudi et al., developed a clear, aqueous nanomicellar formulation of biotinylated 
lipid prodrug for the treatment of corneal herpetic keratitis73. Non-ionic surfactants – vitamin E 
TPGS and octxynol-40 were selected to formulate micellar formulation of biotin-
12Hydroxystearic acid-acyclovir (B-12HS-ACV).  TEM analysis suggested that nanomicelles 
were spherical, homogenous and devoid of aggregates. The average size of formulated 
nanomicelles was 10.78 nm. No significant burst effect we reported for the release of B-12HS-
ACV from nanomicellar formulation. A sustained release of B-12HS-ACV from its nanomicellar 
formulation was observed for a period of 4 days as compared to 100% release of B-12HS-ACV 
in ~6 h from its ethanolic solution.   
Mitra et al. reported application of nanomicellar formulation for posterior segment 
delivery via topical administration74. Vitamin E TPGS and octoxynol-40 of different hydrophilic 
lipophilic balance (HLB) values were used to prepare aqueous mixed nanomicellar formulation 
of voclosporin in order to carry out initial studies. Rapamycin and DEX were also encapsulated 
in an aqueous nanomicellar formulation. Size of nanomicelles encapsulating voclosporin, 
 37 
 
rapamycin and DEX were in the range of 10-25 nm. Voclosporin aqueous mixed nanomicellar 
formulation (0.2%) efficacy was compared with Optimmune® (CyA ophthalmic ointment) in 
canine keratoconjuntivitis sicca model utilizing Schirmer tear test (tear production in an eye) and 
corneal observation as end points. The control values were found way below the threshold value 
(>15mm/min) whereas nanomicellar formulation maintains the value well above the threshold. 
No side effects were noticed with voclosporin nanomicellar formulation administered twice daily 
indicating its safety in animal model. Tolerability studies of nanomicellar formulations (0.02 and 
0.2%) against Restasis® was investigated in New Zealand White (NZW) rabbits. Ocular 
irritation was reported highest in Restasis® compared to voclosporin nanomicelle formulation. 
These results confirmed that voclosporin aqueous nanomicelle formulation is well tolerated and 
induce significantly less ocular irritation as compared to Restasis®. Voclosporin (0.2%) 
nanomicelle formulation showed no dose dependent side effect on particular function and 
histopathological ocular indices in 2 and 13-week studies carried out in NZW rabbits and beagle 
dogs. No toxicity with minimal systemic exposure and accumulation were observed with 
nanomicelle formulation. Anterior and posterior tissues were analysed for voclosporin levels 
following single and once daily drop instillation of nanomicellar formulation in NZW rabbits. 
High drug concentrations were reported in the posterior ocular tissues in relative to minimal 
and/or non-detectable drug levels in aqueous humor, lens and vitreous humor. Adverse effects 
such as increased intraocular pressure or cataract formation can be avoided with nanomicelle 
formulation due to the minimal drug levels in aqueous humor, lens and vitreous humor. Mixed 
nanomicellar aqueous formulations can be utilized to deliver therapeutic agents to the posterior 
ocular tissues via topical instillation. 
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Recently, DEX and rapamycin topical nanomicellar formulations were utilized for 
posterior ocular tissues delivery via non-invasive route 75. Encapsulation of DEX and rapamycin 
in nanomicellar formulation resulted in improved solubility of DEX and rapamycin by 6.7 and 
1000 times, respectively. Ocular tissue distribution studies revealed that 50 ng/g and 370 ng/g of 
DEX and rapamycin, respectively were detected in retina-choroid whereas minimal or no drug 
levels were detected in aqueous ocular chamber suggesting a non-corneal route of drug 
absorption to the posterior segment. 
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CHAPTER 2 
2. HYPOTHESIS AND RATIONALE 
2.1. Statement of the problem and Hypothesis 
Topical administration is the most patient compliant route. Nonetheless, drug delivery to 
intermediate and posterior segment via topical drops is a significant challenge. Less than 5% of 
topically administered dose reaches ocular segments (such as retina and vitreous) owning to 
static and dynamic barriers 76. Typical instillation volume for topically administered formulation 
is usually less than 40-50 µL, to avoid drug loss via reflux tearing and nasolacrimal drainage. 
Low instillation volume entails steroidal agents to be solubilized at higher concentration in 
aqueous solution in order to achieve therapeutic drug level in intermediate and/or posterior 
segments. However, steroids are hydrophobic in nature with poor aqueous solubility and cannot 
be dissolved at higher concentrations in aqueous solution.  
Nanocarriers such as liposomes and nanomicelles are capable of solubilizing highly 
hydrophobic drugs in aqueous medium 77. Micelles represent supramolecular arrangement of 
amphiphilic polymeric systems with typical size in range 10-100 nm. They have been 
investigated extensively to solubilize hydrophobic drugs. Polymeric micelles can be prepared 
with various di-block polymers consisting of hydrophobic and hydrophilic units. Transport of 
nanocarriers across the static and dynamic barriers may depend on the particle size 71. Recently, 
Inokuchi et al. have illustrated that the liposome size of ~110 nm resulted in higher coumarin-6 
accumulation in posterior segment following topical administration 78. A few examples of 
micelle for ODD are also available which delivered drug to the intraocular tissues following 
topical administration. Mixed micelle formulation of dexamethasone from our laboratory also 
resulted in significantly higher concentrations in the intraocular tissues. It was theorized that the 
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nanomicelle preferably follows transscleral pathway due to its hydrophilic surface to achieve 
higher concentrations in the posterior segment. Nanomicelles are gaining attention as potential 
drug delivery vehicle to deliver drugs to the intraocular tissues such as uvea following topical 
administration. The size of the nanocarrier, nanomicelles in this case, may be a major factor 
influencing the permeability of encapsulated therapeutic agents following topical administration. 
Therefore, it is important to delineate influence of nanomicelles size on permeability of drug 
across the sclera as trans-scleral may be the major route of permeation. We hypothesize that 
nanomicelles of mean size less than 50 nm may effectively overcome the conjunctival and scleral 
barriers to provide therapeutic drug concentration in the intermediate and posterior uvea.  
Rationale for using statistical design of experiments  
Recently, there has been a growing interest in utilizing design of experiment (DOE) to 
optimize formulation parameters. Experimental designs such as a 3-level response surface 
methodology may explain the influence of individual factors and their interactions on response 
variables. Typically, DOE is utilized to optimize formulation process parameter within a set 
range for individual factor. However, in our case we aim to use DOE methodology to identify the 
factors and interactions (drug-drug, polymer-drug and polymer-polymer) that may enhance or 
lower drug loading in nanomicelles. Based on information from exploratory model, we will 
modify the nanomicelle preparation method to optimize process thereby achieving higher 
aqueous solubility.  
Rationale for using dexamethasone (DEX) 
Uveitis is an intraocular inflammatory disease responsible for 10-15% blindness in 
developed countries 79. It affects intermediate and/or posterior segments involving sections of 
choroid and retina, which often results in blindness. Steroids have been a mainstay treatment 
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option for this inflammatory condition 76a, 80. Traditionally, steroids are administered by systemic 
routes. However, systemic administrations of steroid are not well tolerated by all patients 80c, 81. 
Topical drops of steroids are well tolerated but drug levels achieved in intermediate and posterior 
ocular segments are often subtherapeutic 80c, 81. In the past decade, clinically recalcitrant uveitis 
has been treated by steroids administered as intravitreal (IVT) injections 80b, 82. IVT injections are 
associated with numerous side effects including retinal detachment, endophthalmitis, cataract 
and elevated intraocular pressure 82a, 83. 
 
2.2. Objectives 
To test above-mentioned hypothesizes, we propose following specific aims.  
1. To synthesize and characterize di-block poly(ε-caprolactone)-block-monomethoxy-
poly(ethylene glycol) (PCL-mPEG) polymers of various molecular weight of PCL and PEG 
segments. An mPEG of molecular weight 750, 2000 and 5000 gm/mol will be employed in 
the synthesis of di-block polymers. Molecular weights of PCL block will be varied to control 
average nanomicelle size of ~10, 30 and 60 nm. The newly synthesized polymers will be 
characterized for proton-NMR (structure, micelle forming behavior), gel permeation 
chromatography (purity, molecular weighs, molecular weight, polydispersity), powder X-ray 
diffraction (physical state), and critical micellar concentration.  
2. To prepare nanomicelle encapsulating dexamethasone using film hydration method. To 
utilize DOE methodology (response surface design) to identify the process parameters 
(factors and interactions) influencing the drug loading for film hydration method. To modify 
the film-hydration method to achieve better drug loading i.e. aqueous solubility of 
dexamethasone in nanomicelles.  
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3. To develop dexamethasone-loaded nanomicelles of mean sizes 10, 30 and 60 nm using 
polymers developed in Aim-1 by modified film-hydration method. To characterize 
dexamethasone-encapsulated nanomicelles for drug loading (solubility), size, polydispersity, 
location of drug and in vitro release of drug.  
4. To determine permeability of dexamethasone from nanomicelles in vitro across human 
conjunctival cells and ex vivo across excised rabbit sclera. Compared the permeability of 
dexamethasone from nanomicelles of various sizes to delineate influence of nanomicelles 
size of trans-scleral permeability.  
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CHAPTER 3 
3. POLYMER SYNTHESIS AND CHARACTERIZATION84 
3.1. Materials 
Dexamethasone (purity ≥99%) was obtained from Enzo Life Sciences (Farmingdale, 
NY). ɛ-Caprolactone, stannous octoate and methoxy poly(ethylene glycol) (mPEG; Mw 2000) 
were procured from Sigma Chemicals (St. Louis, MO). Acetonitrile, methanol, d6-chloroform, 
d6-DMSO, anhydrous diethyl ether, tert-butyl methyl ether (TBME) were also obtained from 
Sigma Chemicals (St. Louis, MO) and used without further purification. Human conjunctival 
epithelial cell (HCE cell, Chang cell, CCL-20.2) was procured from ATCC (American type 
culture collection). Human corneal epithelial cell (SV40) was a generous gift from Dr. Araki-
Sasaki (Kinki Central Hospital, Japan). Lactate dehydrogenase (LDH) and CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation (MTS) assay kits were purchased from Fisher 
Scientific Inc. and Promega corp., respectively. Millipore™ Millex™ Sterile Syringe Filters 
made of Durapore® hydrophilic polyvinylidene fluoride (PVDF) (pore size 0.22 µm) were 
obtained from Fisher Scientific Inc.  
3.2. Methods 
3.2.1. Synthesis 
The di-block polymer were synthesized by ring opening polymerization by following 
published protocol with necessary modifications 85. Synthesis scheme is illustrated in (Figure 
3-1).  
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Figure 3-1 General synthesis scheme for di-block mPEG-PCL 
polymers. 
 45 
 
Briefly, monomer ɛ-caprolactone, initiator mPEG and catalyst stannous octoate (0.5% 
w/w of reactants) were added in a reaction vessel prefilled with nitrogen. Toluene (5 mL) was 
added to reactants, followed by heating at 100 oC under vacuum until the total volume was 
reduced to initial volume. The temperature was then raised to 130 oC. After 12 h, the reaction 
mixture was cooled down to room temperature (RT). The reaction mixture was dissolved in 
dichloromethane and precipitated in cold anhydrous ether. The final product was filtered and 
dried under vacuum. The polymer was characterized by 1H-NMR (Varian 400 MHz), and gel 
permeation chromatography for structure and molecular weight determinations.     
3.2.2. NMR 
To perform 1H-NMR spectroscopy, samples were dissolved in CDCI3 and spectra were 
recorded with Varian-400 NMR instrument. NMR data was processed using VNMRJ or ACD 
labs software.   
3.2.3. Gel permeation chromatography  
Purity, molecular weights and polydispersity of polymers were further confirmed by GPC 
analysis. Polymeric samples were analyzed with refractive index detector (Waters 410). Briefly, 
samples were prepared by dissolving 5 mg of polymeric material in tetrahydrofuran (THF) 
whereas THF was utilized as eluting agent at the flow rate of 1 mL/min. Separation was carried 
out on Styragel HR-3 column and polystyrene samples with narrow molecular weight 
distribution were utilized as standards.  
3.2.4. Critical micelle concentration (CMC) 
CMC was determined using pyrene as a hydrophobic fluorescent probe following a 
previously published method with modifications 86. Briefly, serial dilutions of polymer from 
1000 µg/mL to 0.27 µg/mL were prepared in chloroform. Each dilution was added with 30 µg 
 46 
 
pyrene in chloroform. The chloroform solution, containing polymer and pyrene, were vortexed 
and dried under vacuum. DDW was added to the dried samples and vortexed for 1 min. Solutions 
were incubated at 37 °C for 12 h, then syringe-filtered (0.22 µm) to remove undissolved pyrene. 
Filtrates were measured for pyrene fluorescence. Samples were excited at 330 nm and emissions 
were measured at 372 nm (I2) and 392 nm (I1). A ratio of emission intensities (I2/I1) was plotted 
against polymer concentrations to calculate CMC. The polymer concentration here we observed 
a sharp increase in I2/I1 ratio was considered as CMC for the polymer.  
3.2.5. Cell culture 
Human conjunctival epithelial cells (HCE cells) were maintained in cell culture flask 
containing Minimum Essential Medium (MEM) Earle’s Balanced Salt Solution (BSS) medium 
supplemented with 10% fetal bovine serum (FBS), 100 U/L of penicillin, 100 mg/L of 
streptomycin, sodium bicarbonate (2.2 mg/mL), and 2 mM L-glutamine. Human corneal 
epithelial cells (SV40 cells) were cultured in DMEM/F-12 medium supplemented with 15% (v/v) 
heat inactivated FBS, 22 mM NaHCO3, 15 mM HEPES and 5 mg/L insulin, 10 µg/L human 
epidermal growth factor, 100 mg penicillin and 100 mg streptomycin each. Both cell lines were 
incubated at 37 °C, 5% CO2 and 98% humidity. 
3.2.6. In vitro cytotoxicity 
Cytotoxicity studies were performed for newly synthesized polymer by MTS and LDH 
assays. Polymer concentrations of 25, 50, and 100 mg/mL were examined for cytotoxicity in 
both conjunctival (HCE cells) and corneal (SV40 cells) cell lines. The polymer concentrations 
were chosen such that it would cover the highest concentration of polymer in the final 
formulation obtained by DOE. We went up to 100 mg/mL concentration of polymer to make 
certain that there is no toxicity even at higher concentration. 
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MTS assay: MTS assay was performed according to previously published protocol with minor 
modifications 87. Polymer solutions were prepared in culture medium and sterilized by filtration 
with 0.2 µm syringe filters. In brief, HCE or SV40 cells at a density of 104 per well were 
cultured in 96-well plate and incubated for 24 h. Polymer solutions were prepared in culture 
medium and sterilized by filtration with 0.2 µm syringe filters. Following incubation, medium 
was removed and cells were exposed to three different concentrations of polymer solution i.e., 
25, 50 and 100 mg/mL (n = 6). Cells without treatment were selected as positive control whereas 
cells treated with triton-X 100 (0.1% v/v) as negative control. Following 48 h of incubation, 
culture medium from the 96-well plate was substituted by 100 μL of serum free medium 
containing 20μL of MTS solution. Cells were then incubated at 37 °C and 5% CO2 for 4 h. After 
incubation, absorbance of each well was measured at 450 nm. Cell viability (%) was calculated 
by equation 3.1.  
Cell viability (%) = ((Abs of sample-Abs of negative control)/(Abs of positive control-Abs of 
negative control))*100      ... (3.1) 
 
LDH Assay: HCE or SV40 cells were seeded in 96-well plate at a density of 104 cells per well 
and incubated at 37 °C, 5% CO2, and 98% humidity for 24 h. Polymer solutions were prepared in 
culture medium and sterilized by filtration with 0.2µm syringe filters. Following incubation 
period, cells were exposed to various concentrations of polymer (25, 50 and 100 mg/mL, n = 6) 
and incubated for 48 h. Cells without treatment were selected as negative control whereas cells 
treated with Triton-X 100 (0.1% v/v) as positive control. According to the protocol provided by 
manufacturer, LDH release in cell supernatant was quantified by LDH assay kit (Takara Bio Inc., 
Japan). Samples were analyzed at absorbance wavelength of 450 nm with 96-well plate reader. 
LDH (%) release was calculated by equation 3.2.  
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LDH released (%) = ((Abs of sample-Abs of negative control)/(Abs of positive control-Abs of      
negative control))*100      … (3.2) 
3.3. Results and discussion 
Di-block polymer was synthesized by anionic ring opening polymerization using 
stannous octoate as the catalyst and mPEG as the initiator. A summary of polymers synthesized 
in this project is given in Table 3-1. Polymer was purified by cold ether precipitation and dried 
under vacuum. Structure of the polymer was confirmed by 1H-NMR (Figure 3-2). Proton NMR 
showed all the characteristic peaks for the polycaprolactone and mPEG residues. Weight and 
number average molecular weights (Mw and Mn) and PDI were determined by gel permeation 
chromatography (Table 3-1). GPC chromatogram represented only one peak associated with DB 
polymer (Data not shown). All newly synthesized polymers possessed molecular weight close to 
the feed ratio and acceptable polydispersity.  
Critical micelle concentration (CMC) was obtained by pyrene method in aqueous 
polymer solution (Figure 3-3). CMC for the polymer was 0.13, 4.48 and 6.04 µg/mL for DB1, 
DB2 and DB3, respectively. Such low CMC values indicate greater stability against dilutions 
following topical instillation in tear fluid.  
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Table 3-1 Summary of polymer molecular weights and polydispersity for di-block polymers for 
nanomicelle preparation.  
 
Code 
Block co-polymer 
composition 
Mna 
(gm/mol) 
Mnb 
(gm/mol) 
Mwb 
(gm/mol) 
PDIb 
DB1 mPEG750-PCL700 1450 1627 1972 1.21 
DB2 mPEG2000-PCL1500 3500 3155 4586 1.45 
DB3 mPEG5000-PCL4000 9000 9060 10950 1.21 
Mn-Number average molecular weight, Mw-Weight average molecular weight. 
PDI-polydispersity index. 
a
Theoretical value, calculated according to the feed ratio. 
bDetermined by GPC analysis. 
Value in subscript represents molecular weight (gm/mol) 
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Figure 3-2 Proton NMR for DB1, DB2 and DB3 polymers.  
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Figure 3-3 Critical micelle concentration measurement. Intensity 
ratio I2/I1 verses log polymer concentration (µg/ml) profile for the 
mPEG-PCL polymers. Where, I2 and I1 is ratio of emission 
intensities at 372nm and 392nm, respectively. 
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Cytotoxicity studies of DB polymers were conducted on conjunctival and corneal cells, 
by MTS and LDH assays, prior to development of formulation. Percent cell viability was 
calculated based on amount of formazione released for both HCE and SV40 cells (MTS assay) 
(Figure 3-4). Positive control (medium) and test groups were compared by ANOVA. No 
significant difference in %cell viability was observed at all polymer concentrations (ANOVA 
p>0.05). In addition, cytotoxicity study was also performed by LDH assay to confirm results 
obtained from the MTS assay. Polymers interact with cells via cell membrane, and therefore 
estimating the amount of LDH released in culture medium could be a preferred way to estimate 
the cell wall damage and thus cytotoxicity of polymers. LDH release for cells treated with 
polymer was compared to negative control (blank, medium). Based on ANOVA analysis, no 
significant difference in %LDH release was observed between blank and treatment groups, in 
both HCE and SV40 cells (Figure 3-5). These cytotoxicity studies suggests that the polymers are 
safe to use in the given concentration range for ODD. 
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Figure 3-4 Cytotoxicity study by MTS assay in Corneal and Conjunctival 
epithelual cells. Blank (medium alone) is negative control. Triton-X is 
positive control. 
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Figure 3-5 Cytotoxicity study by LDH assay in conjunctival ad corneal 
epithelial cells. Blank (medium alone) is negative control. Triton-X is 
positive control. 
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CHAPTER 4 
4. PREPARATION AND OPTIMIZATION OF DEX-LOADED NANOMICELLES OF 
MEAN SIZE 30 NM USING DB2 POLYMERS84 
4.1. Methods 
4.1.1. Film-hydration method for nanomicelle preparation (Exploratory model, Method-1) 
DEX-loaded nanomicelles (DEXM) were prepared by film hydration method. The 
calculated amount of polymer and DEX were accurately weighed out and dissolved in 
acetone/chloroform mixture (1:1). Organic solvents were evaporated under vacuum in desiccator 
for 24 h to generate films. Films were then added with 1 mL of DDI (65 oC) and vortexed for 3 
min. Nanomicellar solutions were syringe filtered (0.22 µm) to separate undissolved DEX and 
subsequently analyzed for DEX content by reverse phase HPLC.  
4.1.2. Modified film-hydration method for nanomicelle preparation (Optimization model, 
Method-2)  
Method-1 was modified based on the results obtained from exploratory model to obtained 
higher drug dissolution in nanomicelle core. The modified method is as follows. Briefly, drug 
and polymer films were obtained as described in method-1. The films were then heated at 65 oC 
for 15 min to allow melting of the semi-crystalline polymer. The melted films were added with 1 
mL DDI water (37 oC) and vortexed for ~45 sec. The solutions were allowed to cool down to RT 
and filtered through 0.22 µm syringe filters. Clear micellar solutions were analyzed for DEX 
solubility by reverse phase HPLC. 
4.1.3. Solubility determination (HPLC) 
Reverse phase HPLC method described earlier was used with necessary modifications 88. 
Shimadzu LC pump (Waters, Milford, MA) equipped with a UV detector (SPD-20AV, 
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Shimadzu) was employed for the HPLC analysis. The mobile phase consisted of 65% 
tetrabutylammonium hydrogen sulfate (TBAHS) buffer and 35% ACN on a reverse phase C18 
column (Phenomenex C18 Kinetex® column 100  4.6 mm, 5 µm) as a stationary phase. Mobile 
phase flow rate was set at 0.4 mL/min. UV detector was set at 254 nm for quantifying DEX.  
4.1.4. Exploratory model (Experiment design-1 (ED-1)) 
In order to understand the factors and interactions influencing DEX solubilization in 
nanomicelles, a 2-factor 3-level response surface design (RSD) was employed. The factors under 
investigation were polymer amount (X1) and dexamethasone amount (X2) for their effects on 
DEX solubility (Y) in nanomicelles. The experimental design was generated with statistical 
design software SAS 9.02. The RSD-small composite Hartley method was utilized for the 
aforementioned independent variables and dependent variables (Table 4-1). The primary reason 
for selecting this design is the least number of runs as compared to other designs. The design had 
9 runs in total, including 3 center points. DEX-loaded micelles were prepared by film-hydration 
method (Method-1).  
Statistical Analysis: Influence of two factors (Polymer (X1) and DEX (X2) amount) on one 
dependent variable was studied in exploratory model. Hence, a statistical model with interactive 
and polynomial terms was used to evaluate their influence on the response variable (Y) 
(Equation 4.1).  
Y = b0+b1X1+b2X2+b3X1X2+b4X1X1+b5X2X2  … (4.1) 
Where, Y is response variable (DEX solubility, mg/mL); b0 represents the intercept; b1, 
b2, b3, b4, b5 represents the regression coefficients for factor and interactions. X1 (Polymer 
amount in mg) and X2 (DEX amount in mg) are individual effects. X1X1 and X2X2 are 
 57 
 
polynomial terms of individual effects, which represent the polymer-polymer and drug-drug 
interactions, respectively. X1X2 is the interaction term representing drug-polymer interaction.  
Results from this design were analyzed with one-way analysis of variance (ANOVA). F-
test was carried out at α = 0.05 to determine significance of regression relationship between 
response variable (Y) and a set of independent variables. Significant factors and interactions 
were identified by t-test at 95% significance level. R2 and adjusted R2 were also calculated for 
the regression model. The model was validated by checking model assumptions and lack of fit 
test. Statistical analysis was performed with SAS 9.02 and JMP 9.0. 
4.1.5. Optimization model (Experimental design-2 (ED-2)) 
The primary goal of ED-2 was to predict optimal DEX:polymer ratios providing DEX 
solubility of ≥1 mg/mL. Hence, ED-2 could also be referred to as predictive model. We were 
also interested in delineating the effect of melting (Micelle preparation method-2) on DEX 
solubility. RSD-small composite Hartley method described earlier was employed to achieve 
these goals (Table 4-1). Based on experiments with method-1, we considered that DEX solubility 
of 1 mg/mL would be a significant increase. Hence, DEX solubility of 1 mg/mL was set as 
optimal/target value. Statistical treatment described in earlier section was applied to this design 
as well. In addition, a reduced model was generated by removing insignificant effects. The 
reduced model was utilized to predict the DEX:polymer ratio providing optimal DEX solubility 
and validated by checking model assumptions, lack of fit test and checkpoint analysis. 
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Table 4-1 Details of response surface design.  
 
Design Description: Small Composite Hartley Method 
Number of factors 2 
Number of runs 9 
Factors Unit Low (-1) Medium (0) High (+1) 
Polymer (X1) mg 10 30 50 
Dexamethasone 
(X2) 
mg 1 3 5 
Response variable Unit 
Dexamethasone 
Solubility (Y) 
mg/mL 
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4.1.6. Micelle size, polydispersity and surface morphology 
Mean micelle size and polydispersity index (PDI) were determined with Zeta Sizer 
(Zetasizer Nano ZS, Malvern Instruments Ltd, Worcestershire, UK) at RT. A 500-750 µL of 
solution was used without any dilution. Morphology of nanomicelles was examined by 
transmission electron microscopy (TEM) (Philis CM12 STEM). About 50 µL of micellar 
solution was placed on a carbon-coated copper grid. The excess of solution was removed by 
Kimwipe. Samples were negatively stained by phosphotungstic acid and completely dried before 
taking TEM images. 
4.1.7. Powder X-ray diffraction (XRD) 
XRD analysis was performed for DEX, polymer, dried DEX-polymer film and freeze-
dried DEXM formulation. A Rigaku MiniFlex powder automated X-ray diffractometer (Rigaku, 
The Woodland, Texas, USA) was utilized for the analysis at RT. Cu Kα radiation (λ = 1.5418 Å) 
at 30 kv and 15mA was utilized. The diffraction angle covered from 2ϴ 4.0° to 45.0°, and a step 
of 0.05° with 3 sec/step were applied. The diffraction patterns were processed using Jade 8 
(Materials Data, Inc., Livermore, CA).  
4.1.8. 1H-NMR spectroscopy of nanomicelles 
To perform 1H-NMR spectroscopy, polymeric and DEX combination was dissolved in 
d6-DMSO. Blank or DEXM were prepared in D2O for NMR analysis. Spectra were recorded 
with Varian-400 NMR instrument. NMR data was processed using VNMRJ or ACD labs 
software.   
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4.1.9. In vitro release 
The release mechanism for DEX from nanomicelles was determined by in vitro release 
study in simulated tear fluid (STF compositions: 2 g NaHCO3, 6.7 g NaCl, 0.08 g CaCl2·2H2O, 
and deionized water was added up to 1 L, tween-80 (0.5% w/w)) 55 with a dialysis method 89. 
The optimal formulation obtained from the ED-2 was prepared and characterized for initial drug 
content. A five-hundred µL of micellar solution was added in a dialysis bag (MWCO 2000 Da). 
The bag was tied at both ends and immersed in 10 mL of STF containing tween-80 (0.5% w/w) 
at 37 oC. The release medium was replaced with fresh STF at predetermined time points. 
Amount of DEX released was quantified by a reverse phase HPLC method. Release study was 
performed in triplicates. The results were plotted as mean±SD. The release data was fitted for 
zero order, first order, Higuchi and Korsmeyer-Peppas model to determine the kinetics of DEX 
release. 
4.2. Results and discussion 
4.2.1. Exploratory model (Experimental design-1)  
Preliminary experiments to prepare DEXM with film hydration method did not result in 
appreciable increase in solubility. Hence, a response surface methodology (Small Composite 
Hartley Design) was employed to understand the influence of drug-polymer interactions on drug 
solubility in micelle core and identify the factors/interactions responsible for poor DEX loading 
in nanomicelles. The design runs (coded and uncoded runs) and corresponding DEX solubility 
are presented in Table 4-2.  
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Table 4-2 Design runs and solubility of dexamethasone for ED-1 (Micelle preparation method 1). 
 
Run # 
Coded design Uncoded design Solubility 
Y 
(mg/mL) 
Polymer 
X1 
Dexamethasone 
X2 
Polymer 
X1 (mg) 
Dexamethasone 
X2 (mg) 
1 -1 -1 10 1 0.26 
2 1 1 50 5 0.37 
3 -1.19 0 6.2 3 0.18 
4 1.19 0 53.8 3 0.24 
5 0 -1.19 30 0.6 0.20 
6 0 1.19 30 5.4 0.30 
7 0 0 30 3 0.27 
8 0 0 30 3 0.27 
9 0 0 30 3 0.33 
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Solubility of DEX ranged from 0.18 to 0.37 mg/mL. Among all the runs, the highest 
solubility of DEX was observed for run#2 (0.37 mg/mL), where both drug and polymer were at 
their highest levels (+1). Statistical treatment explained earlier was applied to analyze the data. 
Second order least square equation for the master model is given by equation 4.2. 
Y = 0.28+0.0217*X1+0.0382*X2+0.1052*X1X2-0.0494*X1X1-0.02083*X2X2 … (4.2) 
Master model:  
Table 4-3 summarizes analysis of variance (ANOVA), lack of fit and correlation 
coefficient for the master model. The master model was found to be significant (p = 0.0155), 
indicating solubility of DEX (Y) was considerably dependent on the set of X variables. The 
correlation coefficient (R2) for the regression model was 0.9720. It means that the model 
explains 97.2% of variation in DEX solubility. Lack of fit p-value of 0.5953 also suggested that 
the master model was significant and could predicting DEX solubility.  
Estimated coefficients for each term (factors and interactions) with associated p-values 
are represented in Table 4-4. The estimated coefficients with p <0.05 were considered to be 
significant. Significant terms from the model were amount of DEX (X2, p = 0.0156), DEX-
polymer interaction (X1X2, p = 0.0069) and polymer-polymer interaction (X1X1, p = 0.0157) as 
indicated by pareto chart (Figure 4-1). X1X1 had negative influence, while X1X2 and X2 had 
positive effect on DEX solubility. X2X2 also had negative effect on DEX solubility but the 
interaction was not significant (p = 0.1236). Reduced model was not generated since the aim of 
the exploratory model was to delineate the influence of the set of X variables on DEX solubility.  
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Table 4-3 Summary statistics for master model (ED -1). 
 
Summary of Fit 
RSquare 0.9720 
RSquare Adj 0.9253 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > 
F 
Model 5 0.0249 0.0050 20.8257 0.0155 
Error 3 0.0007 0.0002   
C. Total 8 0.0256    
Lack Of Fit 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > 
F 
Lack Of Fit 1 0.0001 0.0001 0.3917 0.5953 
Pure Error 2 0.0006 0.0003   
Total Error 3 0.0007    
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Table 4-4 Parameter estimates for master model (ED-1). 
 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 0.2800 0.0089 31.36 <.0001 
X1(10,50) 0.0217 0.0077 2.81 0.0671 
X2(1,5) 0.0382 0.0077 4.98 0.0156 
X1*X2 0.1053 0.0158 6.66 0.0069 
X1*X1 -0.0494 0.0100 -4.96 0.0157 
X2*X2 -0.0208 0.0098 -2.12 0.1236 
  
Figure 4-1 Pareto chart for master model (ED-1). * next to p-value 
represents significant term. 
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The response surface curve provides a diagrammatical representation of DEX solubility 
as a function of polymer and DEX amounts (Figure 4-2). The response surface was found to be 
non-planar. Interestingly, increasing the polymer amount had variable effects on DEX solubility 
depending on the amount of DEX. For example, at a high level of DEX (+1 or 5 mg), raising the 
polymer amount had positive influence on solubility of DEX, as anticipated. The increase in 
DEX solubility could be attributed to enhanced DEX-polymer interaction (X1X2), which was the 
most significant term according to master model (p = 0.0069). Nonetheless, solubility increase 
was not linear; such nonlinearity could be attributed to X1X1 interaction in the dried film, which 
may lower DEX solubility. On contrary, increasing the polymer amount at low DEX level (-1 or 
1 mg) resulted in decrease in solubility. Moreover, the decline in solubility was steeper and non-
linear which may be explained by X1X1 interaction. At low level of DEX, X1X1 would be 
dominant interaction compared to X1X2 that may explain the steeper decline in DEX solubility 
with increase in polymer amount.  
To characterize the physical form of DEX and polymer, the dried polymer-DEX film was 
studied by XRD. Polymer:DEX film was prepared at a ratio X1:X2::30:5. XRD showed presence 
of characteristic peaks of PCL (2 = 21.9) and mPEG (2 = 19.2 and 23.8) in the dried film 
(Figure 2C), suggesting that the X1X1 interaction represents crystallization of the polymer upon 
evaporation of organic solvent. Small peaks corresponding to DEX were also present (2θ = 14, 
15.6 and 17) in the dried film, indicative of slight crystallization and X2X2 interaction. From 
exploratory model, it can be concluded that solubility of DEX in micellar core is governed by 
polymer-DEX interaction (X1X2).  
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Figure 4-2 Response surface for master model (ED-1). DEX solubility (Y) 
is plotted as a function of polymer (X1) and DEX (X2) amounts between -
1 and 1. 
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We can also infer that polymer-polymer interaction (X1X1) occurs during solvent 
evaporation leading to significantly lower DEX entrapment. In order to improve DEX solubility, 
we need to overcome X1X1 interactions. In this case, X1X1 interaction represents the 
crystallization of polymer. We hypothesize that heating the dried polymer-DEX film above the 
melting point of polymer (tm = 60-62 
oC) may overcome X1X1 interaction (nanomicelle 
preparation method-2). Lowering X1X1 interaction may allow free polymer to interact with 
DEX thus maximizing DEX entrapment in micelle core.  
4.2.2. Optimization model (Experimental design-2) 
Based on our hypothesis, in order to overcome X1X1 interaction, we modified the 
nanomicelle preparation method-1. A response surface design as explained earlier for exploratory 
model was generated for independent variables polymer amount (X1) and DEX amount (X2); and 
response variable DEX solubility (Y). DEXM were prepared by modified film-hydration method 
(method-2). Table 4-5 summarizes design runs (uncoded design), DEX solubility for each run, 
micelle size and polydispersity index (PDI). Highest solubility of 1.36 mg/mL was obtained for 
design run#4.  
Master model:  
Quadratic equation for the master model is given by equation 4.3, 
Y = 0.733+0.436*X1+0.045*X2+0.011*X1X2+0.037*X1X1-0.066*X2X2 … (4.3) 
Statistical parameters for the master model including parameter estimates, ANOVA for the 
master model and lack of fit analysis are summarized in Table 4-6. The master model was found 
to be significant, based on model p-value (p = 0.0128), lack of fit p-value (p = 0.0901) and adjusted 
R2 of 0.9345. The parameter estimates for master model are shown in Table 4-7.  
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Table 4-5 Summary of uncoded design and corresponding solubility, micelle size and PDI for 
ED-2 (Micelle preparation method 2). 
 
RUN Polymer 
X1 (mg) 
Dexamethasone 
X2 (mg) 
Solubility  
Y 
(mg/mL) 
Size  (nm) PDI 
1 10 1 0.30 26.44 0.094 
2 50 5 1.13 27.32 0.125 
3 6.2 3 0.21 27.99 0.070 
4 53.8 3 1.36 28.01 0.135 
5 30 0.6 0.53 28.38 0.100 
6 30 5. 4 0.75 28.98 0.225 
7 30 3 0.68 27.79 0.076 
8 30 3 0.75 27.99 0.122 
9 30 3 0.77 27.17 0.106 
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Table 4-6 Summary statistics of master model (ED-2). 
 
Summary of Fit 
RSquare 0.9754 
RSquare Adj 0.9345 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > 
F 
Model 5 1.0303 0.2061 23.8266 0.0128 
Error 3 0.0259 0.0086   
C. Total 8 1.0562    
Lack Of Fit 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > 
F 
Lack Of Fit 1 0.0215 0.0215 9.6167 0.0901 
Pure Error 2 0.0045 0.0022   
Total Error 3 0.0259    
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Table 4-7 Parameter estimates for master model (ED-2). 
 
Term Estimate 
Std 
Error 
t Ratio Prob>|t| 
Intercept 0.7333 0.0537 13.66 0.0008 
X1(10,50) 0.4364 0.0465 9.38 0.0026 
X2(1,5) 0.0453 0.0465 0.98 0.4014 
X1*X2 0.0111 0.0956 0.12 0.9147 
X1*X1 0.0365 0.0600 0.61 0.5858 
X2*X2 -0.0660 0.0600 -1.1 0.3519 
 
  
Figure 4-3 Pareto Chart for master model (ED-2). * next to p-value represents significant 
term. 
 71 
 
According to pareto chart, only statistically significant factor was polymer amount (X1, p 
= 0.0026), unlike method-1 where polymer amount did not have any significant effect on DEX 
solubility (Figure 4-3). High DEX solubility may be attributed to melting of polymer in the film 
that allowed polymer to overcome X1X1 interaction, as we hypothesized. No influence of X1X1 
interaction on drug solubility (p = 0.5858) was observed with modified film-hydration method. 
XRD analysis of dried DEX-polymer film was conducted after heating the films to delineate the 
effect of heating on physical form of polymer. DEX-polymer film was prepared at 30:5::X1:X2 
ratio. The peaks for mPEG-PCL were present despite heating the film at 65 oC (Figure 4-4d). 
These results could be explained by the fact that XRD patterns were recorded at RT. Gradual 
cooling of DEX-polymer film to RT could result in recrystallization of polymer. It also worth 
noting that heating the film did not have any effect on physical form of DEX, as predicted.  
Reduced model:  
A reduced or predictive model was generated by removing the non-significant terms with 
p>0.05 from the master model. Hence, terms X1X2 and X1X1 were removed. XRD analysis 
indicated crystallization of DEX in polymer-DEX film (after heating) representing X2X2 
interaction (Figure 2c and 2d). In addition, removing the X2X2 interaction did not improve the 
model p-value, lack of fit p-value or adjusted R2 (Data not shown). Hence, term X2X2 was not 
removed from the master model. Summary statistic for the reduced model is presented in Table 
4-8. The predictive model was compared with master model for p-values of the model, p-value 
of lack of fit and adjusted R2. The reduced model had p-value of 0.0003, lack fit p-value of 
0.2056 and adjusted R2 of 0.9524, indicating that the reduced model was superior in predicting 
DEX solubility (Y). The parameter estimates for the reduced model are shown in Table 4-9. 
Pareto chart for the reduced model is depicted in Figure 4-5.  
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Figure 4-4 X-ray diffraction pattern for (a) Dexamethasone, (b) DB2 (PCL-mPEG) polymer, 
(c) Polymer:DEX film before heating (Polymer:DEX::30:5), (d) Polymer:DEX film after 
heating (Polymer:DEX::30:5), (e) Freeze dried Blank micelles (f) Freeze dried DEXM (0.1% 
w/v DEX). 
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Table 4-8 Summary statistics of reduced model for ED-2. 
 
Summary of Fit 
RSquare 0.9703 
RSquare Adj 0.9524 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > 
F 
Model 3 1.0248 0.3416 54.388 0.0003 
Error 5 0.0314 0.0063   
C. Total 8 1.0562    
Lack Of Fit 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > 
F 
Lack Of Fit 3 0.0269 0.0090 4.0205 0.2056 
Pure Error 2 0.0045 0.0022   
Total Error 5 0.0314    
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Table 4-9 Parameter estimates for reduced model (ED-2). 
 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 0.757 0.0350 21.6 <.0001 
X1(10,50) 0.436 0.0396 11.0 0.0001 
X2(1,5) 0.045 0.0396 1.14 0.3044 
X2*X2 -0.069 0.0429 -1.61 0.1673 
  
Figure 4-5 Pareto chart for reduced model (ED-2).  * next to p-value represents 
significant term. 
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Figure 4-6 Response surface of predictive model for ED-2. DEX solubility 
(Y) is plotted as a function of polymer (X1) and DEX (X2) amounts 
between -1 and 1. 
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Again the only significant term influencing DEX solubility was X1 (p = 0.0001). 
Interactions between DEX molecules (X2X2) was not significant (p = 0.1673) as per model and, 
as expected, and had negative effect on DEX solubility with method-2. Similar observation was 
noted for method-1 (Exploratory model) suggesting that the melting has no influence on DEX 
crystallization. The prediction expression for reduced model is represented by equation 4.4, 
Y = 0.757+0.436*X1+0.045*X2-0.069*X2X2 … (4.4) 
Response surface showing the change in solubility of DEX as a function of DEX and 
polymer amounts is illustrated in Figure 4-6. Unlike exploratory model, we were able to 
overcome negative effect of X1X1 on DEX solubility with the modified method. Hence, 
solubility of DEX increased linearly with increasing polymer amount at all the DEX levels. 
Nonetheless, solubility increase was not linear with increasing DEX amount due to X2X2 
interaction. It is worth noting that despite the ratio for the DEX:polymer is same in runs 1, 2 and 
7, the amount of polymer and DEX are different (Table 4-5). These different amounts resulted in 
variable solubility of DEX depending on the strength of DEX*DEX, polymer*DEX and 
Polymer*Polymer interactions in the film upon drying. Hence, we see different solubility for 
DEX at same DEX:polymer ratios. Furthermore, upon overcoming X1X1 interaction in 
optimized method 2, a significant enhancement in solubility of DEX was observed (Table 4-2 
and Table 4-5) for same amount of DEX and polymers. For example, solubility of DEX was 0.37 
mg/mL and 1.13 mg/mL at 50 mg polymer and 5 mg DEX with method 1 and 2, respectively 
(Run#2 in Table 4-2 and Table 4-5).    
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Table 4-10 Checkpoint analysis for reduced model (ED-2). 
X1:X2 ratio (n 
= 3) 
Predicted 
solubility 
(mg/mL) 
Experimental 
solubility 
(mg/mL) 
Two-tailed P-
value 
% Standard 
error 
20:2 0.499 ± 0.093 0.588 ± 0.038 0.367 5.8% 
50:3.5 1.201 ± 0.127 1.146 ± 0.166 0.672 1.2% 
Figure 4-7 Prediction profile of reduced model depicting solubility (Y) as 
function of polymer (X1) and DEX (X2) amounts. 
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Figure 4-8 Experimental solubility verses predicted solubility for 
predictive model for ED-2. R2 of 0.97 suggests that DEX solubility 
predicted by reduced model are very close to experimental values. 
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The prediction profile was generated to determine the optimal point with the highest 
desirability. The checkpoint analysis was carried out to validate the reduced model at 
X1:X2::20:2 ratio. Ratio X1:X2::20:2 was selected for checkpoint analysis, as it was not a part of 
design runs suggested by the statistical software (SAS 9.02). No statistically significant 
difference was observed between experimental and predicted DEX solubility (p>0.05) (Figure 
4-7 and Table 4-10). The model was also validated by plotting predicted verses actual solubility 
(Figure 4-8). The relationship was found to be linear with R2 of 0.97 indicating predicted 
solubility by model is close to experimental one. Based on checkpoint analysis and experimental 
verses predicted solubility, it was concluded that the reduced model could accurately predict 
DEX solubility. Using prediction profile for reduced model, optimal X1:X2 ratio to obtain DEX 
solubility ≥1mg/mL was obtained.  
4.2.3. Micelle size and morphology 
Nanomicelle size and distribution were determined by dynamic light scattering method 
for all the runs in ED-2. The results are presented in Table 4-5. The size ranged from 26 to 28 nm 
with unimodal distribution irrespective of DEX solubility. The PDI for all the runs were below 
0.23 indicating narrow size distribution. Size distribution showing mean size and PDI for design 
runs #2 is illustrated in Figure 4-9a. The average size was 27.32 nm with PDI of 0.125. It is 
expected that micelle size would increase with increase in DEX solubility from 0.21 mg/mL to 
1.36 mg/mL. However, it is worth noting that even with this increase in solubility, drug loading 
did not vary appreciably. Hence, we did not observe an appreciable increase in nanomicelle size 
or polydispersity with increase in solubility.  
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Figure 4-9 (a) Micelles size distribution for DEXM for design run #2 of 
ED-2. (b) Transmission electron micrograph for DEXM. Nanomicelles 
appear as a white spot on dark background as indicated by arrows.  
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The morphology of nanomicelle was studied by TEM (Figure 4-9b). TEM micrograph of 
nanomicelles indicated that the nanomicelles were spherical in shape.  
4.2.4. 1H-NMR spectroscopy of blank micelles and DEXM 
Process of micelle formation and DEX encapsulation in micelle core were studied with 
proton NMR spectroscopy. 1H-NMR for blank PCL-mPEG micelles was recorded in D2O and 
compared with NMR spectra in CHCl3. Weak 
1H-NMR signal from PCL and sharp signal from 
mPEG protons in D2O clearly indicated micelle formation (Figure 4-10B). During micelle 
formation PCL block assemble to form the hydrophobic core and mPEG segment forms 
hydrophilic corona. Since the core of micelle lacks accessibility to solvent, movement of PCL 
segment in the core is limited and hence the proton NMR signal is very weak compared to signal 
in CDCl3. In contrast, the corona forming mPEG segment is free to move in D2O showing good 
1H-NMR signal intensity. 
1H-NMR spectroscopy was also used to ascertain the presence of DEX in nanomicelle 
core. 1H-NMR spectra for physical mixture of DEX and polymer in d6-DMSO, DEXM in D2O 
and DEX in d6-DMSO were recorded (Figure 4-10). The 
1H-NMR spectra for combination of 
DEX and polymer in d6-DMSO showed all the characteristic peaks corresponding to DEX, PCL 
and mPEG (Figure 4-10d). 1H-NMR for DEXM in D2O also showed presence of characteristic 
peak for mPEG segment at 3.4-3.6 ppm and those for PCL were absent, indicating micellization. 
Characteristic peaks for DEX were absent due to restricted mobility inside micelle core, 
implying that drug was molecularly dispersed in micelle core (Figure 4-10e).   
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Figure 4-10 1H-NMR spectroscopies for (a) PCL-mPEG polymer in 
CDCl3 (b) Blank PCL-mPEG micelles in D2O (c) Dexamethasone in d6-
DMSO, (d) PCL-mPEG (50mg) and dexamethasone (1mg) in d6-DMSO, 
(e) 0.1% DEXM in D2O. 
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4.2.5. Powder XRD analysis of blank micelles and DEXM 
Blank micelles and DEXM were also studied by XRD to seek further insight into 
physical state of polymer and DEX in nanomicelles. The results are presented in Figure 4-4e and 
4f. XRD pattern for freeze-dried DEXM was devoid of DEX peaks indicating that the drug was 
molecularly dispersed in nanomicelle. Both blank micelles and DEXM showed characteristic 
peaks for PCL at 2θ 19° and 23°. PCL, due to its semi-crystalline nature, does not self-assemble 
in water to form micelles at RT. However, at temperatures close to melting point provides PCL 
with necessary chain mobility to self-assemble into micelles. Once the micelles are formed and 
system reaches RT, PCL segments in core reestablishes the polymer-polymer interactions 
regaining its semi-crystalline state in nanomicelle core. We expect that the semi-crystal nature of 
nanomicelle core would provide rigid core to the nanomicelles. Such rigid micelle core may 
provide resistance against sheer stress while transport of nanomicelles across the scleral pores. 
Rigidity has been shown to be beneficial for liposomal formulation during transport across the 
sclera 78.       
4.2.6. Release kinetics of DEX from nanomicelles 
The release study was performed in simulated tear fluid at 37 °C, under sink condition, to 
identify mechanism of DEX release from nanomicelles. Cumulative % DEX released verses time 
profile is illustrated in Figure 4-11a. DEX release from the nanomicellar system lasted for 2.5 
days. About 50% DEX was released by 24 h from nanomicelles. Previously, it has been shown 
mPEG-PCL could sustain the release of hydrophobic agent such as honokiol (log p 5.21, Polar 
surface area 40.46 90) for up to 2 weeks 68. However, DEX is relatively polar molecule with log p 
of 1.68 and large polar surface area of 94.83 90. This may be responsible for poor interaction with 
hydrophobic PCL chains resulting in relatively faster release pattern.  
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Figure 4-11 (a) Release profile of dexamethasone from 
nanomicelles under sink conditions at 37 ˚C (mean ± SD, n 
= 4). (b) Fraction of DEX released at time t (Mt/Mi) vs t1/2 
profile showing sigmoidal shape suggesting case II 
transport as drug release mechanism. 
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Release data was fitted to zero order, first order, Higuchi and Korsmeyer-Peppas model 
to determine the kinetics of DEX release. The best fit was found with the Korsmeyer-Peppas 
model with R2 of 0.9998 compared to other models. The n value was calculated using the data 
points where less than 60% DEX was released. The n value was found to be 1.24 suggesting 
super case II transport as release mechanism. In super case II transport, drug release is controlled 
mainly by the polymer chain relaxation 91.  Polymer chain relaxation may result in loss of DEX-
polymer interaction, which encapsulate DEX in micelle core. In addition, due to semicrystalline 
nature of PCL chains, upon release of DEX from micelles the polymer chain will have more 
freedom to align and form rigid crystalline core. Formation of rigid core upon release will also 
hinder the repartition of DEX back in nanomicelle core. Furthermore, volume of release medium 
was 10 mL with Tween-80 (0.5% w/w) which would aid solubilization released DEX.  To 
confirm super case II release mechanism, fraction of drug release (Mt/Mi) as a function of square 
root of time (t1/2) was plotted. The graph had sigmoidal shape suggesting the mechanism was 
indeed super case II transport (Figure 4-11b).  
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CHAPTER 5 
5. DEVELOPMENT OF DEX-LOADED NANOMICELLES OF MEAN SIZE 60 NM USING 
DB3 POLYMER. 
5.1. Methods 
5.1.1. Modified film-hydration method of nanomicelle preparation 
DEX encapsulated nanomicelles were prepared using DB3 polymer. For details on 
modified-film hydration methods, see section 4.1.2  for method. 
5.1.2. Solubility determination (HPLC) 
See section 4.1.3  for method. 
5.1.3. Small composite Hartley method 
See section 4.1.4 for method. The design details including number of runs, factors, levels 
and response variable are summarized in the Table 5-1. 
5.1.4. Micelle size determination  
See section 4.1.6  for method. 
5.1.5. Powder XRD analysis of blank micelles and DEXM 
See section 4.1.7  for method. 
5.1.6. 1H-NMR spectroscopy of blank micelles and DEXM 
See section 4.1.8  for method. 
5.1.7. Release kinetics of DEX from nanomicelles 
See section 4.1.9  for method. 
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Table 5-1 Details of response surface design. 
 
Design Description: Small Composite Hartley Method 
Number of factors 2 
Number of runs 9 
Factors Unit Low (-1) Medium (0) High (+1) 
Polymer (X1) mg 10 30 50 
Dexamethasone (X2) mg 1 3 5 
Response variable Unit 
Dexamethasone 
Solubility (Y) 
mg/mL 
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5.2. Results and discussion 
5.2.1. Optimization of DEX solubility using DoE 
DEXM were prepared using the modified film-hydration method explained in chapter 4. 
The optimal drug:polymer ratio was identified by using DOE. The design details including 
number of runs, factors, levels and response variable are summarized in the Table 5-1. There 
were total nine runs in this RSD, which were performed in triplicates (Table 5-2). The design 
runs and corresponding DEX solubility and size of nanomicelle are presented in Table 5-2. DEX 
solubility ranged from 0.32 mg/mL (Run#3) to 1.43 mg/mL (Run#4). Highest solubility of 1.43 
mg/mL was observed for combination of 53.8 mg polymer and 3 mg of DEX. The design runs 
were subjected to statistical treatment explained in chapter 4.  
Master model: Summary of fit including analysis of variance (ANOVA), lack of fit and 
correlation coefficient for the master model are summarized in Table 5-3. The master model was 
not found to be significant (p = 0.0738). The correlation coefficient (R2) for the regression model 
was 0.9181 indicating that the model explains 91.8% of variation in DEX solubility. Lack of fit 
p-value was more than 0.05 (p = 0.146) suggesting that the master model was significant and can 
predict DEX solubility.  
The parameter estimates for master model are shown in Table 5-4. According to Pareto 
chart, only statistically significant factor was polymer amount (X1, p = 0.0227) (Figure 5-1), 
which is very similar to DEXM formulated with DB2. No influence of X1X1 interaction on drug 
solubility (p = 0.8830) was observed with modified film-hydration method. Quadratic equation 
for the master model is given by equation 5.1. 
Y = 0.899+0.382X1+0.104X2+0.126X1X2-0.018X1X1-0.219X2*X2 …(5.1) 
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Table 5-2 Summary of uncoded design and corresponding solubility, micelle size and PDI. 
 
Run# Polymer (mg) DEX (mg) Solubility 
(mg/mL) 
Micelle size 
(nm) 
PDI 
1 10 1 0.42 49.61 0.13 
2 50 5 1.16 63.72 0.30 
3 6.2 3 0.32 52.00 0.18 
4 53.8 3 1.43 55.45 0.21 
5 30 0.6 0.36 56.56 0.22 
6 30 5.4 0.81 56.07 0.21 
7 30 3 0.78 55.66 0.22 
8 30 3 1.01 54.55 0.20 
9 30 3 0.91 53.89 0.17 
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Table 5-3 Summary statistics of master model. 
 
Summary of Fit 
RSquare 0.9181 
RSquare Adj 0.7815 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean 
Square 
F 
Ratio 
Prob > F 
Model 5 1.051 0.210 6.723 0.074 
Error 3 0.094 0.031   
C. Total 8 1.145    
Lack Of Fit 
Source DF Sum of 
Squares 
Mean 
Square 
F 
Ratio 
Prob > F 
Lack Of Fit 1 0.068 0.068 5.388 0.146 
Pure Error 2 0.025 0.013   
Total Error 3 0.094    
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Table 5-4 Parameter estimates for master model. 
 
Term Estimate 
Std 
Error 
t Ratio Prob>|t| 
Intercept 0.899 0.102 8.81 0.0031 
X1(10,50) 0.383 0.088 4.33 0.0227 
X2(1,5) 0.105 0.088 1.18 0.3220 
X1*X2 0.126 0.182 0.69 0.5375 
X1*X1 -0.018 0.114 -0.16 0.8830 
X2*X2 -0.220 0.114 -1.93 0.1498 
 
 
  
Figure 5-1 Pareto chart for master model. * next to p-value represents 
significant term. 
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Table 5-5 Summary statistics of reduced model. 
 
Summary of Fit 
RSquare 0.903 
RSquare Adj 0.845 
Analysis of Variance (ANOVA) 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > F 
Model 3 1.034 0.345 15.577 0.0057 
Error 5 0.111 0.022   
C. Total 8 1.145    
Lack Of Fit 
Source DF Sum of 
Squares 
Mean 
Square 
F Ratio Prob > F 
Lack Of Fit 3 0.085 0.028 2.238 0.324 
Pure Error 2 0.025 0.013   
Total Error 5 0.111    
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Table 5-6 Parameter estimates for reduced model. 
 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 0.897 0.066 13.6 <.0001 
X1(10,50) 0.383 0.074 5.15 0.0036 
X2(1,5) 0.105 0.074 1.41 0.2187 
X2*X2 -0.182 0.081 -2.26 0.0731 
 
 
  
Figure 5-2 Pareto chart for reduced model. * next to p-value represents 
significant term. 
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Figure 5-3 Response surface of predictive model. DEX solubility 
(Y) is plotted as a function of polymer (X1) and DEX (X2) amounts 
between -1 and 1. 
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Figure 5-4 Experimental solubility verses predicted solubility for 
predictive model for ED-2. R2 of 0.90 suggests that DEX solubility 
predicted by reduced model are very close to experimental values. 
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Figure 5-5 Prediction profile of reduced model depicting solubility (Y) as 
function of polymer (X1) and DEX (X2) amounts. 
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Table 5-7 Checkpoint analysis for reduced model. 
 
X1:X2 ratio (n 
= 3) 
Predicted 
solubility 
(mg/mL) 
Experimental 
solubility 
(mg/mL) 
Two-tailed P-
value 
% Standard 
error 
20:2 0.608 ± 0.175 0.573 ± 0.062 0.760 3.5% 
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To characterize the physical form of DEX and polymer, the dried polymer-DEX film was 
studied by XRD. Polymer:DEX film was prepared at a ratio X1:X2::30:5. XRD showed presence 
of characteristic peaks of PCL (2 = 21.9) and mPEG (2 = 19.2 and 23.8) in the dried film 
(Figure 5-7c), suggesting that the X1X1 interaction represents crystallization of the polymer 
upon evaporation of organic solvent. Small peaks corresponding to DEX were also present (2θ = 
14, 15.6 and 17) in the dried film, indicative of slight crystallization and X2X2 interaction. XRD 
analysis of dried DEX-polymer film was conducted after heating the films to delineate the effect 
of heating on physical form of polymer. The peaks for mPEG and PCL were present following 
heating of film at 65 oC (Figure 5-7c and Figure 5-7d). These results could be explained by the 
fact that XRD patterns were recorded at RT. Gradual cooling of DEX-polymer film to RT could 
result in recrystallization of polymer. It also worth noting that heating the film did not have any 
effect on physical form of DEX, as predicted (Figure 5-7d).  
Reduced model:  
A reduced or predictive model was generated by removing the non-significant terms with p>0.05 
from the master model. Hence, terms X1X2 (p = 0.5375) and X1X1 (p = 0.8830) were removed. 
XRD analysis indicated crystallization of DEX in polymer-DEX film (after heating) representing 
X2X2 interaction (Figure 5-7c-d). Hence, term X2X2 was included in predictive model. 
Summary statistic for the reduced model is presented in Table 5-5. The predictive model was 
compared with master model for p-values of the model, p-value of lack of fit and adjusted R2. 
The reduced model had p-value of 0.0057, lack fit p-value of 0.324 and adjusted R2 of 0.845, 
indicating that the reduced model was superior in predicting DEX solubility (Y). The parameter 
estimates for the reduced model are shown in Table 5-6. Pareto chart for the reduced model is 
depicted in Figure 5-2. Again the only significant term influencing DEX solubility was X1 (p = 
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0.0036). Interactions between DEX molecules (X2X2) was not significant (p = 0.0731) as per 
model and had negative effect on DEX solubility with method-2. The prediction expression for 
reduced model is represented by equation 5.1. 
Y = 0.897+0.383X1+0.105X2-0.182X2*X2 …(5.2) 
Response surface showing the change in solubility of DEX as a function of DEX and 
polymer amounts is illustrated in Figure 5-3. Solubility of DEX increased linearly with 
increasing polymer amount at all the DEX levels. Nonetheless, solubility increase was not linear 
with increasing DEX amount due to X2X2 interaction. The prediction profile was generated to 
determine the optimal point with the highest desirability.  
The checkpoint analysis was carried out to validate the reduced model at X1:X2::20:2 
ratio (Figure 5-5). Ratio X1:X2::20:2 was selected for checkpoint analysis, as it was not a part of 
design runs suggested by the statistical software (SAS 9.02). No statistically significant 
difference was observed between experimental and predicted DEX solubility (p = 0.7604) (Table 
5-7). The model was also validated by plotting predicted verses actual solubility (Figure 5-4). 
The relationship was found to be linear with R2 of 0.90 indicating predicted solubility by model 
is close to experimental one. Based on checkpoint analysis and experimental verses predicted 
solubility, it can be concluded that the reduced model can accurately predict DEX solubility. 
Using prediction profile for reduced model, optimal X1:X2 ratio to obtain DEX solubility 
≥1mg/mL was obtained.  
5.2.2. Micelle size determination 
Nanomicelle size and distribution were determined by dynamic light scattering method 
for all the runs (Table 5-2). The size ranged from 50 to 64 nm with unimodal distribution 
irrespective of DEX solubility.  
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Figure 5-6 Micelle size distribution for DEXM prepared using DB3 
polymer. 
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Figure 5-7 X-ray diffraction pattern for (a) Dexamethasone, (b) PCL-mPEG polymer, (c) 
Polymer:DEX film before heating (Polymer:DEX::30:5), (d) Polymer:DEX film after 
heating (Polymer:DEX::30:5), (e) Freeze dried Blank micelles (f) Freeze dried DEXM 
(0.1% w/v DEX). 
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Figure 5-8 1H-NMR spectrums for (a) PCL-mPEG polymer in CDCl3 (b) 
Dexamethasone in d6-DMSO, (c) PCL-mPEG (50mg) and dexamethasone 
(1mg) in d6-DMSO, (d) 0.1% DEXM in D2O.  
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Figure 5-9 Release profile of dexamethasone from nanomicelles under 
sink conditions at 37 ˚C (mean ±SD, n = 4). 
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The PDI for all the runs were below 0.22 indicating narrow size distribution. Size 
distribution showing mean size and PDI for DEXM is illustrated in Figure 5-6. The average size 
was 58.1 nm with PDI of 0.25. It is expected that micelle size would increase with increase in 
DEX solubility. However, even with this increase in solubility, drug loading did not vary 
appreciably. Hence, we did not observe an appreciable increase in nanomicelle size or 
polydispersity with increase in solubility. The control over nanomicelle size was achieved by 
controlling the molecular weight of PCL and PEG segments of diblock polymer.  
5.2.3. 1H-NMR spectroscopy of Blank micelles and DEXM 
1H-NMR spectroscopy was used to ascertain the presence of DEX in nanomicelle core. 
1H-NMR spectra for physical mixture of DEX and polymer in d6-DMSO, DEXM in D2O and 
DEX in d6-DMSO were recorded (Figure 5-8). The 
1H-NMR spectra for combination of DEX 
and polymer in d6-DMSO showed all the characteristic peaks corresponding to DEX, PCL and 
mPEG (Figure 5-8c). 1H-NMR for DEXM in D2O also showed presence of characteristic peak 
for mPEG segment at 3.4-3.6 ppm and those for PCL were absent, indicating micellization. 
During micelle formation PCL block assemble to form the hydrophobic core and mPEG segment 
forms hydrophilic corona. Since the core of micelle lacks accessibility to solvent, movement of 
PCL segment in the core is limited and hence the proton NMR signal is very weak compared to 
signal in DMSO. In contrast, the corona forming mPEG segment is free to move in D2O showing 
good 1H-NMR signal intensity. Characteristic peaks for DEX were absent due to restricted 
mobility inside micelle core, implying that drug was molecularly dispersed in micelle core 
(Figure 5-8e).   
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5.2.4. Powder XRD analysis of blank micelles and DEXM 
Blank micelles and DEXM were also studied by XRD to seek further insight into 
physical state of polymer and DEX in nanomicelles. The results are presented in Figure 5-7e and 
Figure 5-7f. XRD pattern for freeze-dried DEXM was devoid of DEX peaks indicating that the 
drug was molecularly dispersed in nanomicelle. Both blank micelles and DEXM showed 
characteristic peaks of PCL (2 = 21.9) and mPEG (2 = 19.2 and 23.8). PCL, due to its semi-
crystalline nature, does not self-assemble in water to form micelles at RT. However, at 
temperatures close to melting point provides PCL with necessary chain mobility to self-assemble 
into micelles. Once the micelles are formed and system reaches RT, PCL segments in core 
reestablishes the polymer-polymer interactions regaining its semi-crystalline state in nanomicelle 
core. We expect that the semi-crystal nature of nanomicelle core would provide rigid core to the 
nanomicelles. Such rigid micelle core may provide resistance against sheer stress while transport 
of nanomicelles across the scleral pores. Rigidity has been shown to be beneficial for liposomal 
formulation during transport across the sclera 78. Similar results were observed for DEXM 
prepared using DB2 polymer.       
5.2.5. Release kinetics of DEX 
The release study was performed in simulated tear fluid at 37 °C, under sink condition, to 
identify mechanism of DEX release from nanomicelles. Cumulative % DEX released verses time 
profile is illustrated in Figure 5-9. DEX release from the nanomicellar system lasted for >3 days. 
About 50% DEX was released by day one from nanomicelles. Very similar results were 
observed for low molecular weight DB2 polymer.   
Release data was fitted to zero order, first order, Higuchi and Korsmeyer-Peppas model 
to determine the kinetics of DEX release. The best fit was found with the Korsmeyer-Peppas 
 106 
 
model with R2 of 0.9993 compared to other models. The n value was found to be 0.92. Value of 
diffusion exponent (n) >0.89 suggests that mechanism of release was super case II transport. In 
super case II transport, drug release is controlled mainly by the polymer chain relaxation 91.  The 
polymer chain relaxation may result in loss of DEX-polymer interaction, which facilitates DEX 
encapsulation in micelle core. In addition, due to semicrystalline nature of PCL chains, upon 
release of DEX from micelles the polymer chain will have more freedom to align and form rigid 
crystalline core. Formation of rigid core upon release will also hinder the repartition of DEX 
back in nanomicelle core.  
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CHAPTER 6 
6. DEVELOPMENT OF DEX-LOADED NANOMICELLES OF MEAN SIZE 10 NM USING 
DB1 POLYMER. 
 
6.1. Methods 
6.1.1. Modified film-hydration method of nanomicelle preparation 
DEX encapsulated nanomicelles were prepared using DB1 following modified-film 
hydration method described in section 4.1.2. 
6.1.2. Solubility determination (HPLC) 
See section 4.1.3  for method. 
6.1.3. Small composite Hartley method 
See section 4.1.4 for method. The design details including number of runs, factors, levels 
and response variable are summarized in the Table 6-1. 
6.1.4. Micelle size determination  
See section 4.1.6  for method. 
6.1.5. Powder XRD analysis of blank micelles and DEXM 
See section 4.1.7  for method. 
6.1.6. 1H-NMR spectroscopy of blank micelles and DEXM 
See section 4.1.8  for method. 
6.1.7. Release kinetics of DEX from nanomicelles 
See section 4.1.9  for method. 
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Table 6-1 Details of response surface design. 
 
Design Description: Small Composite Hartley Method 
Number of factors 2 
Number of runs 9 
Factors Unit Low (-1) Medium (0) High (+1) 
Polymer (X1) mg 30 55 80 
Dexamethasone 
(X2) 
mg 2  3.5 5 
Response variable Unit 
Dexamethasone 
Solubility (Y) 
mg/mL 
 
 
 
  
 109 
 
6.2. Results and discussion 
6.2.1. Preparation of DEXM  
DEXM using DB1 polymer were prepared using the modified film-hydration method 
explained in chapter 4. The optimal drug:polymer ratio was identified by using Small composite-
Hartley method. The design details including number of runs, factors, levels and response 
variable are summarized in the Table 6-1. There were total nine runs in this RSD, which were 
performed in triplicates (Table 6-2). The design runs and corresponding DEX solubility and size 
of nanomicelle are presented in Table 6-2. DEX solubility ranged from 0.6 mg/mL (Run#3) to 
2.3 mg/mL (Run#2). Highest solubility of 2.3 mg/mL was observed for combination of 80 mg 
polymer and 5 mg of DEX. The design runs were subjected to statistical treatment explained in 
chapter 4.  
Master model:  
Summary of fit including analysis of variance (ANOVA), lack of fit and correlation coefficient 
for the master model are summarized in Table 6-3. The master model was found to be significant 
(p = 0.0009), suggesting that solubility of DEX (Y) was dependent on the set of X variables. The 
correlation coefficient (R2) for the regression model was 0.9959 indicating that the model 
explains 99.59% of variation in DEX solubility. Lack of fit p-value was more than 0.05 (p = 
0.3897) suggesting that the master model was significant and can predict DEX solubility. The 
parameter estimates for master model are shown in Table 6-4. According to Pareto chart, 
statistically significant terms were polymer amount (X1, p = 0.0002), X1X1 interaction (p = 
0.0046), DEX*DEX interaction (X2X2, p = 0.0047) and polymer*DEX interaction (X1X2, p = 
0.0055) (Figure 6-1).  
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Table 6-2 Summary of uncoded design and corresponding solubility, micelle size and PDI. 
 
Run# 
Polymer 
(mg) 
DEX 
(mg) 
Solubility 
(mg/mL) 
Micelle 
size (nm) 
PDI 
1 30 2 1.0 10 0.112 
2 80 5 2.3 9.6 0.102 
3 25.3 3.5 0.6 9.9 0.106 
4 84.7 3.5 2.1 9.5 0.094 
5 55 1.7 1.3 9.6 0.091 
6 55 5.3 1.5 9.8 0.080 
7 55 3.5 1.7 9.8 0.080 
8 55 3.5 1.7 9.7 0.073 
9 55 3.5 1.8 9.8 0.074 
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Table 6-3 Summary statistics of master model. 
 
Summary of fit 
RSquare 0.9959 
RSquare Adj 0.9891 
Analysis of Variance (ANOVA) 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Model 5 2.182995 0.436599 146.4546 0.0009 
Error 3 0.008943 0.002981   
C. Total 8 2.191938    
Lack Of Fit 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Lack Of Fit 1 0.003331 0.003331 1.1868 0.3897 
Pure Error 2 0.005613 0.002806   
Total Error 3 0.008943    
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Table 6-4 Parameter estimates for master model. 
 
Term Estimate 
Std 
Error 
t Ratio Prob>|t| 
Intercept 1.750 0.0315 55.53 <.0001 
X1 (30,80) 0.601 0.0273 22.02 0.0002 
X2(2,5) 0.065 0.0273 2.38 0.0972 
X1*X2 0.405 0.0561 7.21 0.0055 
X1*X1 -0.271 0.0352 -7.69 0.0046 
X2*X2 -0.269 0.0352 -7.64 0.0047 
 
 
  
Figure 6-1 Pareto chart for master model. * next to p-value represents 
significant term. 
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Terms with positive influence on DEX solubility were X1 and X1X2 interaction 
suggesting low molecular DB1 polymer had better interaction with DEX resulting in higher 
solubility. On the other hand, X1X1 and X2X2 interactions lead to decrease in solubility. We 
subjected Polymer-DEX film, blank nanomicelles and DEXM to PXRD to understand to nature 
of X1X1 and X2X2 interactions. 
DB1 polymer was completely devoid of characteristic peaks of PCL (2 = 21.9) and 
mPEG (2 = 19.2 and 23.8) suggesting that the low molecular weight mPEG-PCL polymer is 
amorphous in nature (Figure 6-2b). Polymer:DEX film was prepared at a ratio X1:X2::30:5. 
XRD showed complete absence of characteristic peaks of PCL (2 = 21.9) and mPEG (2 = 19.2 
and 23.8) in the dried film (Figure 6-2c), suggesting that the X1X1 interaction does not represent 
crystallization of the polymer in case of DB1. Peaks corresponding to DEX were also very small 
(2θ = 14, 15.6 and 17) in the dried film, indicative of slight crystallization and X2X2 interaction. 
XRD analysis of dried DEX-polymer film was conducted after heating the films to delineate the 
effect of heating on physical form of polymer. The peaks for mPEG-PCL were also absent 
following heating of film at 65 oC (Figure 6-2c and Figure 6-2d). Unknown sharp peaks were 
noted at 2θ = 7.2 and 15 which did not correspond to DEX or polymer.  
Master model by itself served as predictive model as all factors and interactions were 
significant. The prediction expression for reduced model is represented by equation 6.1. 
Y = 1.750 +0.601*X1 +0.065*X2 +0.405*X1X2 -0.271*X1X1 -0.269*X2X2 …(6.1) 
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Figure 6-2 X-ray diffraction pattern for (a) Dexamethasone, (b) PCL-
mPEG polymer, (c) Polymer:DEX film before heating 
(Polymer:DEX::30:5), (d) Polymer:DEX film after heating 
(Polymer:DEX::30:5), (e) Freeze dried Blank micelles (f) Freeze dried 
DEXM (0.1% w/v DEX). 
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Response surface showing the change in solubility of DEX as a function of DEX and 
polymer amount is illustrated in Figure 6-3. In this case, solubility of DEX did not increase 
linearly with increasing polymer amount at all the DEX levels. The non-linearity can be 
attributed the X1X1 and X2X2 interactions. The prediction profile was generated to determine 
the optimal point with the highest desirability (Figure 6-4). The checkpoint analysis was carried 
out to validate the reduced model at X1:X2::80:4 ratio. Ratio X1:X2::80:4 was selected for 
checkpoint analysis, as it was not a part of design runs suggested by the statistical software (SAS 
9.02). No statistically significant difference was observed between experimental and predicted 
DEX solubility (p = 0.8852) (Table 6-5).  
The model was also validated by plotting predicted verses actual solubility (Figure 6-5). 
The relationship was found to be linear with R2 of 0.9959 indicating predicted solubility by 
model is close to experimental one. Based on checkpoint analysis and experimental verses 
predicted solubility, it can be concluded that the reduced model can accurately predict DEX 
solubility. Using prediction profile for reduced model, optimal X1:X2 ratio to obtain DEX 
solubility ≥1mg/mL was obtained.  
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Figure 6-3 Response surface of predictive model. DEX solubility (Y) is 
plotted as a function of polymer (X1) and DEX (X2) amounts between -1 
and 1. 
 117 
 
 
  
Figure 6-4 Prediction profile of reduced model depicting solubility (Y) as 
function of polymer (X1) and DEX (X2) amounts. 
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Table 6-5 Checkpoint analysis for master model. 
 
Polymer:DEX 
amount (mg) 
(n = 3) 
Predicted 
solubility 
(mg/mL) 
Experimental 
solubility 
(mg/mL) 
Two-tailed 
P-value 
% 
Standard 
error 
80:4 2.2 ± 0.093 2.2 ± 0.114 0.8852 1.33 
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Figure 6-5 Experimental solubility verses predicted solubility for 
predictive model for ED-2. R2 of 0.9959 suggests that DEX solubility 
predicted by reduced model are very close to experimental values. 
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6.2.2. Micelle size and morphology 
Nanomicelle size and distribution were determined by dynamic light scattering method 
for all the runs (Table 6-2). The size ranged from 9.8-10 nm with unimodal distribution 
irrespective of DEX solubility. The PDI for all the runs were below 0.11 indicating very narrow 
size distribution. A DSL analysis showing average size and PDI for DEXM is illustrated in 
Figure 6-6a. The average size was 9.5 nm with PDI of 0.11. The control over nanomicelle size 
was achieved by controlling the molecular weight of PCL and PEG segments of diblock 
polymer. The morphology of optimal nanomicelle was studied by TEM (Figure 6-6b). TEM 
micrograph of nanomicelles indicated that the nanomicelles were spherical in shape and the size 
of nanomicelles is consistence with DLS analysis.  
6.2.3. PXRD of blank nanomicelles and DEXM 
Blank micelles and DEXM were also studied by XRD to seek further insight into 
physical state of polymer and DEX in nanomicelles. The results are presented in Figure 6-2e and 
Figure 6-2f. XRD pattern for freeze-dried DEXM was devoid of DEX peaks indicating that the 
drug was molecularly dispersed in nanomicelle. Both blank micelles and DEXM did not show 
characteristic peaks for PCL. Unlike DB2 and DB3 polymers, DB1 is low molecular weight 
polymer with very short PCL and PEG chain length. This short chain length may be a reason for 
absence if characteristic peaks associated with PCL and PEG.  
6.2.4. 1H-NMR spectroscopy of blank micelles and DEXM 
1H-NMR spectroscopy was used to ascertain the presence of DEX in nanomicelle core. 
1H-NMR spectra for physical mixture of DEX and polymer in d6-DMSO, DEXM in D2O and 
DEX in d6-DMSO were recorded (Figure 6-7). 
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Figure 6-6 (a) Micelles size distribution for DEXM. (b) 
Transmission electron micrograph for DEXM. 
Nanomicelles appear as a white spot on dark background as 
indicated by arrows. 
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The 1H-NMR spectra for combination of DEX and polymer in d6-DMSO showed all the 
characteristic peaks corresponding to DEX, PCL and mPEG (Figure 6-7c). 1H-NMR for DEXM 
in D2O also showed presence of characteristic peak for mPEG segment at 3.4-3.6 ppm and those 
for PCL were absent, indicating micellization. During micelle formation PCL block assemble to 
form the hydrophobic core and mPEG segment forms hydrophilic corona. Since the core of 
micelle lacks accessibility to solvent, movement of PCL segment in the core is limited and hence 
the proton NMR signal is very weak compared to signal in DMSO. In contrast, the corona 
forming mPEG segment is free to move in D2O showing good 
1H-NMR signal intensity. 
Characteristic peaks for DEX were also absent due to restricted mobility inside micelle core, 
implying that drug was molecularly dispersed in micelle core (Figure 6-7d).   
6.2.5. Release kinetics of DEX release from DEXM 
The release study was performed in simulated tear fluid at 37 °C, under sink condition, to 
identify mechanism of DEX release from nanomicelles. Cumulative % DEX released verses time 
profile is illustrated in Figure 6-8. DEX release from the nanomicellar system lasted for 3.5 days. 
More than 50% DEX was released by day one from nanomicelles. Overall release pattern was 
similar to that observed for high molecular weight DB3 and DB2 nanomicelles. Release data was 
fitted to zero order, first order, Higuchi and Korsmeyer-Peppas model to determine the kinetics 
of DEX release. The best fit was found with the Korsmeyer-Peppas model with R2 of 0.9862 
compared to other models. The n value was found to be 0.63. Value of diffusion exponent 0.45 < 
n < 0.89 suggests that mechanism of release was anomalous transport. In this case, drug release 
is controlled both diffusion of drug and erosion of polymer.  
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Figure 6-7 1H-NMR spectrums for (a) PCL-mPEG polymer in CDCl3 (b) 
dexamethasone in d6-DMSO, (c) PCL-mPEG (50mg) and dexamethasone 
(1mg) in d6-DMSO, (d) 0.1% DEXM in D2O.  
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Figure 6-8 Release profile of dexamethasone from nanomicelles under 
sink conditions at 37 ˚C (mean ±SD, n = 4). 
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CHAPTER 7 
7. EFFECT OF NANOMICELLE SIZE ON PERMEABILITY. 
7.1. Methods 
7.1.1. In vitro permeability across HCEC cells 
Transwell diffusion chamber system was utilized for determining in vitro permeability of 
DEX from DEXM across conjunctival cells following a published protocol. Cells were seeded at 
a density of 25,000 per well in 12-well collagen-coated Transwell® permeable inserts (Costar®) 
and grown until confluency by changing medium every alternate day. Prior to a transport 
experiment, cell monolayers grown on the Transwell®  inserts were rinsed with DPBS (pH 7.4) 
and incubated at 37 °C for 10 min for twice for both apical (AP) and basolateral (BL) sides. 
Transport was initiated by adding 400 µL of DEX suspension or DEXM (in DPBS, pH 7.4) to 
the donor chamber (AP side) of cells. DPBS pH 7.4 was added in receiver chamber (BL side). 
Transport experiment was conducted for 3 h. Samples (100 µL) were collected from the receiver 
chamber at predetermined time intervals of 30, 60, 90, 120, 150, and 180 min and fresh DPBS 
pH 7.4 was replaced to maintain sink conditions in receiver chamber. The samples were analyzed 
by LC-MS/MS analysis following a previously published method from our laboratory 92. 
Permeability (Papp) of DEX was calculated using equation 7.1. 
Papp = M/A*Cd   … (7.1) 
Where, M represents the slope obtained from plot of cumulative amount of drug 
permeated verses time, A denotes surface area of membrane exposed to drug and Cd is the drug 
concentration in donor chamber at t = 0.  
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 Transport study was conducted in quadruplicate for all test and control sets. A statistical 
significance between permeability of DEX suspension and DEXM at p<0.05 was considered to 
be significant. 
7.1.2. Ex vivo permeability across excised rabbit sclera 
Tissue Preparation: Adult New Zealand male rabbits weighing between 2 and 2.5 kg 
were obtained from Harlan laboratory. All animal handling procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) of University of Missouri-Kansas City 
(UMKC, Kansas City, MO). Rabbits were anesthetized with I.M. administration of ketamine 
HCl (35 mg/kg) and xylazine (5 mg/kg). The animals under deep anesthesia were euthanized by 
an overdose of sodium pentobarbital (100 mg/kg) administered through marginal ear vein. Eyes 
were removed carefully and the posterior segment was separated by cutting along the limbus. 
The sclera was separated from retina and choroid and was placed in a petri dish containing 
Dulbecco’s phosphate-buffered saline (pH 7.4).  
In order to carry out permeability studies, the excised tissue was mounted on a Franz-type 
vertical diffusion cell (PermeGear Inc., Hellertown, PA) with episcleral side facing the donor 
chamber. The receptor chamber was filled with isotonic phosphate buffer saline (IPBS; pH 7.4). 
DEX suspension or DEXM formulation was added to the donor chamber to begin transport 
study. At a regular time interval 200 μL of sample was withdrawn from receptor chamber and 
replaced with an equal volume of fresh IPBS buffer. Experiments were carried under sink 
conditions, for 3 h at 37 oC (n = 4). The samples were analyzed by LC-MS/MS following a 
method published previously from our laboratory92. Permeability (Papp) of was calculated 
according to equation 7.1. 
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7.1.3. Analysis of DEX in buffer samples by LC/MS–MS  
LC-MS/MS method described earlier from our lab 92 was utilized with a few 
modifications for quantitating DEX in buffer samples from ex vivo transport studies. Ninety-
microliter aliquots of buffer samples were spiked with 20 ng of prednisolone (IS) and vortexed 
for 15 s. The analytes were then extracted with 900 µL of ice cold TBME and vortexed for 3.5 
min. Samples were centrifuged at 10,000 rpm for 7 min to separate the aqueous and organic 
layers. Seven hundred and fifty µL of the organic layer was collected and dried in vacuum. Dried 
sample was reconstituted in 100 µL of mobile phase (ACN:Water::40:60, 0.1% formic acid). Ten 
microliter of reconstituted sample was injected onto the LC/MS–MS for analysis. LC/MS-MS 
QTrap® API-3200 mass spectrometer, equipped with Shimadzu quaternary pump, vacuum 
degasser and autosampler (Shimadzu Scientific Instruments, Columbia, MD, USA) was 
employed to analyze samples from ex vivo studies.  
LC separation was performed on an XTerra® MS C18 column 50 mm × 4.6 mm, 5.0 µm 
(Waters, Milford, MA). The mobile phase consisted of 40% ACN and 60% water with 0.1% 
formic acid, pumped at a flow rate of 0.25 mL/min. Multiple reactions monitoring (MRM) mode 
was utilized to detect the compounds of interest. The mass spectrometer was operated in the 
positive ion mode for detection. The precursor to product ions (Q1 → Q3) for DEX and IS 
during quantitative optimization were (m/z) 393.20→355.30 and 361.30→147.20, respectively. 
The operational parameters for the tandem mass spectrum for each analyte were obtained after 
running them in quantitative optimization mode. The turbo ion spray setting and collision gas 
pressure were optimized (IS voltage: ±5500 V, temperature: 350 °C, nebulizer gas: 40 psi, 
curtain gas: 30 psi). The lower limit of quantification was found to be 31.25 ng/mL for DEX.  
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7.2. Results and discussion 
7.2.1. In vitro transport across conjunctival cells  
We examined DEX transport across conjunctival cells (in vitro) and excised rabbit sclera 
(ex vivo) as we hypothesize that the nanomicelles size may influence permeability of 
encapsulated drug. Figure 7-1a illustrates cumulative percentage DEX transported across 
conjunctival cells from nanomicelles and suspension (control). The permeability of DEX from 
suspension was 0.69x10-6 cm/sec (Figure 7-1b). Permeability with all DEXM were significantly 
higher; about 2-fold, compared to control (ANOVA p<0.0001). However, there was no 
significant difference between permeability among nanomicelles of various sizes (ANOVA, p = 
0.3461). These results clearly suggest that the nanomicelles can increase DEX permeability 
across the conjunctival cells. In addition, there was no influence of nanomicelles size on 
permeability.  
7.2.2. Transscleral permeability of DEX  
The sclera acts as a static barrier for transport of drug/nanocarriers towards back of the 
eye following topical administration. Hence, transport of DEX across the excised rabbit sclera 
was carried out for the nanomicelles and compared with DEX suspension (0.1% w/v). 
Cumulative %DEX verses time profile for DEXM and DEX suspension are illustrated in Figure 
7-2a. Figure 7-2b depicts permeability for DEX suspension and DEXM. Permeabilities were 
compared using ANOVA (more than two groups) and t-test (two groups). P-value less than 0.05 
were considered significant. Papp for DEX suspension was 1.19x10
-6 cm/sec. A statistically 
significant increase in Papp was observed with DEXM of all three sizes (Figure 7-2b, ANOVA 
p<0.0001).  
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Figure 7-1 (a) Cumulative % DEX transported across 
conjunctival cells verses time profile for dexamethasone 
suspension (Control) and DEXM. (b) Apparent 
permeabilities of DEX with DEXM and DEX suspension. 
(Data represented as mean ±SD, n=3). 
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In addition, Papp of DEX across the sclera also increased with decrease in micelle size 
(ANOVA, p<0.0001) as we hypothesized. Permeability of DEX from 60nm DEXM was minimal 
and very close to control, statistically significant nonetheless (t-test, p = 0.029). In addition, there 
was a lag time and DEX was below detection at 30 min time points for 60 nm DEXM compared 
to other DEXM and control. This could be attributed to higher size of nanomicelles that 
permeates slowly compared to smaller size DEXM or soluble DEX from suspension. 
Interestingly, no significant difference in Papp of DEX was observed for DEXM of 10 nm and 30 
nm (t-test p = 0.094). 
The increase in permeability with nanomicelles could be attributed to transport through 
the aqueous scleral pores 32. Based on these results, it can be concluded that the nanomicelles of 
mean size 30nm or less may improve bioavailability of drugs in the uveal track following topical 
administration. In addition, the conjunctival-scleral route could be of more importance compared 
to the corneal route in order to achieve higher intraocular levels. Trans-scleral route may be 
favored due to high surface are and absence of tight junctions like in the cornea. Moreover, 
nanomicelles typically have hydrophilic surface, which may limit its permeability across 
hydrophobic corneal tissue. Nanomicelles exhibited significantly high permeability for transport 
across the conjunctival cell line and sclera. Based on these preliminary experiments, we could 
suggest that there is a high possibility of achieving elevated drug levels in the intraocular tissues 
(uveal track) via conjunctival-scleral route. In addition, the in vitro release of DEX from 
nanomicelles was relatively slower and lasted for more than three days. Thus, the frequency of 
topical administrations may also be reduced increasing patient compliance.  
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Figure 7-2 (a) Cumulative % DEX transported across the 
excised rabbit sclera verses time profile for dexamethasone 
suspension (Control) and DEXM. (b) Apparent 
permeabilities of DEX from DEXM and DEX suspension. 
(Data represented as mean ±SD, n=3). 
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CHAPTER 8 
8. SUMMARY AND RECOMMENDATIONS. 
8.1. Summary 
Nanocarriers have been exploited for a long time for enhanced ocular drug delivery as 
they offer a number of advantages over conventional formulations. Nanocarriers such as 
nanoparticles, liposome and nanomicelles have been examined for anterior and posterior segment 
delivery. Nanomicelles, however, have gained a significant attention as ODD vehicle in the past 
decade.  
Drug delivery to the intraocular tissues such as uveal track following topical 
administration is highly challenging task due to structure of the eye, which forms formidable 
barriers to drug delivery. However, a surfactant mixed micelle formulations from our laboratory 
have shown a significant potential in delivering variety of drugs to the intraocular tissues. In 
addition, liposomal formulations have also been shown to be effective in delivery hydrophobic 
molecules to the intraocular tissues. For these formulations, trans-scleral pathway may more 
significant than trans-corneal route to deliver drugs to the intraocular tissues. Therefore, it is 
important to delineate the influence of nanocarrier size on trans-scleral transport of encapsulated 
drugs.  
In order to achieve this goal, we synthesized mPEG-PCL di-block copolymers. Di-block 
polymers were characterized for its structure, molecular weight, polydispersity. All polymers 
possessed acceptable polydispersity. Biocompatibility of these newly synthesized polymers by in 
vitro cell cytotoxicity in ocular cell lines indicated that the polymers are safe for ODD. Control 
over nanomicelles size is very crucial factor in this study. Control over nanomicelle size was 
achieved by simple molecular weight control of polymers, which will ultimately constitute 
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micelles. Nanomicelles of various sizes including 10nm, 30nm and 60nm. DEX was utilized as 
model agent, which is also clinically used to treat ocular inflammation such as uveitis.  
DEX has a very poor aqueous solubility (~90-100 µg/mL). Nanomicelle is an ideal 
system to improve aqueous solubility of DEX by dissolving it in the hydrophobic micelle core. 
Film-hydration method (Method-1) was utilized to dissolve DEX in nanomicelle core as this is 
method is very simple and can be scaled up at industrial level relative to solvent-extraction 
methods. However, this method did not result in very high solubility of DEX in nanomicelles 
prepared using DB2 polymer. Therefore, an exploratory model was employed to identify the 
factors or interactions influencing the DEX solubilization in nanomicelles. A 3-level response 
surface design was utilized as this design has a center points which allows determine the 
curvature effect in the response variable due to second order interactions such as 
polymer*polymer (X1X1) and DEX*DEX (X2X2) interactions in our case. Exploratory model 
suggested that the X1X1 was major interaction resulting in poor DEX solubilization. The nature 
of X1X1 interaction was found to be crystallization of polymer, which was confirmed by PXRD 
analysis of dried polymer-DEX film.   
Based on the results from exploratory model, it was clear that we have to overcome the 
crystallization of polymer during solvent evaporation, which may favor interaction between drug 
and polymer leading to higher solubility. This was achieved by simple heating of the polymer-
DEX film at melting temperature of the PCL polymer (Modified film-hydration method). 
Reconstitution of this melted film in water lead to micelle formation and higher solubility of 
DEX (0.1 wt%) in nanomicelle core. Similar increase in aqueous solubility was observed for 
DB1 and DB3 polymers with modified film-hydration method. PXRD studies with DB2 and 
DB3 polymers indicated that these polymers have relatively similar behaviors in terms of 
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physical state in the dried polymer-DEX film before and after heating.  Low molecular weight 
DB1 was amorphous compared to DB2 and DB3. A very high DEX solubility with DB1 was 
achieved which could be attributed to its amorphous nature which may resulted in better 
polymer-DEX (X1X2) interactions during solvent evaporation compared to crystalline DB2 and 
DB3 polymers. DEX was molecularly dispersed in all nanomicelles prepared with all DB 
polymers as suggested by PXRD analysis of freeze-dried DEXM and proton-NMR of DEXM. 
Kinetic of DEX release from DEXM was studied by performing in vitro release studies in STF. 
Total release duration ranged from 2-3 days for all DEXM. Thus, these nanomicelles may also 
minimize the frequency of topical administration due to long-term release.   
In vitro permeability of DEX with all DEXM were significantly higher; about 2-fold 
higher compared to control (DEX suspension). Nanomicelles increased DEX permeability across 
the conjunctival cells. However, there was no significant influence of nanomicelles size on 
permeability across the conjunctival cells. The sclera acts as a static barrier for transport of 
drug/nanocarriers towards back of the eye following topical administration. Hence, transport of 
DEX across the excised rabbit sclera was carried out for the all nanomicelles and compared with 
DEX suspension. Permeabilities of DEX from 10nm and 30nm nanomicelles were significantly 
high compared to control and 60nm nanomicelles clearly suggesting an influence of 
nanomicelles size on permeability. Interestingly, no significant difference in Papp of DEX was 
observed for DEXM of 10 nm and 30 nm. Based on these results it can be concluded that the 
nanomicelles of mean size 30nm or less may improve bioavailability of drugs in the uveal track 
following topical administration.  
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8.2. Recommendations 
Trans-scleral pathway could be targeted using nanocarriers such as nanomicelles. 
Conjunctiva-scleral route may be favored due to high surface are and absence of tight junctions 
like in the cornea. Moreover, nanomicelles typically have hydrophilic surface that may limit its 
permeability across hydrophobic corneal tissue. Therefore, the trans-scleral route could be of 
more importance compared to the corneal route in order to achieve higher intraocular levels 
following topical administration. 
We have here shown that the size of nanocarrier is a significant parameter that influences 
permeability across porous tissue like sclera. Based on these results, a nano-formulation can be 
designed to achieve higher drug levels in intraocular tissues following topical administration. 
This may be a potential explanation for enhanced retinal drug levels from mixed micelles 
formulation in rabbits. Nevertheless, further in vivo studies may be required. Other parameters 
such as surface charge, hydrophobicity, hydrophobicity may also influence permeation. These 
factors may require further studies. Stability of nanocarrier, especially for nanomicelles and 
liposome is important parameter during transport of nanocarrier across the sclera and 
conjunctiva. Nanocarriers such as nanoparticles may be better option due to their rigid structure 
and sustained release behaviors. In contrary, nanomicelles represent more fluid character and 
faster degradation. The fluid nature of nanomicelles especially ones made from low molecular 
DB1 (amorphous) polymer may fall apart under sheer stress while transport across the sclera. 
This may result in premature release of drug and it may precipitate depending on its aqueous 
solubility. In such case, high molecular weight DB2 polymers may be a suitable candidate. 
Nanomicelles core rigidity may also be enhanced by cross-linking the core forming polymer 
block. However, the cross-linked construct should be biodegradable. 
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PART II: STRATEGIES TO MINIMIZE OCTREOTIDE ACYLATION DURING 
SUSTAINED RELEASE FROM BIODEGRADABLE POLYMERS. 
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CHAPTER 1 
1. LITERATURE REVIEW: SUSTAINED PROTEIN AND PEPTIDE DELIVERY93. 
1.1. Challenges in protein and peptide delivery 
Proteins are large biomolecules with complex tertiary (3) and quaternary (4) structures. 
These macromolecules participate in a number of biological pathways and have diverse 
functionalities such as enzymes, hormones, interferons and antibodies. The complex 3 and 4 
structures impart important properties including selectivity, specificity and high potency. 
Abundance in various biological functions, specificity and potency are most important 
parameters. Newer targets are being discovered at a rapid rate due to advanced understanding of 
pathology such as cancer and autoimmune diseases. Precise number of proteins expressed in the 
human body is not known yet. But various reports suggest that there are at least 84,000 to 
200,000 different proteins in the human body 94. Protein-protein interaction plays a key role in 
most biological pathways. It may be targeted by designing agonist or antagonist peptides and 
proteins 95. Advancement in high throughput (HTS) technology such as hot-spot determination 
has also catalyzed development of novel biotherapeutics 95a, 96. Therapeutic protein  and peptide 
development and production have reached advanced stages owing to innovations in 
manufacturing technology 97, process control 98, and protein characterization 99. Additionally, 
protein biotherapeutics have shown to be very efficacious and specific, such as antibodies. 
However, we are yet to take full advantage of these potent biotherapeutics despite the fast-paced 
advancements in protein therapeutics R&D and production. U.S. biopharmaceutical industry is 
one of most innovative and research intensive enterprise as noted by Congressional Budget 
Office 100. As per recent market survey pharmaceutical/biotech industry invested nearly a $50 
billion every year from 2011 to 2013 in R&D of new medicines and most of it was spent for 
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biopharmaceutical R&D 101. As a result, there are more than 907 biotherapeutics in various 
phases of clinical trials. Of these biotherapeutics, majority are protein biotherapeutics including 
338 monoclonal antibodies, 93 recombinant proteins, 20 interferons and 250 vaccines for various 
conditions such as cancer, autoimmune diseases and infectious diseases94a.  
Proteins and peptides pose a number of delivery related challenges due to a myriad of 
factors. Some of them are large size, hydrophilicity, poor permeability across biological 
membranes (such as GI tract), susceptibility to enzymatic degradation, complex structure and 
immunogenicity 102. Large molecular size and hydrophilicity hinder permeation across biological 
barriers such as GI mucosa leading to poor absorption following oral administration. Extreme 
gastric pH and digestive enzymes degrade these biologics prior to oral absorption. Following GI 
absorption, the first pass metabolism eliminates a significant fraction of absorbed biomolecules. 
Hence, delivery of biologics via most favored - oral route - is highly challenging. Hence, a large 
portion of approved and investigational protein molecules is administered via parenteral routes 
(IV, IM or SC). Proteins and peptides also suffer from a number of physical, chemical and 
biological instability due to their complex secondary, tertiary and quaternary structures. Any 
alteration in “active” confirmation may lead to loss of activity and irreversible aggregation of 
proteins. Vulnerability towards enzymatic degradation under in vivo condition results into short 
half-lives even with parenteral administration. Many biologics are intended for chronic ailments 
such as bevacizumab for age-related macular degeneration. Short half-lives of proteins require 
frequent parenteral administrations to maintain therapeutic levels. However, frequent parenteral 
administrations are not patient compliant. In addition, frequent administrations may not be well 
tolerated. For example, frequent intravitreal injections have been shown to be associated with 
many complications including cataract, retinal hemorrhage and detachment 103.  
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Invasive and non-invasive routes have been investigated with various formulations to 
deliver biologics. As mentioned earlier, most frequently used invasive routes are IV, IM and SC. 
Non-invasive routes include oral, rectal, transdermal and inhalation. Of these, the most preferred 
noninvasive route is per-oral administration, which is also the “Holy Grail” of protein delivery. It 
is highly challenging among the noninvasive routes due to the limitations discussed earlier. 
Major approaches used for oral protein delivery include use of absorption enhancers such as 
surfactants, enzyme inhibitors, polymer–inhibitor conjugates, mucoadhesive particles, thiolated 
polymers, nanoparticles, microparticles and emulsion based formulations77d, 104. Nevertheless, all 
these approaches suffer from certain drawbacks and side effects. For example, cost of effective 
enzyme inhibitors, adverse effects due to frequent oral administrations in chronic diseases, poor 
stability of formulations such as liposomes in GI track, poor loading efficiency of protein in 
particles owing to hydrophilicity, polydispersed size distribution and particle aggregation 104c. 
Similar limitations are also associated with non-invasive routes of delivery105. Moreover, it is 
challenging to achieve controlled protein delivery for extended duration via ‘patient compliant’ 
non-invasive routes. A potential reason for the failure of treatment strategy in chronic diseases 
may be lack of adherence to a given treatment regimen by patient. Therefore, frequent 
administration is not a recommended strategy for chronic ailments. As per an estimate by WHO, 
only 50% of patients suffering from chronic diseases stick to the treatment regime in developed 
countries 106. In developing countries, adherence to prolonged therapy is even lower 106.  
Therefore, proteins are suitable candidate for sustained release formulations. Advantages of 
sustained delivery formulation include better adherence to chronic therapy, in vivo stability, local 
delivery, fewer side effects, reduction in dose and dosing frequency, and improved patient 
compliance. Furthermore, parenteral routes, although not very patient compliant, may be a 
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simpler answer to limitations and drawbacks associated with non-invasive administrations. 
Extended duration of delivery with lower frequency of administration may improve patient 
compliance significantly.    
Ideal protein delivery formulation should be able to provide controlled release to 
maintain therapeutic levels for an extended duration and ensure stability of encapsulated protein. 
Components of delivery system must be biodegradable and/or biocompatible, non-immunogenic, 
non-toxic and preferably FDA approved for human use. If the formulation is intended via 
parenteral route, it should be possible to inject it through a narrow gauge needle to minimize 
pain. In addition, in a few cases, it is impractical to use higher gauge needles. For example, in 
case of intravitreal injections, a 27G to 30G needle is recommended to avoid damage to 
intraocular tissues. Volume of injection should also be considered carefully depending on the 
route of administration. Structure and activity should not be altered during the preparation of 
delivery system and biologics must be in active conformation following in vivo release. In 
particulate and hydrogel based systems, initial burst release is a serious concern. In the case of 
particle-based systems, burst release is due to high surface adsorption of biologics. Higher initial 
burst release may shorten total duration of release and result in dose-dependent adverse effects. 
Therefore, the formulation must be optimized to achieve minimal burst release. Above all these 
factors, method of formulation preparation should be scalable, robust and reproducible. 
Statistical methods such as quality-by-design, design of experiments 107 and in-process quality 
control methods such as six-sigma may be able to aid development of high quality product with 
robust and reproducible method of manufacturing 98, 108. 
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1.2. Microparticles as sustained delivery formulation 
Controlled release of protein from parenteral formulation can be achieved by a matrix-
type delivery system. Microsphere formulation holds distinct advantages and has gained 
popularity in recent years109. More than 200 studies have been published per year pertaining to 
biodegradable microsphere formulations for peptide and protein delivery. Advantage of 
employing microspheres formulation for delivery of proteins is that it offers stability for 
molecules, which are rapidly degraded or eliminated in vivo. Encapsulation in microsphere 
prevents contact of protein from cells or enzymes such as proteases/esterases in surrounding 
tissues, until it has been released from microsphere. Microsphere formulation can be easily 
delivered to the target sites via IV, IM or oral route. Owing to the recent advancements in 
polymer science and synthesis technology, development of controlled release microsphere 
formulations has gained immense popularity. The polymers should not produce harmful side 
effects or toxic degradation products, and neither should it alter any pharmacological properties 
of the active ingredient. It should also be non-toxic, non-irritant and biocompatible if not 
biodegradable110.  
Formulation of microspheres from biodegradable polymer is initiated by selecting an 
appropriate encapsulation method in order to achieve desired/ideal controlled release. Particle 
size and polydispersity is another important aspect as it directly influences syringeability, which 
is one of the important requirement for an ideal microsphere system. During microsphere 
formulation process, there should be no alteration in biological activity of encapsulated protein. 
Methods in which exposure of protein/peptide in strong denaturing solvent are not employed 111.  
Spray drying method has also been employed in formulating microspheres. Volatile 
organic solvents such as dichloromethane or acetone are used to dissolve biodegradable polymer. 
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Then the drug is dispersed into the polymer solution in solid form by high-speed 
homogenization. Volatile organic solvent is then evaporated yielding microspheres of 1 to 100 
mm size range. Proteins such as recombinant human erythropoietin were encapsulated in 
microsphere using spray drying method in nitrogen atmosphere112. Release of active ingredient 
from microspheres occurs via different mechanisms such as diffusion, polymer degradation, or 
combination of them113.  
Chronic ulcerations of the skin have been reported due to the deficiency of prolidase 
enzyme. This enzyme is involved in the later stages of protein catabolism. To overcome this 
problem, PLGA microspheres encapsulating prolidase were formulated by w/o/w multiple 
emulsion technique. Results obtained from ex vivo studies demonstrated that microencapsulation 
imparted stability to protein inside the polymer matrix leading to release of active enzyme from 
the formulation. This technique can be employed for enzyme replacement therapy114. 
Similarly, another formulation of PLGA microspheres has been prepared with β-lacto 
globulin (BLG). Newborns are prone to allergies related to milk proteins, which can be 
prohibited by prompting oral tolerance to these proteins. PLGA microspheres encapsulating a 
major allergenic protein, BLG, were formulated by w/o/w double emulsion technique. Controlled 
release of proteins and higher encapsulation efficiency were reported after introduction of tween 
20 in the formulation. Improved encapsulation efficiency and controlled release resulted in the 
reduction of dose required for specific anti-BLG IgE response following oral administration 115. 
A microsphere formulation encapsulated with Interferon α (IFN α) and comprising of 
calcium alginate core surrounded by PELA (poly D, L-lactide-poly ethylene glycol) was 
prepared by w/o/w multiple emulsion technique. Coated microspheres impart stability to IFN α 
in the PELA matrix. These microspheres also demonstrated enhanced encapsulation efficiency 
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and retention of biological activity as compared to microspheres produced by conventional 
method110. In another study, PLGA microspheres encapsulated with salmon calcitonin exhibited 
5-9 days release following S.C. injection in rats 116. Blends of poly(ethylene glycol) (PEG) with 
poly(lactic acid) (PLA) homopolymer and PLGA copolymer were utilized to prepare insulin-
loaded microspheres by w/o/w multiple emulsion technique. The resulting microspheres 
exhibited high entrapment efficiency and provided controlled release of insulin for 28 days117. In 
another study, ZnO-PLGA microspheres containing insulin demonstrated rapid and long-lasting 
suppression of glucose levels for 9 days following subcutaneous administration in rats118. Table 
1-1 summarizes the clinically approved sustained-release microparticle formulations. 
  
 
 
Table 1-1 Clinically approved sustained-release microparticle formulations. 
Trade name Drug Indications 
Delivery 
System 
Length of 
release 
Approval 
year 
Lupron Depot® 
(TAP) 
Leuprolide Prostate 
cancer, 
endometriosis 
Injectable 
PLGA 
microparticles 
(intramuscular 
injection) 
1-, 3- and 
4- month 
formulations 
1989 
Sandostatin® 
LAR® 
(Novartis) 
Octreotide Acromegaly Injectable 
PLGA 
microparticles 
(intramuscular 
injection) 
1-month 1998 
Somatuline® LA 
(Ipsen) 
Lantreotide Acromegaly Injectable 
PLGA 
microparticles 
(intramuscular 
injection) 
10-14 days 1998 
Nutropin Depot® 
(Alkermes/ 
Genentech) 
Human 
growth 
hormone 
(hGH) 
Growth 
hormone 
deficiency 
Injectable 
PLGA 
microparticles 
(subcutaneous 
injection) 
1-month 1999 
Trelstar Depot® 
(Debiopharm) 
Triptorelin Prostate 
cancer 
Injectable 
PLGA 
microparticles 
(intramuscular 
injection) 
1- and 3- 
month 
formulations 
2000 
Risperdal® 
Consta® 
(Alkermes/Janssen) 
Risperidone Schizophrenia Injectable 
PLGA 
microparticles 
(intramuscular 
injection) 
2 weeks 2003 
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1.3. Nanoparticles-in-gel composite systems 
A considerable attention has been paid to sustained delivery of protein therapeutics via 
encapsulating in nano/micro particles. Nano/micro particles provide a stable environment for 
peptide/protein against catalytic enzymes, allowing improved biological half-lives. However, 
protein-loaded particulate drug delivery systems exhibited major disadvantage of burst effect 
(dose dumping) which may result in severe dose related toxicity. Nanoparticle-in-gel composite 
systems has been investigated to minimize the burst release of proteins and provide localized 
delivery119.  
Posterior segment ocular diseases such as wet age-related macular degeneration (wet-
AMD), diabetic retinopathy, and diabetic macular edema are sight-threatening disorders mainly 
observed in elderly patients. Many protein therapeutics such as bevacizumab, ranibizumab and 
aflibercept are repeatedly injected (intravitreally) for the treatment of above-mentioned ocular 
diseases. Repeated intravitreal injections lead to many complications like endophthalmitis, 
retinal detachment and retinal hemorrhage, and more importantly patient noncompliance. 
Recently, Mitra et al. have described protein encapsulation in pentablock (PB) polymer 
nanoparticles dispersed in PB thermosensitive gel for the sustained delivery of proteins following 
intravitreal delivery 120. PB copolymers exhibited excellent biocompatibility with negligible 
toxicity. A composite formulation (protein-encapsulated PB NPs dispersed in PB 
thermosensitive gel) exhibited nearly zero order release with no burst effect. Recently, we have 
discussed the applicability of a PB polymeric nanoparticles and nanoparticles-in-gel composite 
formulation for the sustained delivery of proteins in the treatment of posterior segment ocular 
diseases 119b, 121. Results demonstrated that model proteins (bovine serum albumin, IgG and 
bevacizumab)-loaded PB composite formulations exhibited nearly zero order release up to 45-60 
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days. Burst effect in nanoparticles is observed due to immediate release of surface adsorbed 
proteins. However, when the NPs are dispersed in thermosensitive gel matrix, an additional 
diffusion layer provided by gelling polymer hinders the release of surface adsorbed drug 
resulting in elimination of burst effect. In addition, biological activity of the protein molecules 
was confirmed by in vitro experiments.  
Administration of vascular endothelial growth factor (VEGF) in appropriate dose may 
prove as a promising treatment for the deficient bladder reconstruction therapy. However, short 
half-lives and high instability due to deamidation, diketopiperazine formation and oxidation of 
proteins (VEGF) resulted in disappointing clinical trials. Due to high instability, large dose of 
protein is required which often attributed to sever side effects such as progression of malignant 
vascular tumors122. In order to achieve sustained release with minimum burst release of VEGF, 
Geng et al. prepared VEGF-encapsulated PLGA nanoparticles and dispersed them in Pluronic-
F127 thermosensitive polymer solutions123. VEGF-NPs exhibited up to ~40% of burst release 
within the first two days which is significantly reduced to ~15% with the formulation of VEGF-
NPs dispersed in thermosensitive gel 123. Controlled delivery of VEGF from a biocompatible 
delivery system may eliminate the requirement of repeated dosing and possible dose related 
toxicity. Promising preliminary results observed with the composite delivery system in the 
treatment of chronic diseases may prove to be cost effective highly patient compliant therapy. 
 
 
  
 147 
 
 
CHAPTER 2 
2. STATEMENT OF PROBLEM, HYPOTHESIS AND OBJECTIVES 
2.1. Statement of problem 
Proteins and peptides based biotherapeutics are currently being introduced rapidly into 
the clinical trials for treatment of a number of diseases. These biologics suffer from a myriad of 
delivery related constrains such as poor bioavailability, permeability across biological 
membranes and in vivo stability. Short in vivo half-life leads to frequent multiple parenteral 
administrations, which lowers patient compliment. Sustained delivery of biologics may address 
these issues and improve their potential as therapeutics. Among the approaches investigated for 
sustained delivery of biologics, nano- and microparticles are in the forefront and clinically 
available for various ailments 93, such as Sandostatin LAR® depot containing octreotide.  
Octreotide is a semisynthetic cyclic octapeptide, a somatostatin analogue, indicated for 
acromegaly ( 
Figure 2-1a)124. It is also recommended for symptomatic relief by suppressing severe 
diarrhea and flushing episodes associated with metastatic carcinoid tumors124-125. Half-life of this 
peptide following S.C. and I.M. administrations is short, about 100 min 126. It is marketed as 
solution for subcutaneous injection (lactate buffer, pH 4.2) and as a depot form for intramuscular 
administration. PLGA-glucose star polymer microparticles (MPs) (size ~40 μm) provide delivery 
over a period of 4 weeks. PLGA has been widely investigated for the delivery of bioactive 
peptide and proteins 93. However, it may not be the best polymer for delivering peptide and 
protein biologics due to acylation of biologics during release127. It has been well documented that 
chemical stability of octreotide is compromised due to acylation during the release127a. Less than 
20% of native octreotide was released from Sandostatin LAR® depot during in vitro release127a.  
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Figure 2-1 (a) Structure of octreotide. (b) Nucleophilic carbonyl-substitution 
mechanism of peptide acylation in PLGA microparticles. Nucleophilic attack of 
amine from peptide on partial positive carbon of degraded PLGA fragment results 
into formation of insoluble adduct (step 1). Alcohol (-OH) and thiol (-SH) groups 
may also act as nucleophile. Hydrolysis of polymer side chain in insoluble peptide 
adduct results in release of soluble acylated peptide (step 2). 
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Nearly 60% octreotide was released as acylated adduct over period of 3 months127a. 
Chemical derivatization of octreotide is because of reaction of peptide with degraded PLGA 
oligomers inside the MP core. Structure of octreotide and mechanism of peptide acylation is 
illustrated in  
Figure 2-1. Preliminary data indicates that nucleophilic attack of amine from peptide on 
partial positive carbonyl carbon is responsible for chemical derivatization of peptide during 
release. Thiol (-SH) and alcohol (-OH) groups have also been reported to act as nucleophiles. 
The mechanism of acylation reaction is nucleophilic carbonyl substitution. Similar phenomenon 
has been reported for other protein and peptides such as bovine serum albumin, human atrial 
natriuretic peptide, human parathyroid hormone, leuprolide, insulin and salmon calcitonin127b, 128. 
Acylation of peptide also leads to formation of water insoluble adducts resulting in incomplete 
release of peptide from MPs ( 
Figure 2-1b, step 1) 127c. As a result, 15% of octreotide was not released, which may be 
attributed to formation of water insoluble adducts127a. 
Several strategies have been undertaken to minimize peptide acylation with limited 
success. Some of them are polymer modifications and encapsulation of divalent cations127a, 128b, 
128d, 129. Thus, there is an unmet need to develop an extended release formulation, which can 
deliver peptides in active form.  
2.2. Strategies and objectives 
There are two primary objectives of this research (1) extended delivery of octreotide (2) 
minimize peptide acylation during release. We aim to examine two strategies to minimize or 
prevent acylation of peptide during extended release from biodegradable polymers.  
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Strategy 1: Effect of various polymer compositions on octreotide acylation will be tested. Effect 
of polycaprolactone (PCL), polylactic acid (PLA) and polyglycolic acid (PGA) will be examined. 
Effect of PLA and PGA on peptide acylation is well established. However, no information is 
available on effect of PCL on peptide acylation. We hypothesize that modification of the 
composition of polymer blocks may minimize acylation and sustained release. MPs of triblock 
polymer (PCL10k-PEG2k-PCL10k) and pentablock co-polymers (PLA3k-PCL7k-PEG2k-PCL7k-PLA3k 
and PGA3k-PCL7k-PEG2k-PCL7k-PGA3k) will be developed for extended delivery of octreotide. 
Further, to sustain the release and minimize the possibility of burst effect130, MPs will be 
suspended in thermo-responsive gel solution. Special emphasis was placed on acylation of 
octreotide during release from caprolactone, glycolide and lactide based polymeric MPs. 
Strategy 2: In the second strategy, we will test potential of reversible hydrophobic ion-paring 
complexation in minimizing acylation of octreotide from polylactide-co-glycolide polymers. 
Amine of peptide is the most reactive nucleophile resulting in peptide acylation. In this strategy, 
the anime functional group will be masked using an ion-pairing agent. The complex is 
hypothesized to be stable at lower pH inside the microparticle core and will dissociate at 
physiological condition to release free native peptide, based on previous studies from our 
laboratory. HIP complex of octreotide will be encapsulated in MPs of PLGA polymer. PLGA 
(50/50) will be utilized to examine potential of HIP complex in minimizing peptide acylation, as 
it is known to cause acylation of peptides and proteins.  
 
Based on these strategies, specific aims of this proposal are as follows.  
1. Synthesis and characterization of triblock polymer (TB = PCL10k-PEG2k-PCL10k). Polymer will 
be characterized for molecular weight, purity, structure and physical property. Pentablock co-
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polymers for nanoparticle preparation (PB = PLA3k-PCL7k-PEG2k-PCL7k-PLA3k and PGA3k-
PCL7k-PEG2k-PCL7k-PGA3k) and thermosensitive gel (PLA250-PCL1250-PEG1500-PCL1250-
PLA250 and PCL1000-PEG1000-PCL1000) were synthesized and characterized earlier.  
2. Preparation of MPs encapsulating octreotide using above-mentioned TB and PB polymers. 
Characterize MPs for size, peptide loading and in vitro release. Concentration of release native 
and acylated peptide will be determined by HPLC assay.  
3. Preparation of hydrophobic ion-pairing complex of octreotide with dextran sulfate and sodium 
dodecyl sulfate. Characterize the effects of ion-pairing agent to octreotide on complexation 
efficiency and mechanism of dissociation.  
4. Encapsulate HIP-complexed octreotide in MPs using PLGA polymers. Characterize MPs for 
size, peptide loading and in vitro release. Concentration of release native and acylated peptide 
will be determined by HPLC assay. 
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CHAPTER 3 
3. EXTENDED RELEASE FORMULATION OF OCTREOTIDE: SIMULTANEOUS 
DIFFUSION AND ACYLATION OF PEPTIDE. 
3.1. Materials 
Octreotide acetate (PubChem CID: 383414)  was procured from ChinaPeptides Co., Ltd 
(Shanghai, China). D,L-lactide (PubChem CID: 65432), glycolide (PubChem CID: 7272), 
caprolactone (PubChem CID: 10401), stannous octoate, Poly(ethylene glycol) (Mw 2000 g/mol) 
and polyvinyl alcohol were obtained from Sigma Aldrich (St Louis, MO). All other 
solvents/chemicals were of analytical reagent grade. 
3.2. Methods 
3.2.1. Preparation of triblock and pentablock co-polymers 
TB (PCL10k-PEG2k-PCL10k) co-polymer was synthesized by ring-opening bulk 
copolymerization following a published protocol from our laboratory 131. Subscript represents 
molecular weight of polymer segment. PEG (Mw 2000 g/mol) with both hydroxyl end was 
vacuum-dried for 4 h, which acted as initiator to polymerize ε-caprolactone using stannous 
octoate (0.5 wt %) as catalyst. The reaction was carried out in a closed vessel under nitrogen, at 
130 °C for 36 h. The resultant polymer was purified by cold ether precipitation. Purified polymer 
was vacuum-dried followed by freeze-drying to remove any residual solvent and moisture. 
Structure and molecular weight of TB copolymers were confirmed by 1H-NMR and gel 
permeation chromatography (GPC). Pentablock (PB) co-polymers for nanoparticle preparation 
(PBA = PLA3k-PCL7k-PEG2k-PCL7k-PLA3k and PBB = PGA3k-PCL7k-PEG2k-PCL7k-PGA3k) and 
thermosensitive gel (PLA250-PCL1250-PEG1500-PCL1250-PLA250 and PCL1000-PEG1000-PCL1000) 
were synthesized and characterized earlier131-132.  
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3.2.2. Preparation of octreotide encapsulated microparticles  
Octreotide-loaded MPs were prepared using TB, PBA or PBB polymer by methanol-
oil/water solvent evaporation method. Briefly, methanol phase (Me) consisted of 5 mg octreotide 
dissolved in 50 µL of methanol containing triethyl amine (TEA) (mole ratio 
Octreotide:TEA::1:2.5). Polymer (TB or PB) was dissolved in dichloromethane (DCM) (100 mg 
in 500 µL DCM) constituting oil (O) phase. The methanolic phase containing octreotide was 
mixed with polymer solution aided by probe sonication for 30 sec at 2 output to make Me-O 
phase. This Me-O phase was slowly added to the water phase (650 µL, 1% PVA with 5% NaCl) 
under constant stirring to form a Me-O/W1 emulsion. Emulsion was further diluted with 3 mL of 
1% PVA (5% NaCl) (W2) and stirred for 3 h under hood to remove organic solvent. The MPs 
were separated by centrifugation at 15,000 RPM for 10 min. Particles were washed three times 
with DDI water. MPs were freeze-dried using mannitol (2% w/v) as a cryoprotectant and stored 
at -20˚C until further use. Ghost MPs were prepared following the same method except no 
octreotide was added during preparation.  
3.2.3. Drug loading (%) and entrapment efficiency (%) 
Amount of octreotide in MPs was measured by UV spectroscopy. A known amount of 
freeze-dried MPs (5 mg, n = 3) were dissolved in 200 µL DMSO. UV absorbance was measured 
at 280 nm. Ghost MPs served as blank. Entrapment efficiency (%EE) and Drug loading (%DL) 
were calculated by following equations 1 and 2, respectively. 
%EE = (Amount of octreotide in MPs/Total amount of octreotide)*100  … (3.1) 
%DL = (Amount of octreotide in MPs /Total weight of MPs)*100  … (3.2) 
 154 
 
 
3.2.4. Powder X-ray diffraction (PXRD) 
Physical state of polymers was investigated by PXRD analysis. MiniFlex automated X-
ray diffractometer (Rigaku, The Woodlands, Texas) with Ni-filtered Cu-kα radiation (30 kV and 
15 mA) was employed to study diffraction patterns at room temperature. 
3.2.5. Scanning electron microscopy 
SEM analysis was performed to analyze particle morphology (size and shape). Briefly, 
freeze-dried MPs were applied to carbon film positioned on an aluminum stub. Surface of 
particles on carbon film was coated with Au-Pd under centrifugation followed by sample 
analysis in Phenom Pro desktop scanning electron microscope. 
3.2.6. Release study 
Freeze-dried MPs were subjected to in vitro release study in PBS buffer (137 mM NaCl, 
2.7 mM KCl, 10 mM Na2HPO4, 1.8 KH2PO4; pH 7.4) at 37 °C. Predetermined amount of MPs 
were suspended in 400 µL of thermosensitive gel solution (20 wt%) maintained at 4°C to prevent 
accidental gelation. TBMPs were suspended in triblock gel (PCL1000-PEG1000-PCL1000) solution. 
PBAMPs and PBBMPs were suspended in PB gel (PLA250-PCL1250-PEG1500-PCL1250-PLA250) 
solution. Preparation and characterization of these gelling polymers has been published earlier132-
133. Composition of MPs and gel are depicted in Table 3-1. Resulting MPs in gel suspension was 
incubated at 37 °C for 2 min followed by slow addition of 800 µL of PBS (pH 7.4), preincubated 
at 37 °C. At predefined time intervals, 700 µL of clear supernatant was collected and replaced 
with fresh PBS. Release samples were evaluated for amount of native and chemically modified 
octreotide using UFLC assay. The experiments were carried out in quadruplets and plotted as 
cumulative octreotide released (%) relative to %EE verses time. Ghost MPs were kept as control.   
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Table 3-1 Compositions of MPs-in-gel formulation for release study. 
 
Octreotide-
encapsulated 
MPs 
Thermoresponsive Gel composition132 
TBMPs PCL1000-PEG1000-PCL1000 
PBAMPs PLA250-PCL1250-PEG1500-PCL1250-PLA250 
PBBMPs PLA250-PCL1250-PEG1500-PCL1250-PLA250 
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3.2.7. Ultra-fast liquid chromatography (UFLC) assay 
Native and acylated octreotide concentration in released media was quantified by UFLC 
assay. A Shimadhu (Shimadzu Scientific Instruments, Columbia, MD, USA) UFLC system 
coupled with pumps (LC-20AT), degasser (DGU-20A3R), DAD detector (SPD-20AV) and 
autosampler (SIL-20AHT) was employed. Phenomenax column (Phenomenex C18 kinetex 
column 100X4.6 mm, 5µm) along with a guard column (Phenomenex SecuritGuard Catridges, 
C18, 4x2 mm) was used at total flow rate of 0.5 mL/min. A gradient elution method was 
employed for separation where mobile Phase A (HPCL water (Sigma) with 0.1% formic acid) at 
10% and mobile phase B (ACN with 0.1% formic acid) at 90% were ran for first 2 min followed 
by a linear gradient to reach 100% phase B at 18 min. Concentration for octreotide standards 
ranged from 100 µg/mL to 3.1 µg/mL prepared in PBS. DAD detector was set at 280 nm to 
determine. Injection volume was 50 µL.  
3.2.8. UFLC-MS analysis 
UFLC-MS was performed using electrospray ionization (ESI) in positive ion mode on a 
QTrap® API-3200 mass spectrometer, equipped with Shimadzu quaternary pump, vacuum 
degasser, DAD detector and autosampler (Shimadzu Scientific Instruments, Columbia, MD, 
USA). Data acquisition and data processing were performed using Analyst 1.4.2 software 
package (Applied Biosystems, Foster City, CA, USA). LC conditions including column and 
gradient composition remains same as explained in the earlier UFLC assay. Injection volumes 
were 30 µL for all samples. UV detector was set on 280 nm and MS was set in range of 200 to 
1700 amu. Total ion chromatogram was extracted for acylated peptide m/z to produced extracted 
ion chromatogram and compared with UV chromatogram to identify native octreotide and 
chemically acylated adducts.  
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3.3. Results and Discussion 
Peptide therapeutics typically exhibit short half-lives following systemic administration 
due to enzymatic degradation. Many of these biologics are indicated for chronic conditions such 
as octreotide for acromegaly and insulin for diabetes. Hence, these biologics are suitable 
candidates for sustained release formulations. Biodegradable block polymers offer many 
advantage over random block polymers such as PLGA. One good example is tunable chemical 
properties such as hydrophobicity and hydrophilicity of polymer. By tuning these properties, 
block co-polymers can be tailored for better entrapment efficiency and controlled release.  
3.3.1. Characterization of polymers 
Nano- and micro-particles based biodegradable systems have been extensively studied for 
extended delivery of proteins and peptide. They protect entrapped biomolecules against 
enzymatic degradation. Nonetheless, when using biodegradable polymers, protein/peptide-
polymer interaction must be carefully investigated. Degradation products of polymers must be 
compatible with biologics. Chemical derivatization i.e. acylation of peptides has been reported 
from lactide and glycolide based polymers. We hypothesized that PCL based polymer may 
minimize or prevent the chemical degradation of octreotide. Hence, TB polymer (PCL10k-PEG2k-
PCL10k) was designed solely based on caprolactone units to investigate the influence on chemical 
stability of peptide during the release without interference of lactide or glycolide units. 
Pentablock co-polymers PBA (PLA3k-PCL7k-PEG2k-PCL7k-PLA3k) and PBB (PGA3k-PCL7k-
PEG2k-PCL7k-PGA3k) were synthesized to lower crystallinity of PCL blocks, which may improve 
loading of peptide in MPs. Block co-polymers were synthesized by well-established ring-
opening polymerization method reported from our laboratory132-133. Weight and number average 
molecular weights and polydispersity indices (PDI) from NMR and GPC are presented in Table 
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3-2. Molecular weight calculated from 1H-NMR was close to molecular weight (Mn) calculated 
based on feed ratio suggesting nearly all monomer reacted to form polymer chain. Polydispersity 
for TB, PBA and PBB polymers were 1.59, 1.39 and 1.42, respectively.  
We have previously shown that PCL possesses semicrystalline structure and the extent of 
crystallinity depends on the molecular weight of PCL segment and polymer composition i.e., 
presence of other block polymers such as PLA and PGA in case of PBA and PBB polymers, 
respectively 84, 131-132, 134. We have also reported that crystallinity of polymer directly influences 
the release rate131, 133. Hence, x-ray diffraction analysis was performed to determine the physical 
state of newly synthesized polymers. XRD patterns are depicted in Figure 3-1. TB polymer 
showed presence of very sharp peaks at 2 21.9 and 23.8 associated with PCL and PEG 
segments, respectively 84. However, incorporation of PLA blocks in triblock polymer diminished 
the intensity of peaks corresponding to PCL and PEG segments. Addition of PGA segment 
further diminished the crystallinity of PCL and PEG and the overall polymer was almost 
amorphous in nature. These observations corroborates with previously published study 131. 
Reduction in crystallinity of PCL could be because of hydrophobic interactions between 
heterogeneous polymer chains (PCL/PLA and PCL/PGA) which would minimize interaction of 
PCL chains leading to crystallization.    
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Table 3-2 Proton-NMR and GPC analysis of polymers. 
 
  
Code 
Block co-polymer 
composition 
Mna 
(gm/mol) 
Mnb 
(gm/mol) 
Mnc 
(gm/mol) 
Mwc 
(gm/mol) 
PDIc 
TB PCL10k-PEG2k-PCL10k 22000 21271 16781 26824 1.59 
PBA PLA3k-PCL7k-PEG2k-PCL7k-
PLA3k 
22000 20783 17246 24024 1.39 
PBB PGA3k-PCL7k-PEG2k-PCL7k-
PGA3k 
22000 20122 17032 24185 1.42 
Mn-Number average molecular weight, Mw-Weight average molecular weight.  
a
Theoretical value, calculated according to the feed ratio. 
b
Calculated from 1H-NMR results 
c
Determined by GPC analysis 
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3.3.2. Preparation and characterization of octreotide-loaded MPs 
Octreotide was encapsulated in MPs of TB and PB polymers by methanol-oil/water 
emulsion solvent evaporation method. Addition of TEA converted ionized amine of octreotide to 
its more hydrophobic base-form and hence it preferably partitioned into oil phase improving the 
entrapment efficiency. Particles were characterized for entrapment efficiency (%EE) and drug 
loading (%DL) by simple UV method. Table 3-3represents entrapment efficiency and drug 
loading for TBMPs, PBAMPs and PBBMPs. Order of %EE and %DL for polymers was 
PBB>PBA>TB (ANOVA p<0.05). Higher %EE could be attributed to minimal crystallinity of 
PCL segment in PB copolymers (Figure 3-1). Similar results have been observed in previously 
published studies, where nanoparticles were prepared with TB and PB polymers131, 133. SEM 
analysis was performed to determine surface morphology of MPs (Figure 3-2). MPs prepared 
using Me-O/W method were spherical in shape and non-porous. MPs also were slightly 
polydispersed with particle size less than 100 µm based on SEM analysis (Figure 3-2). 
3.3.3. Kinetics of octreotide release 
Primary objectives of this research were to deliver octreotide over period of months and 
investigate chemical instability of peptide during release. Hence, octreotide release kinetics from 
TBMPs, PBAMPs and PBBMPs was investigated by in vitro release studies. Release studies 
were performed by suspending MPs in the thermosensitive gels (Table 3-1). Release samples 
were analyzed by UFLC assay to quantitate native and acylated octreotide. Hydrophobic 
octreotide adducts eluted following the elution of native octreotide. Similar results have been 
observed by other investigators127a, 135.  
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Table 3-3 %EE and %DL for MPs prepared by emulsion solvent evaporation method. 
 
Polymer %DL %EE 
TB 2.02±0.25 45.3±9.4 
PB-A 3.10±0.51 59.5±10.9 
PB-B 4.24±0.15 82.0±3.3 
Data represented as mean ± SD, n = 4. 
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Figure 3-1 Powder X-ray diffraction patterns for TB (PCL10k-PEG2k-
PCL10k), PBA (PLA3k-PCL7k-PEG2k-PCL7k-PLA3k) and PBB 
(PGA3k-PCL7k-PEG2k-PCL7k-PGA3k) polymers. Crystallinity of PCL 
segment decreased progressively in pentablock PBA and PBB polymers. 
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Figure 3-2 Scanning electron 
micrograph for TBMPs, PBAMPs 
and TBMPs. 
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Peaks in UV chromatogram were assigned to native and chemically modified octreotide 
using UFLC-MS analysis. The phenomenon of peptide acylation has been well studied and it is 
known that the process occurs during the release, within MPs core, and not while preparation or 
following the release in media127a, 127c. Octreotide possesses excellent stability at pH 7.4 at 37 °C, 
which is the release condition 127c. In addition, UFLC chromatogram did not show any peak 
corresponding to degraded peptide, suggesting the peptide possesses excellent stability 
throughout release period. Further, to distinguish junk peaks from native and acylated peptides in 
chromatogram, corresponding ghost MPs were kept for release and sampled at same time 
intervals along with octreotide-loaded MPs.  
Figure 3-3, Figure 3-4 and Figure 3-5 depict the release profiles of native, acylated and 
total octreotide from TB, PBA and PBB MPs-in-gel, respectively. A summary of cumulative 
octreotide release (total, native and acylated) is depicted in Table 3-4. In case of TBMPs and 
PBAMPs, near complete release of octreotide was achieved (Figure 3-3 and Figure 3-4). Only 
53±3.2% of total octreotide was released over period of 10 months from glycolide-based PBB 
polymer (Figure 3-5 and Table 3-4). No substantial burst release (<10%) was observed from all 
MPs compositions owing to thermosensitive gel (Table 3-4), which is in accordance with 
previously published reports131-132. Burst release occurs due to quick release of surface bound 
drug upon hydration of particles in release media. Thermosensitive gel provides an additional 
diffusion barrier to the drug released from MPs and minimizes burst phase131-132. 
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Table 3-4 Summary of in vitro release of octreotide in PBS buffer at 37 °C. 
 
MPs 
polymer 
Total 
Octreotide 
released (%) 
Native 
octreotide 
released 
(%) 
aAcylated 
octreotide 
released 
(%) 
Burst 
release 
(%) 
bAcylated 
octreotide 
released 
(%) 
Release 
duration 
TB 97.4±6.9 87.8±6.4 9.5±0.6 8.4±0.8 13±0.4% 105 Days 
PBA 87.2±12.6 47.0±7.9 45.9±5.1 7.1±2.3 53±3.0% 330 Days 
PBB 53.4±3.2 8.9±0.3 49.0±3.0 1.4±0.3 92±0.5% 330 Days 
Data represented as mean ± SD, n = 4. 
Burst release is total octreotide (%) released at 24h. 
a calculated with respect to %EE. 
b Calculated with respect to total octreotide released. 
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Figure 3-3 In vitro release of total, native and acylated octreotide from 
TBMPs-in-gel. Data presented as Mean ± SD, n=4. 
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Figure 3-4 In vitro release of total, native and acylated octreotide from 
PBAMPs-in-gel. Data presented as Mean ± SD, n=4. 
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Figure 3-5 In vitro release of total, native and acylated octreotide from 
PBBMPs-in-gel. Data presented as Mean ± SD, n=4. 
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MPs with all polymers resulted in sustained release of peptide over a period of months. 
TB polymer, consisting polycaprolactone blocks, was the most efficient in preserving chemical 
stability of encapsulated peptide among three polymers used in this study. Only 10% of peptide 
was released as acylated adduct and 88% of peptide was released in its native form (Figure 3-3 
and Table 3-4). In contrary, a significant fraction of peptide was acylated during the release from 
PBAMPs and PBBMPs. Release profile for acylated octreotide showed a steady release of 
acylated adducts over a long period for PBAMPs and PBBMPs (Figure 3-4 and Figure 3-5). 
Total 87% was released, where 46% of peptide was acylated adducts from PBAMPs over period 
of 10 months. PBBMPs resulted in release of total 53% peptide, where only 9% was in native 
form. Fraction of acylated peptide was significantly higher in case of PBBMPs, where 49% was 
released as derivatized peptides, which was 92% of total released peptide (Table 3-4). The 
propensity of protein and peptide to undergo acylation from lactide and glycolide based polymer 
has been reported127b, 128. Peptides are more prone to acylation in polymers rich in glycolide 
compared to lactide 127c. Presence of methyl group close to carbonyl carbon in lactide sterically 
hinders nucleophilic attack127a. While PGA offers no steric hindrance and nucleophilic attack of 
peptide is relatively facile resulting in significant peptide derivatization. The order for extent of 
octreotide derivatization was PBBMPs>PBAMPs>TBMPs. It is worth noting that a substantial 
fraction of peptide was not released from PBB polymers matrix. This phenomenon can be 
explained by formation of water insoluble adducts upon acylation ( 
Figure 2-1b, step 1; Pg#148). Subsequent release of peptide is dependent on hydrolytic 
degradation of polymer chain ( 
Figure 2-1b, step 2; Pg#148).  
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Rate limiting factors controlling drug release from a biodegradable system may include 
dissolution, diffusion and/or degradation of polymer. Dissolution may not be a rate-limiting 
factor, as octreotide possesses excellent aqueous solubility. We have utilized a composite system 
consisting of microparticles embedded in hydrogel to achieve long-term delivery. The 
mechanism of release may further be complicated due to acylation of peptide. We theorize that 
the release mechanism could be diffusion and/or degradation controlled. Figure 3-6 represents 
hypothetical steps leading to release of native and acylated peptide from biodegradable MPs-in-
gel composite system. Release of native peptide may be controlled by rate of polymer erosion 
and diffusion through hydrogel matrix (Figure 3-6). Release of acylated peptide may be a 
complicated process influenced by bulk erosion, rate of peptide acylation, polymer side-chain 
hydrolysis and diffusion through the hydrogel matrix (Figure 3-6). Polymer degradation may or 
may not contribute as rate limiting factor depending on the composition of polymer and rate of 
polymer degradation. 
Various mechanistic and kinetic models were explored in order to determine the 
mechanism and order of octreotide release. Data was fitted to Higuchi, Korsmeyer-Peppas and 
Hixson-Crowell models to delineate the mechanism of release. Zero and first order models were 
utilized to determine the order of release process. Zero order rate indicates that the release rate is 
independent of drug concentration as opposite to first order rate where rate of release is directly 
proportional to the initial drug concentration. The model explaining most variability was 
identified by coefficient of determination (R2) value. Table 3-5 lists calculated R2 values and 
associated parameters for all models. It is evident that release of octreotide (total, native and 
acylated) was a first order process suggesting that release rate is dependent on concentration 
(Table 3-5).  
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Figure 3-6 Process of native and acylated octreotide release from MPs-in-gel 
combination. Release of native peptide may be controlled by rate of polymer degradation 
and diffusion through hydrogel matrix. Release of acylated peptide may be influenced by 
rate of polymer degradation, rate of peptide acylation, polymer side-chain hydrolysis and 
diffusion through the hydrogel matrix. 
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Table 3-5 Summary of fit (R2) for kinetic and mechanistic models for in vitro release of total, 
native and acylated octreotide from TB, PBA and PBB MPs-in-gel. 
 
MPs 
polymer 
Octreotide 
Kinetic and Mechanistic Models 
Higuchi 
Model 
Korsmeyer-
Peppas model 
Hixson-
Crowell 
model 
Zero 
Order 
First order 
R2 R2 n R2 R2 R2 Rate 
constant 
k (Day-1) 
TB Total 0.9265 0.9559 0.6157 0.8442 0.1569 0.9975 0.3316 
native 0.8984 0.9534 0.6089 0.6325 0.0315 0.9400 0.0203 
Acylated 0.9501 0.9865 0.7700 0.8986 0.8894 0.9571 0.0009 
PBA Total 0.7886 0.9211 0.3897 0.5746 0.2120 0.9714 0.0053 
native 0.2620 0.8472 0.2469 0.7002 0.6466 0.7261 0.0012 
Acylated 0.9905 0.9817 0.6217 0.8856 0.8167 0.9777 0.0018 
PBB Total 0.9770 0.9959 0.5882 0.9474 0.8928 0.9946 0.0023 
native 0.7329 0.9688 0.3307 0.3570 0.4230 0.8372 0.0002 
Acylated 0.9406 0.9967 0.6893 0.9722 0.9406 0.9958 0.0021 
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Higuchi model describes Fickian release from a solid or semisolid matrix type of planar 
system and the drug release occurs via diffusion through porous matrix 136. Korsmeyer-Peppas 
model is widely applied to distinguish between diffusion-controlled (Fickian) and anomalous 
(non-Fickian) release mechanisms for polymeric delivery systems 137. The value of release 
exponent n≤0.45 indicates diffusion-controlled release whereas 0.45<n<0.89 indicates 
anomalous release mechanism. The Hixson-Crowell cube root model indicates that the drug 
release from systems undergoing a change in surface area and diameter of particles 138. 
According to R2 values, release of total octreotide from TB and PB polymers can be 
explained by Korsmeyer-Peppas model (Table 3-5). Values of release exponent (n) for total 
octreotide release from TBMPs and PBBMPs were 0.62 and 0.59, suggesting anomalous 
mechanism of release involving degradation of polymer and diffusion of released peptide 
through the hydrogel. On contrary, n-value for total octreotide was <0.45 from PBAMPs 
suggesting diffusion controlled release mechanism.  
The mechanism for release of native octreotide from TBMPs was non-Fickian according 
to Korsmeyer-Peppas model. On the other hand, release of native octreotide was diffusion-
controlled for PBAMPs and PBBMPs. Release of native octreotide may be dependent on 
polymer degradation and diffusion of native peptide out of MPs-in-gel depot (Figure 3-6). 
Slower degradation of PCL polymer 133, in combination with additional diffusion barrier by 
hydrogel may be responsible for the non-Fickian mechanism of release from TB polymer. 
However, PBA and PBB polymers are nearly amorphous in comparison to TB polymers. 
Polymer degradation may not be a rate-limiting factor for PBA and PBB polymers due to rapid 
degradation of polymer. Therefore, diffusion through porous hydrogel is the only rate-limiting 
factors for PBA and PBB polymers.  
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Similarly, release mechanism for acylated octreotide from MPs of TB, PBA and PBB 
polymers can be explained by Korsmeyer-Peppas model. Release exponents (n) were >0.45, 
suggesting the mechanism of acylated peptide release was non-Fickian for all MPs. The n-values 
for acylated octreotide were the highest compared to total and native octreotide from all 
polymers. In case of PBAMPs, best fit for acylated peptide release was observed for Higuchi 
model (R2 = 0.9905) suggesting diffusion-controlled release. However, Korsmeyer-Peppas 
model also had high R2 value for fit (R2 = 0.9817) with n-value of 0.62 indicating non-Fickian 
mechanism. We theorize that Korsmeyer-Peppas model could better explain mechanism of 
acylated octreotide release from PBAMPs because of possibility of additional steps involving 
polymer degradation. We hypothesized that the release of acylated peptide may be influenced by 
polymer degradation. As shown in Figure 3-6, release of acylated octreotide is a multistep 
process, where peptide is first released inside microenvironment of particle via polymer 
degradation followed by acylation. Octreotide acylation may led to formation of water insoluble 
adduct, which may require further hydrolysis of polymer side-chain to form water-soluble 
acylated adduct. Water-soluble acylated octreotide is then diffused out through porous hydrogel. 
Thus, influence of polymer degradation cannot be neglected and release mechanism for acylated 
peptide release may be anomalous as predicted by Korsmeyer-Peppas model.  
3.3.4. Identification acylated octreotide adducts 
The chemical instability, acylation, of peptide is a major concern with biodegradable 
particulate delivery systems; hence, the aim of this research was to identify polymer composition 
that can provide maximal chemical stability to the peptide during release. The peaks in the UFLC 
chromatogram were assigned to native and acylated adducts by UFLC-MS analysis. Figure 3-7, 
Figure 3-8 and Figure 3-9 depicts UV and MS spectrums (extracted ion chromatograms) for 
 176 
 
 
TBMPs, PBAMPs and PBBMPs release samples. Native octreotide eluted at 8.5 min (UV, 
Figure 3-7a) and corresponding peak in MS (EIC) appears at 8.6 min (Figure 3-7b). Octreotide 
appeared as +1 and +2 charge states (z) resulting in species of 1019.3 m/z and 510.3 m/z. Peak at 
RT 9.8 min (UV, Figure 3-7a) corresponds to C-octreotide (m/z 1133.5, RT 9.99 min) as shown 
in chromatograms. The MS profile was also extracted for 1246.8 m/z, associated with CC-
Octreotide. Two peaks at 12.1 and 12.4 min were only observed in MS chromatogram (Figure 
3-7d). Low concentration of CC-octreotide may be due to low aqueous solubility. CC-octreotide 
following hydrolysis at CC ester linkage would result in release of C-octreotide eventually. 
Unlike native octreotide, masses with multiple charge states (z>1) were not observed for acylated 
adduct.  
Similarly, release samples for PBAMPs and PBBMPs were analyzed by UFLC-MS. As 
expected, retention time (RT) for native octreotide remained unchanged (Figure 3-8a-b). PBA 
polymer consisted of PLA segment; therefore, we observed m/z 1091.5 (UV chromatogram RT 
9.7 min and EIC RT 9.8 min) and 1163.2 (UV chromatogram RT 9.8 min and EIC RT 10.1 min) 
associated with mono and di-lactoyl adducts, respectively (Figure 3-8c-d). In case of PBBMPs, 
acylated adducts mono-, di- and tri-glycolide derivatives of octreotide were observed (Figure 
3-9c-e). Di-glycoyl (GG-octreotide) and Tri-glycoyl (GGG-octreotide) adducts were observed at 
two different RT, like CC-octreotide adduct. This observation is in corroboration with published 
literature 135a. It is possible for di- and tri- adducts to form with different structures and same 
total mass, resulting in multiple peaks due to different RT owing to different hydrophobicity. It is 
worth noting that the thermosensitive gel used for release studies also contained PLA segment. 
Interestingly, mono lactoyl adduct (m/z 1091.5) was observed in the release samples of PBBMPs 
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(EIC RT 9.8 min, Figure 3-9f). This observation consistent with L-octreotide elution in release 
samples of PBAMPs at same RT of 9.8 min (Figure 3-8c).  
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Figure 3-7 UFLC-MS spectrum of release sample (Day 105) from TBMPs-in-gel. (a) UV 
chromatogram. Extracted ion chromatogram (EIC) for (b) octreotide, m/z 510.3 (c) 
caprolactoyl-octreotide, m/z 1133.5 and (d) di-caprolactoyl-octreotide, m/z 1246.8. EIC 
for octreotide (m/z 510.3) shows peak at 8.64 RT which corresponds to peak at 8.56 min 
in UV chromatogram. Acylated adduct caprolactoyl-octreotide elutes at RT 9.85 min 
(UV chromatogram) and at corresponding retention time in EIC (m/z 1133.5 and RT 9.99 
min). Di-caprolactoyl-octreotide adduct (m/z 1246.8) appears at two RT however no 
corresponding peak in UV chromatogram is observed due to possibility of low 
concentration. 
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Figure 3-8 UFLC-MS spectrum of release sample (Day 171) from PBAMPs-in-gel. (a) 
UV chromatogram. Extracted ion chromatogram (EIC) for (b) octreotide, m/z 510.3 (c) 
Lactoyl-octreotide, m/z 1091.5 and (d) Di-lactoyl-octreotide, m/z 1163.2. 
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Figure 3-9 UFLC-MS spectrum of release sample (Day 171) from PBBMPs-in-gel. (a) UV 
chromatogram. Extracted ion chromatogram (EIC) for (b) octreotide, m/z 510.3 (c) Glycoyl-
octreotide, m/z 1077.5 (d) Di-glycoyl-octreotide, m/z 1135.5 (e) Tri-glycoyl-octreotide, m/z 
1193.5 (f) Lactoyl-octreotide, m/z 1091.5. 
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Figure 3-10 Schematic depicting electron withdrawal effect of electronegative atoms and 
electron donating effect of alkyl group responsible for partial positive charge on carbonyl 
carbon in PLA, PGA and PCL oligomers. 
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Table 3-6 Summary of octreotide adducts identified using UFLC-MS analysis.  
 
 Polymer
  
 Acylated 
species 
M+H/Z Retention time (min) 
 TB C-Octreotide 1133.5 9.9 
CC-Octreotide 1246.8 12.1, 12.4 
 PBA L-Octreotide 1091.5 9.8 
LL-Octreotide 1163.2 10.1 
C-Octreotide 1133.5 9.9 
CC-Octreotide 1246.8 ND 
 PBB 
  
G-Octreotide 1077.5 9.6 
GG-Octreotide 1135.5  9.7, 10.4, 13.6 
GGG-Octreotide 1193.5  12.9, 14.1 
L-Octreotide 1091.5 9.8 
C-Octreotide 1133.5 ND 
CC-Octreotide 1246.8 ND 
C- Caprolactoyl, L- Lactoyl, G- Glycoyl, ND- Not detected. 
Four samples for TBMPs and nine samples for PBAMPs and 
PBBMPs, at a month time interval, were selected for analyses. 
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This observation indicates that the acylation of peptide may also take place in hydrogels 
matrix apart from the MPs core. The summary of octreotide adducts identified using UFLC-MS 
analysis is depicted in Table 3-6 along with corresponding observed mass (m/z) and RT.  
Only 10% octreotide was acylated for TB polymer despite absence of steric hindrance 
like in case of PBA. There may be two reasons for this observation. First, it may be due to slow 
degradation of polymer owing to its semicrystalline nature. It is established that the peptide 
acylation occurs inside the MPs. The process is facilitated because the area is rich in degraded 
polymer products and released peptide. Hence, less or negligible acylation of peptide in TP 
polymer may be attributed to slower degradation of the polymer. In case of PBA and PBB 
polymers, PLA and PGA blocks degrade at rapid rate than PCL segment resulting in formation 
of corresponding acylated adducts. Secondly, it might be due to relatively lower reactivity of 
carbonyl carbon of PCL compared to PLA or PGA segment. Low reactivity could be attributed 
to hydrophobic effects and/or electron donating inductive effect of alkyl chains adjacent to 
carbonyl carbon. The carbonyl carbon in PCL may carry less partial positive charge because of 
electron donating effect of alkyl group (-CH2-) as depicted in Figure 3-10c. Where as in case of 
PLA and PGA oligomers, the electron withdrawal effect of electronegative oxygen dominates 
resulting in stronger partial positive charge on carbonyl carbon making it facile target for 
nucleophilic attack (Figure 3-10a-b).  
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CHAPTER 4 
4. REVERSIBLE HYDROPHOBIC ION-PARING COMPLEXATION TO MINIMIZE 
ACYLATION OF OCTREOTIDE DURING LONG-TERM DELIVERY FROM PLGA 
MICROPARTICLES. 
4.1. Materials 
Octreotide acetate (D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol; MW 1019.23 Da) was 
procured from ChinaPeptides Co., Ltd (Shanghai, China). Poly(D, L-lactic-co-glycolide) (50:50, 
Mw 40-70 kDa), dextran sulfate sodium-salt (Mw 9-20 kDa) and sodium dodecyl sulfate (SDS) 
were obtained from Sigma Aldrich (St Louis, MO). Dextran sulfate sodium-salt (Mw 36-50 kDa) 
was obtained from MP Biomedicals (Illkirch, France). MicroBCA™ protein assay kit was 
purchased from Thermo Scientific (Rockford, IL). All solvents were of analytical reagent grade.  
4.2. Methods 
4.2.1. Preparation of HIP complex 
HIP complex was prepared by simple mixing of aqueous solutions containing ion-pairing 
agent and octreotide139. Briefly, stock solutions of octreotide and ion-pairing agents were prepared 
in 10 mM citrate buffer at pH 4. Solutions were then mixed in calculated proportions and vortexed. 
After 3 h, water insoluble complex was separated by centrifugation at 12,000 rpm for 10 min. HIP 
complex pellet was freeze-dried and stored at -20˚C until further use. Supernatant was analyzed 
for the amount of free peptide using microBCA™ assay following the protocol provided by the 
manufacturer 135a. The percentage of octreotide complexed (complexation efficiency (%CE)), was 
calculated according to equation 4.1. 
% Complexation efficiency = (1-Mt/Mo)*100  …(4.1) 
Mt = Amount of octreotide in supernatant 
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Mo = Initial amount of octreotide 
4.2.2. Effect of mole ratio of ion-pairing agent to octreotide on complexation efficiency 
Three ion-pairing agents, dextran sulfate (9-20kDa, DSA), dextran sulfate (36-50kDa, 
DSB) and SDS, were employed to prepare HIP complex with octreotide acetate. HIP complex was 
prepared following a method explained earlier. The solutions were mixed at various mole ratios of 
ion-pairing agent to octreotide.  
4.2.3. Dissociation of HIP complex 
HIP complex of octreotide with ion-pairing agents was prepared at optimal mole ratio 
producing maximum %CE following the method explained earlier. Freeze-dried HIP complex was 
incubated in an isotonic phosphate buffer saline (IPBS) at pH 7.4 to study the dissociation under 
simulated physiological condition. Mechanistic studies were carried out to investigate the effects 
of ionic strength and pH on complex dissociation. HIP complex was incubated in 10 mM phosphate 
buffer (NaH2PO4 (monobasic) and Na2HPO4 (dibasic), pH 7.4) containing various strengths of 
NaCl (10 mM, 100 mM and 154 mM), DDI water and 10 mM citrate buffer (100 mM NaCl, pH 
4.2) to delineate the influence of concentration of counter-ions and pH on complex dissociation. 
Following 30 min incubation, the insoluble complexes were separated by centrifugation at 12,000 
RPM for 10 min. Amount of dissociated octreotide in supernatant was quantitated using 
microBCA™ assay and the percentage of dissociated octreotide was calculated according to 
equation 4.2.  
% Dissociation = (Ms/Mi)*100  …(4.2) 
Ms = Amount of octreotide in supernatant 
Mi = Initial amount of octreotide in HIP complex 
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4.2.4. Preparation of Microparticles 
HIP complexes of octreotide were prepared using ion-pairing agents DSA and DSB at 
optimal mole ratio following the method described previously. MPs encapsulating HIP-complexed 
octreotide were prepared by solid/oil/water (S/O/W) emulsion solvent evaporation method. 
Briefly, oil phase (O) consisted of 100 mg PLGA (50/50, Mw 40-70kDa) in 900 µL DCM. The oil 
phase was added to a vial containing 10 mg octreotide equivalent HIP complex and vortexed for 
2 min. The resulting suspension was tip-sonicated for 30 sec at power output of 2W to form S/O 
suspension. The suspension was added drop-wise to constantly stirred water phase (5 mL) 
containing 2% w/v PVA as a stabilizer to form S/O/W emulsion. The resulting emulsion was kept 
in the hood under constant stirring to evaporate the organic solvent. After 6 h, the resulting MPs 
were separated by centrifugation at 13,000 RPM for 10 min. MPs were washed with DDI water 
and centrifuged twice to remove un-entrapped peptide. MPs were suspended in solution containing 
2% w/v mannitol for freeze-drying. Freeze-dried particles were then store at -20°C until further 
use. Ghost MPs without octreotide were also prepared in an identical manner where equivalent 
amount of ion-pairing agent were suspended in oil phase.       
4.2.5. Drug loading (%) and entrapment efficiency (%) 
Encapsulation efficiency was determined by UV spectroscopy using Nanodrop™ (Thermo 
Fisher Scientific Inc.). Briefly, five mg of freeze-dried particles (n = 3) were dissolved in 200 µL 
DMSO. Ghost MPs containing corresponding ion-pairing agents served as blank. Standard of 
octreotide were prepared in DMSO ranging from 2.72 to 0.043 mg/mL. UV absorbance was 
measured at 280 nm. Entrapment efficiency and drug loading were calculated by equation 4.3 and 
4.4, respectively.  
%EE = (Amount of octreotide in MPs/Total amount of octreotide)*100  …(4.3) 
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%DL = (Amount of octreotide in MPs/Total weight of MPs)*100  …(4.4) 
4.2.6. Scanning electron microscopy of MPs 
Scanning electron microscopy (SEM) analysis was performed to analyze particle 
morphology (size and shape). Freeze-dried MPs were applied to carbon film positioned on an 
aluminum stub. Surface of particles on carbon film was coated with Au-Pd under centrifugation 
followed by sample analysis in Phenom Pro desktop scanning electron microscope. 
4.2.7. In vitro release of octreotide from MPs-in-gel composite formulation 
Freeze-dried MPs were subjected to In vitro release study in PBS buffer (pH 7.4) at 37 
°C. PLGA MPs encapsulating HIP-complexed octreotide (DSA and DSB) were suspended in 
400 µL of thermosensitive gel solution (20 wt%) maintained at 4°C. Pentablock polymer 
PLA250-PCL1250-PEG1500-PCL1250-PLA250 was utilized to prepare thermoreversible gel solution. 
Preparation and characterization of gelling polymer has been published earlier from our 
laboratory 132. Resulting MPs-in-gel suspension was incubated at 37 °C for 2 min to form 
hydrogel followed by slow addition of 1.5 mL of PBS (pH 7.4) which was pre-incubated at 37 
°C. At pre-defined time intervals, 1 mL of clear supernatant was collected and replaced with 
equal volume of fresh PBS. Release samples were evaluated for native and chemically modified 
octreotide using ultra-fast liquid chromatography (UFLC) assay. The experiments were carried 
out in triplicate and plotted as cumulative octreotide released (%) with respect to %EE verses 
time.  
4.2.8. Ultra-fast liquid chromatography assay 
See section 3.2.7 for detailed method. 
4.2.9. UFLC-MS analysis 
See section 3.2.8 for detailed method. 
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4.3. Result and Discussion 
Hydrophobic Ion-Paring (HIP) complexation involves the formation of reversible 
complex. This process can to increase hydrophobicity of biologics thereby improving entrapment 
efficiency in polymeric formulations. It has been shown that peptide/protein retains activity and 
conformational stability with HIP complex in various studies139-140. We hypothesize that 
acylation of peptides can be prevented or minimized by masking the reactive nucleophile amine 
with reversible HIP complex. HIP complex, formed by charge-charge interaction, may be stable 
at lower pH and thus prevent the nucleophilic attack of amines on PLGA degradation products 
inside MPs core (Figure 4-1b). HIP complex may dissociate to release native peptides at 
physiological pH and in presence of counter ions (Figure 4-1c). A schematic presentation of 
overall hypothesis is depicted in Figure 4-1. Hence, the aim of our current study was to prepare 
and characterize HIP complex of octreotide using various ion-pairing agents and evaluate 
acylation of octreotide during release from PLGA microspheres.  
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Figure 4-1 (a) chemical derivatization of peptide occurs in MPs core, largely via 
nucleophilic attack of amine on carbonyl carbon of degraded polymer oligomers. (b) HIP 
complex may not dissociate at lower pH, preventing acylation. (c) At physiological pH 
and in presence of counter ions, the HIP complex may dissociate to produce free native 
peptide. 
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4.3.1. Preparation of HIP Complex  
We investigated SDS and dextran sulfate as the complex forming agents. Dextran sulfate 
of molecular weights 9-20k and 36-50k Da were examined. Reversible HIP complex was prepared 
by simple mixing of solutions containing octreotide and ion-pairing agents at low pH. Citrate 
buffer (pH 4) was selected to dissolve octreotide and ion-pairing agents based on published reports 
from our laboratory139a, 139c. Octreotide has two pKa, 7 and 10.15 associated with amine of lysine 
and guanidine group of terminal arginine. As a result, a large fraction of amines is ionized at pH 
4. The ion-pairing agents have pKa of <2 due to sulfonic acid group, resulting in complete 
ionization at pH 4. Water insoluble HIP complex is formed via ionic interactions between 
oppositely charged amine and sulfonate groups. Ionization of charged groups is primarily 
responsible for aqueous solubility of octreotide and ion-pairing agents. Hence, following charge 
neutralization, the complex can no longer remain in aqueous solution resulting in precipitation.  
4.3.2. Effect of mole ratio of ion-pairing agent to octreotide on complexation efficiency 
Stoichiometric balance i.e. charge ratio and corresponding mole ratio of ion-pairing agent 
to octreotide is an important parameter that may directly influence the efficiency of complex 
formation. The aim of this experiment was to identify mole ratio producing complete complexation 
of octreotide to avoid loss of uncomplexed peptide. Effect of mole ratio of ion-pairing agent to 
octreotide on complexation efficiency is illustrated in Figure 4-2. Mole ratios were selected based 
on charge ratio of ion-pairing agent to octreotide. For SDS, DSA and DSB, fraction of octreotide 
complexed reached maximum at mole ratios of 2, 0.028 and 0.009, respectively and nearly all 
octreotide was complexed. At these optimal mole ratios, the charge ratio also approaches to 1:1 
for all ion-pairing agents resulting in near complete binding Figure 4-2.  
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Figure 4-2 Effect of charge/mole ratio of ion-
pairing agent/octreotide on % octreotide 
complexation. Data represented as mean±SD, 
n=3. 
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However, fraction of octreotide complexed declined upon further increment in mole ratio. 
Similar results were observed with lysozyme and IgG-FAB with these ion-pairing agents139. This 
may be due to incomplete charge neutralization in DSA and DSB at higher mole ratio. In case of 
SDS, it may be attributed to formation of micelles, which subsequently solubilized hydrophobic 
SDS-oct complex 140. 
4.3.3. Dissociation of HIP complex 
HIP complexes of octreotide with SDS, DSA and DSB were incubated in IPBS buffer 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4; pH 7.4) and free octreotide in 
solution was quantified for dissociated octreotide. Dextran sulfate complexes resulted in 
significantly higher dissociation compared to SDS-oct complex (t-test p<0.001) (Figure 4-3). 
Percent of octreotide dissociated was 90% and 100% with DSA and DSB (t-test, one tailed p = 
0.11), respectively. Incomplete dissociation (20%) was observed for SDS-oct complex. Similar 
incomplete dissociation with SDS-IgG-FAB complex has been reported earlier 139c. HIP complex 
is governed by electrostatic interactions between opposite charges. Nonetheless, hydrophobic 
interaction may also play a key role in stabilization of water insoluble complex. If an ionic 
interaction were the only force responsible for the stabilization of HIP complex, then SDS-oct 
complex should have dissociated completely. Instead, only a fraction of octreotide was 
dissociated suggesting the role of hydrophobic interaction in stabilization of SDS-oct complex.  
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Figure 4-3 Dissociation of SDS-oct, DSA-oct and DSB-oct HIP complex 
in IPBS buffer at pH 7.4. Data represented as mean±SD, n=3. 
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For successful application of HIP complex to minimize acylation of peptide, the complex 
should remain stable at lower pH (Figure 4-1b). Following release, the complex must dissociate 
completely to produce native peptide (Figure 4-1c). Thus, the dissociation of complex directly 
affects bioavailability of peptide. Therefore, mechanistic studies were performed to investigate 
the factors influencing dissociation phenomenon. We examined the influence of concentration of 
counter ion on dissociation in phosphate buffer (pH 7.4) containing increasing concentration of 
NaCl. The complex was incubated in DDI water, which acted as a negative control with absence 
of counter ions. As shown in Figure 4-4, less than 5% octreotide dissociated upon incubation in 
DDI water because of the absence of counter ions. A proportional increase in fraction of 
dissociated peptide was observed with an increase in concentration of counter ion at pH 7.4 in 
phosphate buffer. Dissociation of complex in phosphate buffer (Figure 4-4) and IPBS (Figure 
4-3) clearly indicates that the dissociation of complex depends on concentration of counter ions. 
Again, near complete dissociation was observed in cases of DSA and DSB compared to SDS at 
154 mM NaCl. Dissociation of HIP complexes at acidic condition was also studied by incubating 
complex in 10 mM citrate buffer with 100 mM NaCl at pH 4. Importance of pH on dissociation 
of complex is evident because a substantially low fraction of complex was dissociated at pH 4 
despite presence of counter ions. Based on these results, it can be inferred that HIP complex may 
be able to mask reactive amines groups in acidic microenvironment inside microparticle core and 
prevent acylation of peptide (Figure 4-1c).   
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Figure 4-4 Dissociation of SDS-oct, DSA-oct and DSB-oct HIP complex at various ionic 
strength and pH. 
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4.3.4. Preparation and characterization of MPs 
Ion-pairing agents DSA and DSB were selected for further studies based on the 
dissociation of complex at simulated physiological condition and stability at low pH. MPs were 
prepared by S/O/W method and characterized for octreotide loading and encapsulation efficiency 
following direct method of analysis. PLGA 50/50 at polymer to drug weight ratio of 10:1 was 
utilized. Excellent entrapment efficiency and drug loading for both DSA and DSB ion-pairing 
agents were achieved with S/O/W method (Table 4-1). MPs were characterized for particle size 
and morphology with scanning electron microscopy. MPs were spherical in shape with smooth 
surfaces (Figure 4-5). DSAMPs were slightly polydispersed and had overall size less than 100 
µm. On the other hand, DSBMPs appears to be less polydispersed with a size of 200 µm or less. 
Larger size of DSBMPs could be attributed to higher molecular weight of DSB (36-50kDa) 
compared to DSA (9-20kDa), which resulted in larger size DSB-Oct complex. 
4.3.5. Mechanism and kinetics of release 
In vitro release studies were carried out to investigate the mechanism and kinetics of 
octreotide release from DSAMPs and DSBMPs in PBS buffer at 37 °C. Samples were analyzed 
by UFLC to determine the concentration of released peptide (native and acylated). Release 
profiles depicting the release of total, native and acylated octreotide from DSAMPs and 
DSBMPs are illustrated in Figure 4-6 and Figure 4-7. Pentablock thermoresponsive polymer was 
utilized to sustain the release of octreotide. MPs were suspended in an aqueous solution of 
pentablock polymer (20% w/w), which phase transform to gel at 37 °C to entrap MPs within gel 
matrix. The hydrogel provides additional diffusion barrier to peptide released from MPs and thus 
may extend duration of release132-133.  
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Table 4-1 Summary of entrapment efficiency and drug loading for DSAMPs and DSBMPs. 
 
 
  
Polymer 
Ion-pairing 
agent 
Polymer:octreotide  
weight ratio 
%EE %DL 
PLGA (50/50) DSA 10:1 74.7±8.4 7.8±0.3 
PLGA (50/50) DSB 10:1 81.7±6.3 7.9±0.5 
Data represented as mean+SD, n = 3. 
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Figure 4-5 Scanning electron micrograph showing 
surface morphology for (a) DSAMPs and (b) 
DSBMPs. 
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DSAMPs and DSBMPs sustained release of octreotide over a period of 55 days. Near 
complete release was observed for both DSAMPs and DSBMPs. No significant difference in 
initial burst release was observed for DSAMPs (17.8±1.1%) and DSBMPs (15.6±0.5%) (t-test p 
= 0.146). Mechanism of release for total octreotide was delineated by fitting the data in 
mechanistic models including Higuchi, Korsmeyer-Peppas, and Hixson-Crowell models136-138. 
Table 4-2 summarizes the coefficient of determination (R2) and associated parameter for all the 
models. Best fit was observed for Korsmeyer-Peppas model based on the R2 value for both MPs 
among all three models (Table 4-2). The n-value for both MPs was found to be 0.64 suggesting 
the release mechanism to be non-Fickian 137. This mechanism suggests that the release of peptide 
was both diffusion and degradation controlled. Data was also fitted to zero- and first-order 
equations to determine the order of release. Process of release was first order kinetics indicated 
by R2 values for both DSAMPs and DSBMPs (Table 4-2). First order kinetic suggests that the 
release rate is proportional to the concentration. As a result, slower release was observed for both 
MPs in the later phase of release (Figure 4-6 and Figure 4-7). Compared to DSBMPs, release rate 
was faster for DSAMPs, as indicated by first order rate constant. This result can be attributed to 
accelerated erosion of polymer matrix due to smaller particle size. 
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Figure 4-6 In vitro release profiles of total, native and acylated octreotide 
from DSAMPs-in-gel composite formulation. 
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Figure 4-7 In vitro release profiles of total, native and acylated octreotide 
from DSBMPs-in-gel composite formulation. 
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Table 4-2 Summary of fit for kinetic models and associated parameters for release of octreotide 
from DSAMPs and DSBMPs in gel formulations. 
 
MPs 
Mechanistic and kinetic models 
Higuchi 
Model 
Korsmeyer-Peppas 
model 
Hixson-
Crowell 
model 
Zero 
Order 
First order 
R2 R2 n R2 R2 R2 Rate 
constant 
k (Day-
1) 
DSAMPs 0.5988 0.9964 0.6403 0.7884 0.5821 0.9124 0.107 
DSBMPs 0.6224 0.9935 0.6378 0.7582 0.5948 0.8385 0.040 
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4.3.6. Acylation of peptide during release 
Dissociation of HIP complex under acidic pH suggests that peptide complex remains 
stable at acidic pH inside MPs and may prevent acylation of peptide during release. Amount of 
native and acylated peptide released from DSAMPs and DSBMPs were quantified by UFLC. 
Only 6.3% and 5.8% of peptide were acylated for DSAMPs and DSBMPs, respectively. This 
small amount of acylation may be explained by dissociation of small fraction of peptide at acidic 
pH (Figure 4-4). Significantly large fractions, 85% from DSMPs and 95% DSAMPs, were 
chemically intact following the release as we hypothesized. UFLC-MS analysis was performed 
to identify the peaks associated with native and acylated peptide in the LC chromatogram. 
UFLC-MS profile for release samples on day 16 from DSAMPs and DSBMPs are represented in 
Figure 4-8 and Figure 4-9. Native octreotide eluted at 8.89 min in extracted ion-chromatogram as 
m/z of 510.3 corresponding to peak at 8.67 min in UV chromatogram (Figure 4-8a and Figure 
4-9a). Parent ion for native octreotide at m/z 1019.3 was also observed (Data not shown). 
Presence of 1019.3 and 510.3 m/z suggest that the peptide maintained its native cyclic chemical 
structure. In both MPs, a very small amount of lactoyl-octreotide (m/z 1091.6, 9.8 min) and 
glycoyl-octreotide (m/z 1077.7, 9.7 min) adducts were observed as acylated species (Figure 
4-8b-d and Figure 4-9b-d), which eluted following native peptide due to higher hydrophobicity. 
Similar findings have been reported by other investigators 135a.  
Table 4-3 depicts the chemically modified species observed in the release samples for 
DSAMPs and DSBMPs. The observations in Table 4-3 are based on UFLC-MS analysis of 
release samples on day 1, 9 and 16. The gelling polymer contained polycaprolactone block but 
caprolactoyl-octreotide (m/z 1133.5) was not detected. Moreover, di-lactoyl and di-glycoyl 
adducts were not observed.   
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Figure 4-8 UFLC-MS spectrum of release sample (Day 16) from DSAMPs-in-gel. (a) UV 
chromatogram. Extracted ion chromatogram (EIC) for (b) octreotide, m/z 510.3 (c) 
Lactoyl-octreotide, m/z 1091.6 and (d) Glycoyl-octreotide, m/z 1077.7. 
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Figure 4-9 UFLC-MS spectrum of release sample (Day 16) from DSBMPs-in-gel. (a) UV 
chromatogram. Extracted ion chromatogram (EIC) for (b) octreotide, m/z 510.3 (c) 
Lactoyl-octreotide, m/z 1091.6 and (d) Glycoyl-octreotide, m/z 1077.7. 
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Table 4-3 Summary of octreotide adducts identified using UFLC-MS analysis in release samples. 
 
MPs Acylated species M+H/Z 
Retention 
time (min) 
DSAMPs L-Octreotide 1091.6 9.8 
G-Octreotide 1077.7 9.7 
LL-Octreotide 1163.2 ND 
GG-Octreotide 1135.5 ND 
C-Octreotide 1133.5 ND 
DSBMPs 
 
 
L-Octreotide 1091.6 9.8 
G-Octreotide 1077.7 9.7 
LL-Octreotide 1163.2 ND 
GG-Octreotide 1135.5 ND 
C-Octreotide 1133.5 ND 
C- Caprolactoyl, L- Lactoyl, G- Glycoyl, ND- Not detected. 
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CHAPTER 5 
5. SUMMARY AND RECOMMENDATIONS 
5.1. Summary 
In order to sustain release of octreotide and minimize its acylation during release from 
biodegradable systems, we tested two different strategies (a) polymer modification (b) HIP 
complexation.  
In the first strategy, we focused on effect of various polymer compositions on octreotide 
acylation and duration of release. Effect of polycaprolactone (PCL), polylactic acid (PLA) and 
polyglycolic acid (PGA) were evaluated. Effect of PLA and PGA on peptide acylation is well 
established. However, no information is available on effect of PCL on peptide acylation. 
Octreotide encapsulated MPs with excellent entrapment efficiency were successfully prepared 
and characterized. MPs-in-gel composite formulation was selected to sustain release of 
octreotide over period of months. A large fraction of released peptide was acylated during 
release from lactide-based PBA and glycolide-based PBB polymers. In addition, release of 
octreotide was incomplete from PBB polymers even after 10 months of release. PB polymers 
having PLA and PGA segments are less suitable polymer for peptide delivery due to instability 
of peptide, despite having significantly better entrapment efficiency and duration of release. TB 
polymer resulted in minimal chemical derivatization of peptide and sustained release of 
octreotide over a period of three months suggesting TB polymers could be best suited for 
sustained peptide delivery. 
In the second strategy, we tested potential of reversible hydrophobic ion-paring 
complexation in minimizing acylation of octreotide from polylactide-co-glycolide polymers. 
Process of HIP complex preparation and characterization has been well established in our 
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laboratory previously. HIP complex formation with octreotide was very simple and 
straightforward involving simple mixing of solutions. Complexation efficiency of nearly 100% 
was achieved with all ion-pairing agents. HIP complex with dextran sulfate was reversible unlike 
SDS at simulated physiological condition. HIP complex also resulted in excellent encapsulation 
and loading efficiency in MPs due to increased hydrophobicity. MPs-in-gel composite 
formulation resulted in sustained release of peptide. More than 95% of released peptide 
maintained native chemical structure and less than 7% octreotide was acylated with DSA-oct 
HIP complex. Reversible HIP complex is a viable strategy to maintain chemical stability of 
peptide during long-term delivery from lactide and glycolide based polymers. 
5.2. Recommendations 
In present study, we have shown that the PCL based polymers and HIP complex may be 
suitable means to enhance the stability of peptide during sustained release. However, an 
individual strategy have certain limitations despite being successful in minimizing peptide 
acylation during sustained delivery.  
PCL based polymers resulted in enhanced stability of peptide during release. However, 
PCL based TB polymers did not results in high encapsulation efficiency. In addition, PCL 
polymers exhibits slow degradation, which may result in accumulation of polymer in body. PBA 
and PBB resulted in significantly high entrapment efficiency and degrade fasters than TB 
polymers, but the stability of peptide was poor during release. HIP complex resulted in excellent 
octreotide loading in PLGA polymers. Entrapment efficiency and stability of peptide with HIP 
complex was very high. However, release profile was biphasic where release rate was very high 
for first 20 day followed by very slow release rates.  
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Limitations of these individual approaches may be overcome by combining these 
approaches. For example, combination of HIP complexation with PBA or PBB polymer MPs. 
HIP complex can minimize peptide acylation by itself from lactide and glycolide based 
polymers. PBA and PBB polymers have faster rate of degradation due to low crystallinity and 
may sustain release of HIP complexed octreotide for longer duration.  
 
  
 210 
 
 
APPENDIX 
 
 211 
 
 
 
 
 212 
 
 
 
 
 213 
 
 
  
 214 
 
 
REFERENCES 
1. Kwatra, D.; Vaishya, R.; Gaudana, R.; Jwala, J.; Mitra, A. K., Ocular Delivery Using 
Prodrugs. In Prodrugs and Targeted Delivery, Wiley-VCH Verlag GmbH and Co. KGaA: 2010; 
pp 181-205. 
2. Dingeldein, S. A.; Klyce, S. D., Imaging of the cornea. Cornea 1988, 7 (3), 170-82. 
3. Lacouture, A., [Anatomy-physiology of the eye]. Rev Infirm 2006,  (120), 16-7. 
4. Edelhauser, H.; Ubels, J., Cornea and sclera. In Physiology of the eye, Kaufman, P.; Aam, 
A., Eds. Moses, RA, Mosby, CV: St. Louis, 2003; pp 47-116. 
5. Ambati, J.; Canakis, C. S.; Miller, J. W.; Gragoudas, E. S.; Edwards, A.; Weissgold, D. 
J.; Kim, I.; Delori, F. C.; Adamis, A. P., Diffusion of high molecular weight compounds through 
sclera. Investigative ophthalmology and visual science 2000, 41 (5), 1181-5. 
6. (a) Sharma, R.; Ehinger, B., Development and structure of retina. In Physiology of the 
eye, Kaufman, P.; Aam, A., Eds. Moses, RA Mosby, CV: St. Louis, 2003; pp 47-116; (b) Cour, 
M., The retinal pigmented epithelium. In Physiology of the eye, Kaufman, P.; Aam, A., Eds. 
Moses, RA Mosby, CV: St. Louis, 2003; pp 47-116. 
7. Andersen, H.; Sander, B., The vitreous. In Physiology of the eye, Kaufman, P.; Aam, A., 
Eds. Moses, RA Mosby, CV: St. Louis, 2003; pp 47-116. 
8. Ananthula, H.; Vaishya, R.; Barot, M.; Mitra, A., Bioavailability in ocular pharmacology. 
In Duane's Foundations of Clinical Ophthalmology, W, T.; EA, J., Eds. Lippincott Williams and 
Wilkins: 2009; Vol. 3. 
9. L, S.; Yu, A. B., Applied Biopharmaceutics and Pharmacokinetics 4th ed.; McGraw-
Hill/Appleton and Lange: 1999. 
10. Tiffany, J. M., Tears in health and disease. Eye 17 (8), 923-926. 
11. Ashton, P.; Podder, S. K.; Lee, V. H., Formulation influence on conjunctival penetration 
of four beta blockers in the pigmented rabbit: a comparison with corneal penetration. Pharm Res 
1991, 8 (9), 1166-74. 
12. Dursun, D.; Monroy, D.; Knighton, R.; Tervo, T.; Vesaluoma, M.; Carraway, K.; Feuer, 
W.; Pflugfelder, S. C., The effects of experimental tear film removal on corneal surface 
regularity and barrier function. Ophthalmology 2000, 107 (9), 1754-60. 
13. Lens, A.; Langley, T.; Nemeth, S. C.; Shea, C., Ocular Anatomy and Physiology John H. 
Bond: 1999. 
14. Ronald D. Schoenwald, R. L. W., Relationship between steroid permeability across 
excised rabbit cornea and octanol-water partition coefficients. Journal of Pharmaceutical 
Sciences 1978, 67 (6), 786-788. 
15. Prausnitz, M. R.; Noonan, J. S., Permeability of cornea, sclera, and conjunctiva: a 
literature analysis for drug delivery to the eye. J Pharm Sci 1998, 87 (12), 1479-88. 
16. George M. Grass, J. R. R., Mechanisms of corneal drug penetration II: Ultrastructural 
analysis of potential pathways for drug movement. Journal of Pharmaceutical Sciences 1988, 77 
(1), 15-23. 
17. Marshall, W. S.; Klyce, S. D., Cellular and paracellular pathway resistances in the "tight" 
Cl- -secreting epithelium of rabbit cornea. J Membr Biol 1983, 73 (3), 275-82. 
18. Kaur, I. P.; Smitha, R., Penetration enhancers and ocular bioadhesives: two new avenues 
for ophthalmic drug delivery. Drug Dev Ind Pharm 2002, 28 (4), 353-69. 
 215 
 
 
19. Kaur, I. P.; Kanwar, M., Ocular Preparations: The Formulation Approach. Drug 
Development and Industrial Pharmacy 2002, 28 (5), 473 - 493. 
20. (a) Barsotti, M. F.; Bartels, S. P.; Freddo, T. F.; Kamm, R. D., The source of protein in 
the aqueous humor of the normal monkey eye. Investigative ophthalmology and visual science 
1992, 33 (3), 581-95; (b) Schlingemann, R. O.; Hofman, P.; Klooster, J.; Blaauwgeers, H. G.; 
Van der Gaag, R.; Vrensen, G. F., Ciliary muscle capillaries have blood-tissue barrier 
characteristics. Exp Eye Res 1998, 66 (6), 747-54. 
21. Anand, B.; Nashed, Y.; Mitra, A., Novel dipeptide prodrugs of acyclovir for ocular 
herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr Eye 
Res 2003, 26 (3-4), 151-63. 
22. Hornof, M.; Toropainen, E.; Urtti, A., Cell culture models of the ocular barriers. Eur J 
Pharm Biopharm 2005, 60 (2), 207-25. 
23. Cunha-Vaz, J. G., The blood-retinal barriers system. Basic concepts and clinical 
evaluation. Exp Eye Res 2004, 78 (3), 715-21. 
24. Gardner, T. W.; Antonetti, D. A.; Barber, A. J.; Lieth, E.; Tarbell, J. A., The molecular 
structure and function of the inner blood-retinal barrier. Penn State Retina Research Group. Doc 
Ophthalmol 1999, 97 (3-4), 229-37. 
25. Stewart, P. A.; Tuor, U. I., Blood-eye barriers in the rat: correlation of ultrastructure with 
function. J Comp Neurol 1994, 340 (4), 566-76. 
26. Cunha-Vaz, J. G., The blood-ocular barriers: past, present, and future. Doc Ophthalmol 
1997, 93 (1-2), 149-57. 
27. Janoria, K. G.; Gunda, S.; Boddu, S. H.; Mitra, A. K., Novel approaches to retinal drug 
delivery. Expert opinion on drug delivery 2007, 4 (4), 371-88. 
28. Reddy, I. K., Ocular Therapeutics and Drug Delivery: A Multi-disciplinary Aapproach. 
CRC Press: 1995. 
29. Ghate, D.; Edelhauser, H. F., Ocular drug delivery. Expert opinion on drug delivery 
2006, 3 (2), 275-87. 
30. Edman, P., Biopharmaceutics of Ocular Drug Delivery. Informa Health Care: 1993. 
31. Barar, J.; Javadzadeh, A. R.; Omidi, Y., Ocular novel drug delivery: impacts of 
membranes and barriers. Expert opinion on drug delivery 2008, 5 (5), 567-81. 
32. Hamalainen, K. M.; Kananen, K.; Auriola, S.; Kontturi, K.; Urtti, A., Characterization of 
paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Investigative 
ophthalmology and visual science 1997, 38 (3), 627-34. 
33. Raghava, S.; Hammond, M.; Kompella, U. B., Periocular routes for retinal drug delivery. 
Expert opinion on drug delivery 2004, 1 (1), 99-114. 
34. (a) Van Santvliet, L.; Ludwig, A., Determinants of eye drop size. Survey of 
Ophthalmology 2004, 49 (2), 197-213; (b) Urtti, A.; Salminen, L., Minimizing systemic 
absorption of topically administered ophthalmic drugs. Survey of Ophthalmology 1993, 37 (6), 
435-456; (c) Shell, J. W., Pharmacokinetics of topically applied ophthalmic drugs. Survey of 
Ophthalmology 1982, 26 (4), 207-218. 
35. (a) Letocha, C. E., Methods for self-administration of eyedrops. Ann Ophthalmol 1985, 
17 (12), 768-9; (b) Mishima, S.; Gasset, A.; Klyce, S. D., Jr.; Baum, J. L., Determination of tear 
volume and tear flow. Invest Ophthalmol 1966, 5 (3), 264-76. 
36. Fraunfelder, F. T.; Meyer, S. M., Systemic side effects from ophthalmic timolol and their 
prevention. J Ocul Pharmacol 1987, 3 (2), 177-84. 
37. Gray, R. H., The influence of drop size on pupil dilatation. Eye 1991, 5 ( Pt 5), 615-9. 
 216 
 
 
38. Duvall, B.; Kershner, R. M., Ophthalmic Medications and Pharmacology. 2nd ed.; Slack 
Incorporated: 2006. 
39. Pinilla, I.; Larrosa, J. M.; Polo, V.; Honrubia, F. M., Subconjunctival injection of low 
doses of mitomycin C: effects on fibroblast proliferation. Ophthalmologica 1998, 212 (5), 306-9. 
40. Ripart, J.; Lefrant, J. Y.; de La Coussaye, J. E.; Prat-Pradal, D.; Vivien, B.; Eledjam, J. J., 
Peribulbar versus retrobulbar anesthesia for ophthalmic surgery: an anatomical comparison of 
extraconal and intraconal injections. Anesthesiology 2001, 94 (1), 56-62. 
41. Canavan, K. S.; Dark, A.; Garrioch, M. A., Sub-Tenon's administration of local 
anaesthetic: a review of the technique. Br J Anaesth 2003, 90 (6), 787-93. 
42. TRIVEDI, H.; TODKAR, H.; ARBHAVE, V.; BHATIA, P., OCULAR ANAESTHESIA 
FOR CATARACT SURGERY. Lancet 2003, 3, 1312-1313,1319. 
43. Ebner, R.; Devoto, M. H.; Weil, D.; Bordaberry, M.; Mir, C.; Martinez, H.; Bonelli, L.; 
Niepomniszcze, H., Treatment of thyroid associated ophthalmopathy with periocular injections 
of triamcinolone. Br J Ophthalmol 2004, 88 (11), 1380-6. 
44. van den Berg, A. A., An audit of peribulbar blockade using 15 mm, 25 mm and 37.5 mm 
needles, and sub-Tenon's injection. Anaesthesia 2004, 59 (8), 775-80. 
45. Vaishya, R. D.; Khurana, V.; Patel, S.; Mitra, A. K., Controlled ocular drug delivery with 
nanomicelles. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2014, 6 
(5), 422-37. 
46. Vaishya, R.; Gokulgandhi, M.; Patel, S.; Minocha, M.; Mitra, A. K., Novel 
Dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. AAPS 
PharmSciTech 2014  
47. Ribeiro, A.; Sosnik, A.; Chiappetta, D. A.; Veiga, F.; Concheiro, A.; Alvarez-Lorenzo, 
C., Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained 
release of ethoxzolamide for topical glaucoma therapy. Journal of The Royal Society Interface 
2012, 9 (74), 2059-2069. 
48. Pepić, I.; Hafner, A.; Lovrić, J.; Pirkić, B.; Filipović-Grčić, J., A nonionic 
surfactant/chitosan micelle system in an innovative eye drop formulation. Journal of 
Pharmaceutical Sciences 2010, 99 (10), 4317-4325. 
49. Lin, H.-R.; Chang, P.-C., Novel pluronic-chitosan micelle as an ocular delivery system. 
Journal of Biomedical Materials Research Part B: Applied Biomaterials 2013, 101B (5), 689-
699. 
50. (a) Ho, S.; Clipstone, N.; Timmermann, L.; Northrop, J.; Graef, I.; Fiorentino, D.; 
Nourse, J.; Crabtree, G. R., The mechanism of action of cyclosporin A and FK506. Clinical 
immunology and immunopathology 1996, 80 (3 Pt 2), S40-5; (b) Di Tommaso, C.; Como, C.; 
Gurny, R.; Möller, M., Investigations on the lyophilisation of MPEG–hexPLA micelle based 
pharmaceutical formulations. European Journal of Pharmaceutical Sciences 2010, 40 (1), 38-47. 
51. Pepić, I.; Jalšenjak, N.; Jalšenjak, I., Micellar solutions of triblock copolymer surfactants 
with pilocarpine. International journal of pharmaceutics 2004, 272 (1–2), 57-64. 
52. Ribeiro, A.; Sandez-Macho, I.; Casas, M.; Alvarez-Perez, S.; Alvarez-Lorenzo, C.; 
Concheiro, A., Poloxamine micellar solubilization of alpha-tocopherol for topical ocular 
treatment. Colloids and surfaces. B, Biointerfaces 2013, 103, 550-7. 
53. (a) Di Tommaso, C.; Como, C.; Gurny, R.; Moller, M., Investigations on the 
lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations. European journal 
of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical 
Sciences 2010, 40 (1), 38-47; (b) Di Tommaso, C.; Torriglia, A.; Furrer, P.; Behar-Cohen, F.; 
 217 
 
 
Gurny, R.; Moller, M., Ocular biocompatibility of novel Cyclosporin A formulations based on 
methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. International 
journal of pharmaceutics 2011, 416 (2), 515-24; (c) Di Tommaso, C.; Bourges, J. L.; 
Valamanesh, F.; Trubitsyn, G.; Torriglia, A.; Jeanny, J. C.; Behar-Cohen, F.; Gurny, R.; Moller, 
M., Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, 
ocular distribution and efficacy studies. Eur J Pharm Biopharm 2012, 81 (2), 257-64; (d) Di 
Tommaso, C.; Valamanesh, F.; Miller, F.; Furrer, P.; Rodriguez-Aller, M.; Behar-Cohen, F.; 
Gurny, R.; Moller, M., A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro 
and in vivo evaluation. Invest Ophthalmol Vis Sci 2012, 53 (4), 2292-9. 
54. Tu, J.; Pang, H.; Yan, Z.; Li, P., Ocular permeability of pirenzepine hydrochloride 
enhanced by methoxy poly(ethylene glycol)-poly(D, L-lactide) block copolymer. Drug 
development and industrial pharmacy 2007, 33 (10), 1142-50. 
55. Lin, H. R.; Chang, P. C., Novel pluronic-chitosan micelle as an ocular delivery system. 
Journal of biomedical materials research. Part B, Applied biomaterials 2013, 101 (5), 689-99. 
56. Rafie, F.; Javadzadeh, Y.; Javadzadeh, A. R.; Ghavidel, L. A.; Jafari, B.; Moogooee, M.; 
Davaran, S., In vivo evaluation of novel nanoparticles containing dexamethasone for ocular drug 
delivery on rabbit eye. Curr Eye Res 2010, 35 (12), 1081-9. 
57. Gupta, A. K.; Madan, S.; Majumdar, D. K.; Maitra, A., Ketorolac entrapped in polymeric 
micelles: preparation, characterisation and ocular anti-inflammatory studies. International 
journal of pharmaceutics 2000, 209 (1-2), 1-14. 
58. Qu, X.; Khutoryanskiy, V. V.; Stewart, A.; Rahman, S.; Papahadjopoulos-Sternberg, B.; 
Dufes, C.; McCarthy, D.; Wilson, C. G.; Lyons, R.; Carter, K. C.; Schatzlein, A.; Uchegbu, I. F., 
Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 
order of magnitude. Biomacromolecules 2006, 7 (12), 3452-9. 
59. Kim, H.; Choi, J. S.; Kim, K. S.; Yang, J. A.; Joo, C. K.; Hahn, S. K., Flt1 peptide-
hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of 
ocular neovascularization. Acta biomaterialia 2012, 8 (11), 3932-40. 
60. Liaw, J.; Chang, S. F.; Hsiao, F. C., In vivo gene delivery into ocular tissues by eye drops 
of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric 
micelles. Gene therapy 2001, 8 (13), 999-1004. 
61. Kuwano, M.; Ibuki, H.; Morikawa, N.; Ota, A.; Kawashima, Y., Cyclosporine A 
formulation affects its ocular distribution in rabbits. Pharm Res 2002, 19 (1), 108-11. 
62. Luschmann, C.; Herrmann, W.; Strauss, O.; Luschmann, K.; Goepferich, A., Ocular 
delivery systems for poorly soluble drugs: an in-vivo evaluation. International journal of 
pharmaceutics 2013, 455 (1-2), 331-7. 
63. Civiale, C.; Licciardi, M.; Cavallaro, G.; Giammona, G.; Mazzone, M. G., 
Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. International journal of 
pharmaceutics 2009, 378 (1-2), 177-86. 
64. Luschmann, C.; Tessmar, J.; Schoeberl, S.; Strau, O.; Luschmann, K.; Goepferich, A., 
Self-assembling colloidal system for the ocular administration of cyclosporine a. Cornea 2014, 
33 (1), 77-81. 
65. Pepic, I.; Lovric, J.; Filipovic-Grcic, J., Polymeric Micelles in Ocular Drug Delivery: 
Rationale, Strategies and Challenges. Chemical and Biochemical Engineering Quarterly 2012, 
26 (4), 365. 
66. Aliabadi, H. M.; Lavasanifar, A., Polymeric micelles for drug delivery. Expert opinion on 
drug delivery 2006, 3 (1), 139-62. 
 218 
 
 
67. Chi, S. C.; Yeom, D. I.; Kim, S. C.; Park, E. S., A polymeric micellar carrier for the 
solubilization of biphenyl dimethyl dicarboxylate. Archives of pharmacal research 2003, 26 (2), 
173-81. 
68. Gong, C.; Wei, X.; Wang, X.; Wang, Y.; Guo, G.; Mao, Y.; Luo, F.; Qian, Z., 
Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. 
Preparation and characterization. Nanotechnology 2010, 21 (21), 215103. 
69. Kim, S.; Park, K., 19 Polymer Micelles for Drug Delivery. 
70. Chien, Y., Novel Drug Delivery Systems. Marcel Dekker Inc.: 1982. 
71. Amrite, A. C.; Kompella, U. B., Size-dependent disposition of nanoparticles and 
microparticles following subconjunctival administration. J Pharm Pharmacol 2005, 57 (12), 
1555-63. 
72. Pepic, I.; Jalsenjak, N.; Jalsenjak, I., Micellar solutions of triblock copolymer surfactants 
with pilocarpine. International journal of pharmaceutics 2004, 272 (1-2), 57-64. 
73. Vadlapudi, A. D.; Cholkar, K.; Vadlapatla, R. K.; Mitra, A. K., Aqueous Nanomicellar 
Formulation for Topical Delivery of Biotinylated Lipid Prodrug of Acyclovir: Formulation 
Development and Ocular Biocompatibility. Journal of ocular pharmacology and therapeutics : 
the official journal of the Association for Ocular Pharmacology and Therapeutics 2013. 
74. Mitra, A. K.; Velagaleti, P. R.; Natesan, S., Ophthalmic Compositions Comprising 
Calcineurin Inhibitors or mTOR Inhibitors. Google Patents: 2011. 
75. Velagaleti PR, A. E., Khan IJ, Gilger BC, and Mitra AK, Topical delivery of 
hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior 
and posterior segments of the eye. Drug Delivery Today 2010, 10 (4), 42-47. 
76. (a) Gaudana, R.; Ananthula, H. K.; Parenky, A.; Mitra, A. K., Ocular drug delivery. 
AAPS J 2010, 12 (3), 348-60; (b) HariKrishna Ananthula; Ravi Vaishya; Megha Barot; Mitra, 
A., Bioavailability. Tasman W; EA, J., Eds. Philadelphia: Lippincott Williams and Wilkins: 
2009. 
77. (a) Tang, D. L.; Song, F.; Chen, C.; Wang, X. L.; Wang, Y. Z., A pH-responsive 
chitosan-b-poly(p-dioxanone) nanocarrier: formation and efficient antitumor drug delivery. 
Nanotechnology 2013, 24 (14), 145101; (b) Gu, Q.; Xing, J. Z.; Huang, M.; He, C.; Chen, J., SN-
38 loaded polymeric micelles to enhance cancer therapy. Nanotechnology 2012, 23 (20), 205101; 
(c) Zhang, Z.; Mei, L.; Feng, S. S., Paclitaxel drug delivery systems. Expert opinion on drug 
delivery 2013, 10 (3), 325-40; (d) Sun, M.; Su, X.; Ding, B.; He, X.; Liu, X.; Yu, A.; Lou, H.; 
Zhai, G., Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine 
2012, 7 (7), 1085-100. 
78. Inokuchi, Y.; Hironaka, K.; Fujisawa, T.; Tozuka, Y.; Tsuruma, K.; Shimazawa, M.; 
Takeuchi, H.; Hara, H., Physicochemical properties affecting retinal drug/coumarin-6 delivery 
from nanocarrier systems via eyedrop administration. Investigative ophthalmology and visual 
science 2010, 51 (6), 3162-70. 
79. Nussenblatt, R. B., The natural history of uveitis. Int Ophthalmol 1990, 14 (5-6), 303-8. 
80. (a) Gaudana, R.; Jwala, J.; Boddu, S. H.; Mitra, A. K., Recent perspectives in ocular drug 
delivery. Pharm Res 2009, 26 (5), 1197-216; (b) Taylor, S. R.; Isa, H.; Joshi, L.; Lightman, S., 
New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010, 224 Suppl 1, 46-
53; (c) Lowder, C.; Belfort, R., Jr.; Lightman, S.; Foster, C. S.; Robinson, M. R.; Schiffman, R. 
M.; Li, X. Y.; Cui, H.; Whitcup, S. M., Dexamethasone intravitreal implant for noninfectious 
intermediate or posterior uveitis. Arch Ophthalmol 2011, 129 (5), 545-53. 
 219 
 
 
81. Robert H Janigian Jr; Jr, R. H. J. Uveitis Evaluation and Treatment 
http://emedicine.medscape.com/article/1209123-overview (accessed 06/25/2013). 
82. (a) Saraiya, N. V.; Goldstein, D. A., Dexamethasone for ocular inflammation. Expert 
Opin Pharmacother 2011, 12 (7), 1127-31; (b) Couch, S. M.; Bakri, S. J., Intravitreal 
triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol 
2009, 3, 41-7. 
83. Kim, S. H.; Lutz, R. J.; Wang, N. S.; Robinson, M. R., Transport barriers in transscleral 
drug delivery for retinal diseases. Ophthalmic Res 2007, 39 (5), 244-54. 
84. Vaishya, R. D.; Gokulgandhi, M.; Patel, S.; Minocha, M.; Mitra, A. K., Novel 
dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. AAPS 
PharmSciTech 2014, 15 (5), 1238-51. 
85. (a) Park, S. H.; Choi, B. G.; Joo, M. K.; Han, D. K.; Sohn, Y. S.; Jeong, B., Temperature-
Sensitive Poly(caprolactone-co-trimethylene carbonate)−Poly(ethylene 
glycol)−Poly(caprolactone-co-trimethylene carbonate) as in Situ Gel-Forming Biomaterial. 
Macromolecules 2008, 41 (17), 6486-6492; (b) Gou, M.; Men, K.; Shi, H.; Xiang, M.; Zhang, J.; 
Song, J.; Long, J.; Wan, Y.; Luo, F.; Zhao, X.; Qian, Z., Curcumin-loaded biodegradable 
polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 2011, 3 (4), 1558-
67. 
86. (a) Kalyanasundaram, K.; Thomas, J. K., Environmental effects on vibronic band 
intensities in pyrene monomer fluorescence and their application in studies of micellar systems. 
Journal of the American Chemical Society 1977, 99 (7), 2039-2044; (b) Basu Ray, G.; 
Chakraborty, I.; Moulik, S. P., Pyrene absorption can be a convenient method for probing critical 
micellar concentration (cmc) and indexing micellar polarity. Journal of Colloid and Interface 
Science 2006, 294 (1), 248-254. 
87. Gagarinova, V. M.; Alferov, V. P.; Kuznetsov, V. P.; Ostrovskaia, S. A.; Lapis, G. A.; 
Piskareva, N. A., [Human leukocytic interferon as an agent for emergency prevention of 
influenza and other acute respiratory diseases in children's preschool institutions]. Pediatriia 
1990,  (11), 74-8. 
88. Gaudana, R.; Parenky, A.; Vaishya, R.; Samanta, S. K.; Mitra, A. K., Development and 
characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by 
HIP complexation. Journal of microencapsulation 2011, 28 (1), 10-20. 
89. (a) Boddu, S. H.; Jwala, J.; Vaishya, R.; Earla, R.; Karla, P. K.; Pal, D.; Mitra, A. K., 
Novel nanoparticulate gel formulations of steroids for the treatment of macular edema. Journal 
of ocular pharmacology and therapeutics : the official journal of the Association for Ocular 
Pharmacology and Therapeutics 2010, 26 (1), 37-48; (b) Choi, S. H.; Park, T. G., Hydrophobic 
ion pair formation between leuprolide and sodium oleate for sustained release from 
biodegradable polymeric microspheres. International journal of pharmaceutics 2000, 203 (1-2), 
193-202; (c) Duvvuri, S.; Gaurav Janoria, K.; Mitra, A. K., Effect of polymer blending on the 
release of ganciclovir from PLGA microspheres. Pharm Res 2006, 23 (1), 215-23. 
90. ChemAxon http://www.chemicalize.org/structure/#!mol=honokiolandsource=calculate 
(accessed 7/8/13). 
91. Palmer, D.; Levina, M.; Douroumis, D.; Maniruzzaman, M.; Morgan, D. J.; Farrell, T. P.; 
Rajabi-Siahboomi, A. R.; Nokhodchi, A., Mechanism of synergistic interactions and its influence 
on drug release from extended release matrices manufactured using binary mixtures of 
polyethylene oxide and sodium carboxymethylcellulose. Colloids and surfaces. B, Biointerfaces 
2013, 104, 174-80. 
 220 
 
 
92. Earla, R.; Boddu, S. H.; Cholkar, K.; Hariharan, S.; Jwala, J.; Mitra, A. K., Development 
and validation of a fast and sensitive bioanalytical method for the quantitative determination of 
glucocorticoids--quantitative measurement of dexamethasone in rabbit ocular matrices by liquid 
chromatography tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis 
2010, 52 (4), 525-33. 
93. Vaishya, R.; Khurana, V.; Patel, S.; Mitra, A. K., Long-term delivery of protein 
therapeutics. Expert opinion on drug delivery 2014, 1-26. 
94. (a) America, P. R. a. M. o. Biologic Medicines in Development; February 7, 2013, 2013; 
(b) Davison, D. B., The Number of Human Genes and Proteins. Nano Science and Technology 
Institute: 2002; pp. 6-11. http://www.nsti.org/procs/ICCN2002/1/T11.02. 
95. (a) Valkov, E.; Sharpe, T.; Marsh, M.; Greive, S.; Hyvonen, M., Targeting protein-
protein interactions and fragment-based drug discovery. Topics in current chemistry 2012, 317, 
145-79; (b) Thiel, P.; Kaiser, M.; Ottmann, C., Small-molecule stabilization of protein-protein 
interactions: an underestimated concept in drug discovery? Angewandte Chemie 2012, 51 (9), 
2012-8. 
96. Voet, A.; Zhang, K. Y., Pharmacophore modelling as a virtual screening tool for the 
discovery of small molecule protein-protein interaction inhibitors. Current pharmaceutical 
design 2012, 18 (30), 4586-98. 
97. Su, J.; Mazzeo, J.; Subbarao, N.; Jin, T., Pharmaceutical development of biologics: 
fundamentals, challenges and recent advances. Therapeutic delivery 2011, 2 (7), 865-71. 
98. Rathore, A. S., Roadmap for implementation of quality by design (QbD) for 
biotechnology products. Trends in biotechnology 2009, 27 (9), 546-53. 
99. (a) Kaltashov, I. A.; Bobst, C. E.; Abzalimov, R. R.; Wang, G.; Baykal, B.; Wang, S., 
Advances and challenges in analytical characterization of biotechnology products: mass 
spectrometry-based approaches to study properties and behavior of protein therapeutics. 
Biotechnology advances 2012, 30 (1), 210-22; (b) Gilg, D.; Riedl, B.; Zier, A.; Zimmermann, M. 
F., Analytical methods for the characterization and quality control of pharmaceutical peptides 
and proteins, using erythropoietin as an example. Pharmaceutica acta Helvetiae 1996, 71 (6), 
383-94. 
100. Office, C. B. Research and Development in the Pharmaceutical Industry; 2006. 
101. Pharmaceutical Research and Manufacturers of America, P. Key Industry and PhRMA 
Facts; Pharmaceutical Research and Manufacturers of America, PhRMA: 2013. 
102. Jiskoot, W.; Randolph, T. W.; Volkin, D. B.; Middaugh, C. R.; Schoneich, C.; Winter, 
G.; Friess, W.; Crommelin, D. J.; Carpenter, J. F., Protein instability and immunogenicity: 
roadblocks to clinical application of injectable protein delivery systems for sustained release. 
Journal of pharmaceutical sciences 2012, 101 (3), 946-54. 
103. Vaishya, R. D.; Khurana, V.; Patel, S.; Mitra, A. K., Controlled ocular drug delivery with 
nanomicelles. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2014, 
n/a-n/a. 
104. (a) Aungst, B. J., Intestinal permeation enhancers. Journal of pharmaceutical sciences 
2000, 89 (4), 429-42; (b) Gupta, S.; Jain, A.; Chakraborty, M.; Sahni, J. K.; Ali, J.; Dang, S., 
Oral delivery of therapeutic proteins and peptides: a review on recent developments. Drug 
delivery 2013, 20 (6), 237-46 *review on recent development in oral protein delivery; (c) Park, 
K.; Kwon, I. C.; Park, K., Oral protein delivery: Current status and future prospect. Reactive and 
Functional Polymers 2011, 71 (3), 280-287. 
 221 
 
 
105. (a) Sakagami, M., Systemic delivery of biotherapeutics through the lung: opportunities 
and challenges for improved lung absorption. Therapeutic delivery 2013, 4 (12), 1511-25 
*Protein delivery through lungs. ; (b) Pisal, D. S.; Kosloski, M. P.; Balu-Iyer, S. V., Delivery of 
therapeutic proteins. Journal of pharmaceutical sciences 2010, 99 (6), 2557-2575. 
106. Sabaté, E., Adherence to Long-Term Therapies - Evidence for Action. World Health 
Organization: 2003. http://apps.who.int/medicinedocs/en/d/Js4883e/. 
107. Yandrapu, S.; Kompella, U. B., Development of sustained-release microspheres for the 
delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications 
of the eye. Journal of ocular pharmacology and therapeutics : the official journal of the 
Association for Ocular Pharmacology and Therapeutics 2013, 29 (2), 236-48. 
108. Koenig, J., Does process excellence handcuff drug development? Drug discovery today 
2011, 16 (9-10), 377-81. 
109. Wang, L.; Liu, Y.; Zhang, W.; Chen, X.; Yang, T.; Ma, G., Microspheres and 
microcapsules for protein delivery: strategies of drug activity retention. Current pharmaceutical 
design 2013, 19 (35), 6340-52  *A comprehensive review focusing on strategies for protein 
activity retention. 
110. Degim, I. T.; Celebi, N., Controlled delivery of peptides and proteins. Current 
pharmaceutical design 2007, 13 (1), 99-117. 
111. Sinha, V. R.; Trehan, A., Biodegradable microspheres for protein delivery. Journal of 
controlled release : official journal of the Controlled Release Society 2003, 90 (3), 261-80. 
112. Bittner, B.; Morlock, M.; Koll, H.; Winter, G.; Kissel, T., Recombinant human 
erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the 
encapsulation technique and polymer purity on microsphere characteristics. European journal of 
pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur 
Pharmazeutische Verfahrenstechnik e.V 1998, 45 (3), 295-305. 
113. Johnson, O. L.; Cleland, J. L.; Lee, H. J.; Charnis, M.; Duenas, E.; Jaworowicz, W.; 
Shepard, D.; Shahzamani, A.; Jones, A. J.; Putney, S. D., A month-long effect from a single 
injection of microencapsulated human growth hormone. Nature medicine 1996, 2 (7), 795-9. 
114. Genta, I.; Perugini, P.; Pavanetto, F.; Maculotti, K.; Modena, T.; Casado, B.; Lupi, A.; 
Iadarola, P.; Conti, B., Enzyme loaded biodegradable microspheres in vitro ex vivo evaluation. 
Journal of controlled release : official journal of the Controlled Release Society 2001, 77 (3), 
287-95. 
115. Fattal, E.; Couvreur, P.; Pecquet, S., [Oral tolerance induced by poly (lactide-co-
glycolide) containing B lactoglobulin]. Annales pharmaceutiques francaises 2002, 60 (1), 44-9. 
116. Zhou, S.; Deng, X.; He, S.; Li, X.; Jia, W.; Wei, D.; Zhang, Z.; Ma, J., Study on 
biodegradable microspheres containing recombinant interferon-alpha-2a. The Journal of 
pharmacy and pharmacology 2002, 54 (9), 1287-92. 
117. Yeh, M. K., The stability of insulin in biodegradable microparticles based on blends of 
lactide polymers and polyethylene glycol. Journal of microencapsulation 2000, 17 (6), 743-56. 
118. Takenaga, M.; Yamaguchi, Y.; Kitagawa, A.; Ogawa, Y.; Mizushima, Y.; Igarashi, R., A 
novel sustained-release formulation of insulin with dramatic reduction in initial rapid release. 
Journal of controlled release : official journal of the Controlled Release Society 2002, 79 (1-3), 
81-91. 
119. (a) Kang, C. E.; Baumann, M. D.; Tator, C. H.; Shoichet, M. S., Localized and sustained 
delivery of fibroblast growth factor-2 from a nanoparticle-hydrogel composite for treatment of 
spinal cord injury. Cells, tissues, organs 2013, 197 (1), 55-63; (b) Sulabh Patel, R. V., Gyan 
 222 
 
 
Prakash Mishra, Viral Tamboli, Dhananjay Pal, and Ashim K. Mitra, Tailor-made Pentablock 
Copolymer Based Formulation for Sustained Ocular Delivery of Protein Therapeutics. Journal of 
drug delivery 2014, In press. 
120. Mitra, A. K.; Mishra, G. P., Pentablock Polymers. Google Patents: 2011. 
121. Sulabh P Patel, R. D. V., Dhananjay Pal, Ashim K. Mitra, Novel Pentablock Copolymer-
Based Nanoparticulate Systems for Sustained Protein Delivery. AAPS PharmSciTech 2014. 
122. Lee, R. J.; Springer, M. L.; Blanco-Bose, W. E.; Shaw, R.; Ursell, P. C.; Blau, H. M., 
VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 
2000, 102 (8), 898-901. 
123. Geng, H.; Song, H.; Qi, J.; Cui, D., Sustained release of VEGF from PLGA nanoparticles 
embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix. 
Nanoscale research letters 2011, 6 (1), 312. 
124. Feelders, R. A.; Hofland, L. J.; van Aken, M. O.; Neggers, S. J.; Lamberts, S. W.; de 
Herder, W. W.; van der Lely, A. J., Medical therapy of acromegaly: efficacy and safety of 
somatostatin analogues. Drugs 2009, 69 (16), 2207-26. 
125. (a) De Martino, M. C.; Hofland, L. J.; Lamberts, S. W., Somatostatin and somatostatin 
receptors: from basic concepts to clinical applications. Progress in brain research 2010, 182, 
255-80; (b) Modlin, I. M.; Latich, I.; Kidd, M.; Zikusoka, M.; Eick, G., Therapeutic options for 
gastrointestinal carcinoids. Clinical gastroenterology and hepatology : the official clinical 
practice journal of the American Gastroenterological Association 2006, 4 (5), 526-47. 
126. Chanson, P.; Timsit, J.; Harris, A. G., Clinical pharmacokinetics of octreotide. 
Therapeutic applications in patients with pituitary tumours. Clinical pharmacokinetics 1993, 25 
(5), 375-91. 
127. (a) Ghassemi, A. H.; van Steenbergen, M. J.; Barendregt, A.; Talsma, H.; Kok, R. J.; van 
Nostrum, C. F.; Crommelin, D. J.; Hennink, W. E., Controlled release of octreotide and 
assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared 
to PLGA microspheres. Pharm Res 2012, 29 (1), 110-20; (b) Ibrahim, M. A.; Ismail, A.; Fetouh, 
M. I.; Gopferich, A., Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-
co-glycolic acid) microspheres. Journal of controlled release : official journal of the Controlled 
Release Society 2005, 106 (3), 241-52; (c) Murty, S. B.; Goodman, J.; Thanoo, B. C.; DeLuca, P. 
P., Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) 
microspheres under in vitro release conditions. AAPS PharmSciTech 2003, 4 (4), E50. 
128. (a) Ghalanbor, Z.; Korber, M.; Bodmeier, R., Protein release from poly(lactide-co-
glycolide) implants prepared by hot-melt extrusion: thioester formation as a reason for 
incomplete release. International journal of pharmaceutics 2012, 438 (1-2), 302-6; (b) Zhang, 
Y.; Schwendeman, S. P., Minimizing acylation of peptides in PLGA microspheres. Journal of 
controlled release : official journal of the Controlled Release Society 2012, 162 (1), 119-26; (c) 
Na, D. H.; Youn, Y. S.; Lee, S. D.; Son, M. W.; Kim, W. B.; DeLuca, P. P.; Lee, K. C., 
Monitoring of peptide acylation inside degrading PLGA microspheres by capillary 
electrophoresis and MALDI-TOF mass spectrometry. Journal of controlled release : official 
journal of the Controlled Release Society 2003, 92 (3), 291-9; (d) Lucke, A.; Fustella, E.; 
Tessmar, J.; Gazzaniga, A.; Gopferich, A., The effect of poly(ethylene glycol)-poly(D,L-lactic 
acid) diblock copolymers on peptide acylation. Journal of controlled release : official journal of 
the Controlled Release Society 2002, 80 (1-3), 157-68. 
129. Qi, F.; Yang, L.; Wu, J.; Ma, G.; Su, Z., Microcosmic Mechanism of Dication for 
Inhibiting Acylation of Acidic Peptide. Pharm Res 2015. 
 223 
 
 
130. Wang, J.; Wang, B. M.; Schwendeman, S. P., Characterization of the initial burst release 
of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. Journal of controlled 
release : official journal of the Controlled Release Society 2002, 82 (2-3), 289-307. 
131. Patel, S. P.; Vaishya, R.; Pal, D.; Mitra, A. K., Novel Pentablock Copolymer-Based 
Nanoparticulate Systems for Sustained Protein Delivery. AAPS PharmSciTech 2014. 
132. Patel, S. P.; Vaishya, R.; Yang, X.; Pal, D.; Mitra, A. K., Novel thermosensitive 
pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment 
diseases. Protein and peptide letters 2014, 21 (11), 1185-200. 
133. Tamboli, V.; Mishra, G. P.; Mitra, A. K., Novel pentablock copolymer (PLA-PCL-PEG-
PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions 
on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Colloid 
and polymer science 2013, 291 (5), 1235-1245. 
134. Patel, S. P.; Vaishya, R.; Mishra, G. P.; Tamboli, V.; Pal, D.; Mitra, A. K., Tailor-made 
pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. 
Journal of drug delivery 2014, 2014, 401747. 
135. (a) Na, D. H.; Murty, S. B.; Lee, K. C.; Thanoo, B. C.; DeLuca, P. P., Preparation and 
stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery. 
AAPS PharmSciTech 2003, 4 (4), E72; (b) Lucke, A.; Gopferich, A., Acylation of peptides by 
lactic acid solutions. Eur J Pharm Biopharm 2003, 55 (1), 27-33. 
136. Higuchi, T., Mechanism of Sustained-Action Medication. Theoretical Analysis of Rate of 
Release of Solid Drugs Dispersed in Solid Matrices. J Pharm Sci 1963, 52, 1145-9. 
137. Korsmeyer, R. W.; Gurny, R.; Doelker, E.; Buri, P.; Peppas, N. A., Mechanisms of solute 
release from porous hydrophilic polymers. International journal of pharmaceutics 1983, 15 (1), 
25-35. 
138. Hixson, A. W.; Crowell, J. H., Dependence of Reaction Velocity upon surface and 
Agitation. Industrial and Engineering Chemistry 1931, 23 (8), 923-931. 
139. (a) Gaudana, R.; Gokulgandhi, M.; Khurana, V.; Kwatra, D.; Mitra, A. K., Design and 
evaluation of a novel nanoparticulate-based formulation encapsulating a HIP complex of 
lysozyme. Pharmaceutical development and technology 2013, 18 (3), 752-9; (b) Gaudana, R.; 
Khurana, V.; Parenky, A.; Mitra, A. K., Encapsulation of Protein-Polysaccharide HIP Complex 
in Polymeric Nanoparticles. Journal of drug delivery 2011, 2011, 458128; (c) Patel, A.; 
Gaudana, R.; Mitra, A. K., A novel approach for antibody nanocarriers development through 
hydrophobic ion-pairing complexation. Journal of microencapsulation 2014, 31 (6), 542-50. 
140. Shi, K.; Cui, F.; Yamamoto, H.; Kawashima, Y., Investigation of drug loading and in 
vitro release mechanisms of insulin-lauryl sulfate complex loaded PLGA nanoparticles. 
Pharmazie 2008, 63 (12), 866-71. 
 
  
 224 
 
 
VITA 
Ravi D. Vaishya was born on 18th June 1986, in Ahmedabad, Gujarat, India. He 
completed his Bachelor of Pharmacy from Hemchandracharya North Gujarat University in 2007. 
After completion of his B. Pharm. degree, he joined the Interdisciplinary Ph.D. program at 
UMKC in January 2008 to pursue a Ph.D. degree in Pharmaceutical Science and Chemistry. He 
is an active member of American Association of Pharmaceutical Scientists (AAPS), Association 
of Research in Vision and Ophthalmology (ARVO) and Pharmaceutical Sciences Graduate 
Student Association (PSGSA). He served as the Treasurer of PSGSA student chapter, UMKC, 
for one year. He completed his doctoral studies in April 2015 under the guidance of Dr. Ashim 
K. Mitra. He has authored/co-authored several peer reviewed publications and book chapters, 
and has presented his work in a number of international and national conferences such as AAPS, 
ARVO and PGSRM. 
 
